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Abstract
Observational data, such as electronic health records, are a valuable source of infor-
mation for researchers seeking to answer health-related questions. Since treatment
allocation is not typically randomized in studies using observational data, there is
confounding  systematic differences in the characteristics of patients in different
treatment groups. Propensity score analysis (PSA) can be used to handle confound-
ing by modelling the probability of being allocated to a particular treatment, based
on patient characteristics. However, a common issue in analyses of observational
data is missing data. In general, not dealing appropriately with missing data can
lead to loss of efficiency and biased estimates of the treatment effect. Further-
more, having partially observed covariate data can complicate the estimation of the
propensity score.
The missingness pattern approach (MPA) has been proposed to handle partially
observed covariate data in PSA. One key objective of my thesis is to understand
when the approach is appropriate, by exploring its underlying assumptions. I began
by comparing different statements of the MPA's underlying assumptions given in the
literature. I considered the plausibility of the MPA's assumptions in simple scenar-
ios, finding that they are separate to the conventional classification of missingness
mechanisms. I used d-separation (a rule for testing conditional independence state-
ments) with single world intervention graphs, representing a variety of scenarios, in
order to develop guidance for when the assumptions seem plausible.
I also explored the connection between using the MPA and using missing indi-
cators in the context of PSA, finding that the use of missing indicators is a simpli-
fication of the MPA. I extended this work to outcome regression, mathematically
proving that using missing indicators is valid under the MPA's assumptions as well
as an additional simplifying assumption. I also conducted simulation studies to as-
sess bias when using missing indicators to handle partially observed covariate data
in outcome regression.
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Chapter 1
Introduction
Establishing the efficacy and safety of commonly used drugs remains a challenge
in pharmacoepidemiological research. Real world evidence  arising from obser-
vational data obtained outside the context of highly controlled randomized clinical
trials, typically data generated during routine clinical practice  plays an increas-
ingly important role in a wide range of pharmacoepidemiological investigations. The
expectation that routinely collected health data will be used to measure medication
effects  both harms and benefits  is now written into EU legislation [1]. In the
US, legislation has noted the potential benefits of using routinely collected health
data for regulatory decisions [2].
Important questions that can be usefully addressed using large scale routine
health data include the investigation of long-term and rare effects of medications,
treatment interactions, efficacy of drugs in patients with rare conditions, long-term
resistance to treatments such as antibiotics, and establishing optimal treatment
policies for chronic conditions [3].
These questions are all, at heart, causal questions. Causal inference is the process
of drawing conclusions about questions regarding causal relationships, such as the
comparative effect of different treatments on a health outcome [4].
A framework for the formal definition and estimation of causal effects, based
on the idea of counterfactuals  the idea of what would have happened had a
different treatment been prescribed  has been proposed and is widely used in
15
pharmacoepidemiological research to address causal questions [5].
Randomized controlled trials are commonly considered to be the `gold-standard'
for the estimation of causal effects. Evidence from randomized trials has a number
of limitations. The patients recruited to randomized controlled trials are often not
representative of the general population. More specifically, they tend to include
patients who are younger, more often male and who have fewer comorbidities. Trials
often exclude the very patients who tend to be treated with the treatments under
investigation in clinical practice. Also, the treatment administration and monitoring
in trials is highly controlled, often leading to much higher adherence to the prescribed
treatment. As such, patients' use of treatments in trials may not be reflective of use
in clinical practice.
Real-world evidence, reflecting the effectiveness of treatments in routine clinical
practice for large samples of the general population over long periods of time, can
be obtained by the analysis of routinely collected health data with limited exclusion
criteria [6]. Hence, observational studies can be used to answer research questions
surrounding the effectiveness and safety of treatments in long-term routine clinical
practice; such research questions may be difficult or infeasible to address through
randomized controlled trials.
Routinely collected health-related information is increasingly been stored elec-
tronically. These electronic health records (EHRs) offer rich opportunities for phar-
macoepidemiological research investigating treatments in real-world settings. Exam-
ples of EHR databases in the UK include the Clinical Practice Research Datalink,
Hospital Episode Statistics, and The Health Improvement Network [79]. These
EHR databases contain large numbers of anonymised patient records, with informa-
tion on demographic characteristics, as well as prescriptions, diagnostic tests and
procedures.
Since EHR data are not collected for the purposes of research, but rather as part
of routine clinical or administrative practice, treatment allocation is not random
and is instead dependent on a range of factors including age, sex and comorbidities.
So, characteristics for one treatment group (say, the active treatment) may system-
16
atically differ from those of another treatment group (say, the control treatment). If
these characteristics are risk factors for the outcome under study, then these charac-
teristics may `confound' the causal relationship between treatment and control and
lead to biased results. Hence, observational studies using EHR must use strategies
for dealing with confounding bias.
While multivariable regression has a long history of use as a method to account
for confounding in observational data, methods based on the propensity score have
been increasingly applied, particularly to the analysis of large-scale health data. The
popularity of propensity score methods in this context is in part due to the ability
to estimate marginal population-level effects, which are typically more relevant for
policy makers. Further, propensity score methods can more readily handle large
amounts of potential confounding data, which is a major advantage when investi-
gating rare outcomes.
Propensity score analysis compares patients in the active treatment group to
patients from the control group with the same propensity for being allocated to the
active treatment group [10]. The basic premise relies on the idea that patients who
have a similar `likelihood' of receiving the treatment  whether or not they actually
do receive a prescription for that treatment  are, on average, similar. Therefore,
propensity score analysis compares outcomes of patients with similar propensity
scores to obtain estimates of treatment effect.
Whatever analytic approach is used to account for confounding bias, the prob-
lem of missing data is likely to arise. In EHR data, while health outcomes and
treatment prescriptions are usually well recorded, variables that potentially lead to
confounding bias are less so. For example, these potential `confounders' include pa-
tient characteristics, such as ethnicity or BMI. Further, the extent of missing data
in EHR is typically much greater than is likely to arise in more traditional study
designs. Therefore, the problem of missing confounder data in studies using EHR is
likely to pose considerable challenges.
To deal with the problem of missing confounder data, patients records are often
excluded from analysis. However, this leads to a loss of information and can result
17
in biased estimates of the treatment effect.
This thesis focuses on propensity score based methods, due to its popularity
in the analysis of EHR data. In such studies, there are a number of methods for
dealing with missing confounder data, some of which have been specifically proposed
for the context of propensity score analysis. One method that has been proposed is
the missingness pattern approach (MPA), which incorporates information about the
pattern of missing variables into the propensity score. The assumptions underlying
the MPA have been discussed in the literature, however, the MPA has not been used
much, possibly due to lack of understanding regarding these assumptions.
1.1 Motivating example
Renin angiotensin system blocking using ACE inhibitors (ACEI) and angiotensin
receptor blockers (ARBs) is a common treatment for a wide range of conditions,
including hypertension and heart failure. However, some patients may experience
adverse effects. For instance, acute kidney injury (AKI)  a sudden decline in
kidney function  is thought to be associated with use of ACEI/ARBs [11]. This
relationship is biologically plausible, however evidence to support a causal link is
limited: randomized evidence is scarce due to insufficient or no reporting of renal
events in randomized trials of ACEI/ARBs [11]. Despite this limited evidence,
guidelines recommend reducing or ceasing ACEI/ARB use during acute illness [11].
Mansfield et al. (2016) used data taken from UK primary care linked data, from
the Clinical Practice Research Datalink (CPRD), to investigate the relationship
between use of ACEI/ARBs and the risk of AKI [11]. The large amount of missing
data in two potential confounders was handled using a missing category approach.
The assumptions under which this approach would have provided valid inference had
not yet been clearly outlined in the literature, thus the validity of the assumptions
underlying this approach could not be fully explored.
I obtained ethics approval to use this data from The Medicines and Healthcare
products Regulatory Agency, CPRD division and the London School of Hygiene and
Tropical Medicine (Appendix A).
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1.1.1 The Clinical Practice Research Datalink
The CPRD, formerly known as the General Practice Research Database, contains
anonymised primary care records from over 1600 general practices for 11 million
registered, alive patients as of 4th September 2019 [12]. These patients are fairly
representative of the general UK population [7,13,14]. Data are collected by general
practice staff as part of routine clinical care [7]. Data are recorded in a number
of ways in the CPRD: clinical measures such as symptoms and diagnoses can be
classified using Read codes [15] or recorded numerically [7], and prescription data
is recorded with British National Formulary codes and dosage information [7]. Ad-
ditional notes can be recorded as free-text, but are not available to researchers as
standard.
CPRD data can be linked to other data sources, including Hospital Episode
Statistics (HES) data, to provide more complete information about the patient path-
way. Hospital Episodes Statistics (HES) contains records of all patients admitted to
NHS hospitals in England, covering every hospital stay. Data for HES are recorded
by clinicians and entered into an electronic database by dedicated clinical coding
departments [8]. Data are recorded in a number of ways in HES, including: ICD-10
codes for the classification of diagnoses [16], OPCS codes to classify operations and
procedures [17].
Linkage of CPRD and other datasets is carried out by a trusted third party,
NHS Digital [18]. Linkage uses pseudonymised identifiers and a deterministic linkage
algorithm that produces a ranking variable that indicates the quality of links [19].
1.1.2 Study design
Mansfield et al. (2016) used data taken from the CPRD linked to HES to investigate
the relationship between use of ACEI/ARBs and the risk of AKI, using a cohort of
new users of antihypertensive drugs to limit confounding by indication [11] (i.e. to
avoid confounding bias arising from a comparison of ACEI/ARBs users and healthy
patients with no antihypertensive prescriptions).
More than 500,000 new users of antihypertensives between 1997-2014 were in-
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cluded in Mansfield et al.'s study. Being an observational comparative effectiveness
study, strategies to deal with confounding were required: the authors chose to use
multivariable Poisson regression, adjusting for age, sex, various chronic comorbidi-
ties, time exposed to other antihypertensive drugs and calendar period [11]. In this
study, many of the baseline characteristics were not balanced across the treatment
groups, indicating potential confounding bias (see Table 5.1 in the research paper
pre-print in Chapter 5). By using propensity score analysis, potential confounders
can be balanced using the propensity score to summarise all of the covariates, re-
placing the need to include all covariates separately in a regression model.
A key comorbidity and potential confounder, baseline chronic kidney disease
(CKD) stage, had missing values in over 50% of patients. Ethnicity also had over
50% missing data. Restricting analysis to patients with complete records would lead
to a large loss of data; only a fifth of the patients in the study had both ethnicity
and baseline CKD stage recorded. Mansfield et al. opted to use a `missing baseline
CKD stage' category to minimize selection bias and performed a sensitivity analysis
excluding patients with missing baseline CKD stage [11]. They also used sensitivity
analysis to compare the main results for the cohort to the results for a subset of
patients with known ethnicity, finding that neither of the sensitivity analyses had
much effect on the results of the study [11]. However, they do not comment beyond
this on the assumptions about missing data inherent in their analyses.
1.2 Aims and objectives
The overall aim of this thesis is to investigate missing data methods incorporating
missingness information to deal with partially observed confounder data when using
causal inference methods in observational studies, with a focus on gaining a clear
understanding of the assumptions required and providing practical guidance for
assessing their plausibility. The specific objectives are listed below.
Objective 1: to explore the assumptions underlying the missingness
pattern approach. The missingness pattern approach (MPA) has been proposed
as a method to handle missing confounder data in propensity score analysis. I will
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explore the assumptions under which the MPA would provide valid inference, by: (i)
investigating the connection between the MPA and the conventional classification
of missing data proposed by Rubin (1976) [20], (ii) identifying settings where the
assumptions are likely to be plausible, and (iii) developing ways of assessing the
assumptions using causal diagrams.
Objective 2: to develop guidance for assessing the assumptions un-
derlying the missingness pattern approach By developing the work from
Objective 1, I will develop practical guidance for assessing the MPA's assumptions
in a given setting and I will demonstrate the practical guidance on the motivating
example using electronic health data.
Objective 3: to investigate the missing indicator approach for propen-
sity score analysis. I will explore the relationship between the MPA and the
missing indicator approach in the context of propensity score analysis, in particular
investigating the implications of this relationship on the assumptions under which
the missing indicator approach can provide valid inference.
Objective 4: to investigate the missing indicator approach for outcome
regression. I will extend the work from Objective 3 to investigate the use of the
missing indicator approach in the context of outcome regression.
Objective 5: to investigate variance estimation for missing confounder
methods incorporating missingness patterns for propensity score analysis.
I will derive a variance estimator for inverse probability of treatment weighting after
using the MPA to deal with partially observed confounder data.
1.3 Thesis overview
I begin in Chapter 2 with an overview of the potential outcome framework for causal
inference and the principles of propensity score analysis. I also describe missing data
methods for propensity score analysis, introduce causal diagrams for representing
causal relationships and review the use of the MPA for propensity score analysis in
health research.
In Chapter 3, I explore the assumptions underlying the validity of the MPA, by
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considering connections with prior work from the literature. I also devise ways of
assessing the assumptions using causal diagrams.
In Chapter 4, I consider ways to communicate how to assess the assumptions
in practice and provide the initial guidance developed for assessing the MPA's as-
sumptions.
In Chapter 5, I present a research paper pre-print that explores the assumptions
underlying the MPA and provides the current guidance for assessing the MPA's
assumptions. This research paper has been submitted for publication in Statistics
in Medicine.
In Chapter 6, I derive a variance estimator inverse probability of treatment
weighting after using the MPA and discuss potential for future simple simulation
studies to empirically assess the performance of this estimator.
In Chapter 7, I explore the connection between the MPA and the approach
where a missingness category for partially observed characteristics is added to the
propensity score model. I then extend these findings to investigate the use of missing
indicators in standard outcome regression.
In Chapter 8, I present a research paper pre-print that explores the use of the
missing indicator approach in standard outcome regression. This research paper has
been provisionally accepted for publication by the Biometrical Journal.
In Chapter 9, I conclude with a discussion and propose new avenues for research
in this area.
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Chapter 2
Background
In this chapter, I provide some background information on the methodology used
in my PhD. I begin with an overview of causal inference and the potential outcome
framework, including propensity score analysis. Next, I describe missing confounder
data methods, introducing key concepts in missing data methodology. I then in-
troduce causal diagrams, which are a way of visually representing relationships in
a scenario of interest. Finally, I review the existing literature using the missingness
pattern approach.
2.1 Causal inference and the potential outcome
framework
Causal inference is the process of drawing conclusions about questions regarding
cause and effect. Causal questions in pharmacoepidemiological research concern the
effects of drugs, medical devices or other medical interventions in a large population
[3]. For example, my motivating example is a comparative effectiveness study that
investigates the association between use of renin-angiotensin system blocking drugs,
compared to other antihyperhensive drugs, and the risk of AKI in a cohort of over
500,000 adults [11]. Causal questions in medical research typically concern the effect
of a treatment, exposure or intervention on health outcomes [21]; in this thesis I
discuss causal effects in terms of treatments, to correspond with the motivating
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example.
The Neyman-Rubin framework was developed to make inferences about causal
effects and relies on the concept of counterfactuals: what would have happened
had the cause not been present [10]. For example, suppose individuals in a study
are allocated to one of two treatment groups, say an active treatment or a control.
Each individual has an observed outcome and a counterfactual outcome (i.e. the
outcome that would have happened if, counter to fact, the individual had a different
treatment allocation). We refer to these collectively as potential outcomes. Each
individual then has two potential outcomes: the outcome that would have been
observed if they were allocated to the active arm, and the outcome that would have
been observed if they were allocated to the control arm [10,22]. Thus a contrast of
potential outcome values for an individual gives the causal effect of treatment for
this individual. However, the `fundamental problem of causal inference' [22] is that
this comparison cannot be made directly since only one of these potential outcomes
can be observed and the other is counterfactual [23].
Instead, inferences are made by considering a group of individuals, some of whom
are allocated to the active arm and others allocated to the control arm. The average
outcomes from each treatment arm are compared to estimate the average treatment
effect. This estimate is unbiased when the individuals in the active treatment arm
are comparable with the individuals in the control arm [24]. An example of when
the treatment arms are comparable is when treatment allocation is randomized [22].
When randomization is not feasible, observational data can be used to estimate
treatment effects. However, in non-randomized settings, obtaining unbiased esti-
mates of the treatment effect is more complex and relies on assumptions that are
untestable in practice.
2.1.1 Notation and estimands of causal effect
Consider a group of n patients, with information on p characteristics represented
by a row vector Xi = (Xi1, . . . , Xip)
T where i = 1, . . . , n and Xi is fully observed.
Throughout this thesis, treatment allocation is assumed to be binary, denoted by
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Zi = 1 if patient i is in the treatment group or Zi = 0 if they are in the control group.
Correspondingly, the two potential outcomes for patient i are denoted as Yi(z),
where z = 0, 1. The observed outcome for patient i is denoted as Yi. Henceforth,
the subscripts are omitted where unambiguous.
An estimand is a quantity that we want to make inferences about. In this thesis,
the estimand of interest is the average treatment effect (ATE): E[Y (1) − Y (0)].
Restricting attention to binary outcomes, this estimand is the risk difference [25,26].
The risk difference is often of interest in public health questions and is easy to
interpret (as it is an absolute measure) [27]. In addition, the risk difference has the
desirable property of being collapsible, unlike the odds ratio [27]. An alternative
estimand would be the marginal risk ratio, E[Y (1)/Y (0)], which is also collapsible
[25].
While I focus on causal inference for the whole population, sometimes the pop-
ulation of interest in a research question is the subgroup of patients in the treat-
ment arm, for which the corresponding estimand is called the average treatment
effect in the treatment group (ATT), E[Y (1) − Y (0)|Z = 1] [25, 28]. Similarly, if
the population of interest is the subgroup of patients in the control arm, the cor-
responding estimand is the average treatment effect in the control group (ATC),
E[Y (1) − Y (0)|Z = 0]. The choice between the ATE, ATT and ATC depends on
the context of the research [26,28,29]; analogous definitions of the estimands can be
made in terms of risk ratios or odds ratios as required [25]. In this thesis, attention
is restricted to the ATE in terms of the risk difference.
2.1.2 Identification of causal effects
Although the Neyman-Rubin framework was developed for randomized controlled
trials [30], we can use observational data to obtain estimates of the ATE under
certain `identifiability' assumptions [31]. In this thesis, we assume the following
hold: the consistency assumption, the strongly ignorable treatment assignment as-
sumption, the `no interference' assumption, and the positivity assumption. Note
that different identifiability assumptions may be used in other causal inference ap-
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proaches, such as analyses using instrumental variables [10,32].
The consistency assumption states that, if an individual is assigned a particu-
lar treatment then the corresponding potential outcome will be observed for that
individual, irrespective of the way in which they were assigned to that treatment
group [31]. This can be expressed as:
Yi = Yi(1)× Zi + Yi(0)× (1− Zi).
The `no interference' assumption states that the treatment received by one pa-
tient does not affect the potential outcomes of another patient: [3335]
Yi(z1, . . . , zi, . . . , zn) = Yi(zi),
where Yi(z1, . . . , zi, . . . , zn) is the hypothetical potential outcome where Zi is set to
zi for all values of i = 1, . . . , n.
The strongly ignorable treatment assignment (SITA) assumption is that there is
no unmeasured confounding: [33]
(
Yi(1), Yi(0)
) ⊥ Zi|Xi∀i . (2.1)
The SITA assumption has also been referred to as `conditional exchangeability' since
the treatment and control groups are exchangeable based on the observed covariate
information [36].
Finally, the positivity assumption states that, on the basis of their characteristics,
it must be possible for each individual to be allocated to treatment or to control
[23,37], and can be expressed as:
0 < P (Zi = 1|Xi) < 1 ∀ i .
Throughout, we assume that these assumptions hold in the complete data.
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2.1.3 Treatment effect estimation in observational studies
Randomized controlled trials are considered to be the gold-standard for causal infer-
ence. When treatment allocation is randomized, patient characteristics are balanced
on average across the two treatment groups (i.e. have similar distributions in the
two groups) and so the ATE can be identified as:
ATE = E[Y |Z = 1]− E[Y |Z = 0] .
When randomization is not feasible, observational data can be used to estimate
treatment effects. Furthermore, observational studies can be used to answer research
questions that could not feasibly be addressed using randomized controlled trials,
such as the long-term efficacy and safety of treatments in routine practice. However,
a common issue with observational data is confounding bias: systematic differences
in patient characteristics between treatment groups. Since patient characteristics
are not balanced across treatment groups, the SITA assumption does not hold and
the ATE cannot be identified. One solution is to identify a set of confounders which
satisfy the SITA assumption and thus identify the ATE using strategies to account
for those confounders.
Conventionally, a variable is considered to be a `confounder' in the epidemio-
logical sense if it (i) is associated with treatment allocation, (ii) is associated with
the outcome, and (iii) does not lie on the causal pathway between treatment and
outcome [38]. In this thesis, we use the more formal definition: a variable is a con-
founder if it is a member of some set of variables that is sufficient to control for
confounding [39]. Causal diagrams provide a way of identifying a set of measured
variables which satisfies the SITA assumption of no unmeasured confounding.
When estimating the treatment effect in observational studies, two key ap-
proaches to deal with confounding are: (i) outcome regression models conditioning
on confounders; or (ii) propensity score methods, as described below. In this thesis,
I focus on propensity score methods for estimating marginal treatment effects.
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2.1.4 Propensity score analysis
The propensity score e(x) is the probability of being assigned to the treatment group,
as opposed to the control group, given a set of observed characteristics:
ei(xi) = P (Zi = 1|Xi = xi), (2.2)
for patient i (i = 1, . . . , n) with a vector of confounder values Xi = xi.
The propensity score is a balancing score: at each level of the propensity score,
the distributions of observed characteristics are the same for treated individuals as
for controls on average [33]. Rosenbaum and Rubin (1983) showed that at each
value of the propensity score, the difference in mean outcomes for the treated and
control groups is an unbiased estimate of the ATE at that value of the propensity
score under the identifiability assumptions described above [33].
Typically, propensity scores are unknown and must be estimated from the data.
Often, they are estimated using a logistic regression model for the treatment, with
observed confounders as covariates [28]. The predictions obtained from this model
are the individual estimated propensity scores. Sometimes factors that are not
necessarily confounders but are associated with the outcome of interest can also
be included as covariates to increase precision [25]. Alternative strategies for the
estimation of propensity scores, such as classification trees, random forests and gen-
eralised boosted modelling, are discussed elsewhere [28, 40] but are not considered
further here.
Rosenbaum and Rubin (1983) showed that, provided the above identifiability as-
sumptions hold, matching, stratification and adjustment on the estimated propensity
score can give unbiased estimates of the ATE [33]. In propensity score matching,
treated and control individuals are `matched', according to their propensity score
and, for each matched pair, the difference in their observed outcomes are calculated.
The average of these differences then provides an estimate of the ATT [33]. To
estimate the ATE, each individual in the sample must be matched, which means
that some individuals will appear more than once in the matched sample [23]. Al-
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ternatively, the ATC can be estimated by matching each control individual with a
treated individual [23,25].
Propensity score stratification involves separating individuals into strata (e.g.
quintiles), based on their propensity scores [33,41]. The treatment effect is estimated
in each of the strata and a weight for each stratum is calculated, corresponding to the
size of the stratum. Then a weighted average of the treatment effects is calculated,
providing an estimate of the ATE [23]. Estimates of average treatment effects in
the treatment and control subgroups, the ATT and ATC, can be obtained by using
weights corresponding to the proportions of treated individuals in each stratum, or
weights representing the proportions of control individuals respectively [23].
In propensity adjustment, an outcome regression model (e.g. a logistic regression
model for a binary outcome) is fitted including treatment and the propensity score as
covariates [28,33], and often also including potential confounders as covariates [42].
The resulting treatment coefficient is often reported as an estimate of the treatment
effect. In this report, an extension of the propensity adjustment method will be
considered, as follows. Potential outcomes for each individual can be predicted using
the outcome regression model with treatment and propensity score as covariates,
and the difference between potential outcomes can be calculated for each individual
and averaged to estimate the ATE [43]. This method can also be used to estimate
the average treatment effect in the treatment group and the average treatment
effect in the control group by restricting to the appropriate subset of individuals as
required [23].
Another propensity score method that can be used to estimate the causal effect
of treatment is inverse probability of treatment weighting (IPTW). IPTW uses the
estimated propensity scores as weights to construct `pseudo-populations' in which
the distributions of observed confounders are balanced across treatment groups: the
pseudo-population where everyone had treatment and the pseudo-population where
everyone had control [28, 36]. The mean outcome in each is calculated, and the
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difference between these, provides an estimate of the ATE: [23]
ÂTEIPTW =
∑
i
YiZi
eˆi∑
i
Zi
eˆi
−
∑
i
Yi(1−Zi)
(1−eˆi)∑
i
(1−Zi)
(1−eˆi)
. (2.3)
Different weights can be applied to construct pseudo-populations which reflect the
distribution of observed confounders in the treatment group or control group to
obtain the ATT or ATC, respectively [23].
Throughout this thesis, IPTW is used to estimate treatment effects.
2.2 Missing confounder data
So far, the discussion of propensity score methods has assumed that data is fully
observed. However, in practice, observational studies suffer from large amounts of
missing data. For example, a valuable source of observational data for investigating
treatments in routine clinical practice is data from electronic health records (EHRs).
Whilst health outcomes and treatment prescriptions are usually well recorded, EHRs
tend to suffer from missing data in recording of patient characteristics. This can be
seen in the motivating example introduced in Chapter 1, where two key confounders,
ethnicity and baseline chronic kidney disease (CKD) stage, each had over 50% of
missing data.
Having missing data is problematic as there is a loss of information, or efficiency,
from the available data [44]. Missing data can also lead to bias if the assumptions
underlying a chosen missing data method are not satisfied [44,45].
2.2.1 Further notation and concepts related to missing data
We assume throughout that Y and Z are fully observed, and that any missing data
is in the confounders  often the case in EHRs. Let Rij be a missing indicator
indicating whether the confounder j (j = 1, . . . , p) for patient i (i = 1, . . . , n) is
observed (Rij = 1) or not (Rij = 0). Following D'Agostino and Rubin (2000) and
other established missing data literature [4547], the set of confounder values Xij
(i = 1, . . . , n; j = 1, . . . , p) can be partitioned into those that are observed and those
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that are missing, where Xobs represents the set of values that are observed and Xmis
represents the set of values that are missing:
X = {Xobs, Xmis} where Xobs = {Xij|Rij = 1} and Xmis = {Xij|Rij = 0}.
We will use Ri = (Ri1, ..., Rip) to refer to the vector of missing indicators for patient
i, omitting the subscript i where unambiguous.
We can use missing indicators to define missingness patterns, which are a way
of representing the knowledge of which characteristics are observed or unobserved.
Subjects can be separated into sets according to the possible combinations of being
observed or missing, i.e. the missingness patterns.
Suppose two covariates, A and B, are measured for a group of individuals and
that there is missing data present in both. We denote the respective missing indi-
cators as RA and RB. In this case, there are four possible combinations of being
observed or missing, and hence 4 distinct missingness patterns defined by:
(i) the set of patients for whom both A and B are observed (i.e. RA = 1 and
RB = 1),
(ii) the set of patients for whom only A is observed (RA = 1 and RB = 0),
(iii) the set of patients for whom only B is observed (RA = 0 and RB = 1),
(iv) the set of patients for whom neither A nor B are observed (RA = 0 and
RB = 0).
2.2.2 Taxonomy of missingness mechanisms
Missingness mechanisms refer to the process by which data become missing, cor-
responding to the relationship between the reason for missingness in a particular
sample and the actual values of the observed and missing data [44]. The most com-
mon classification of missingness mechanisms is Rubin's taxonomy, in which data
are missing completely at random (MCAR), missing at random (MAR) or missing
not at random (MNAR). [20, 44,48]
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The first missingness mechanism, where data are MCAR, means that the prob-
ability of being missing does not depend on the observed data or the unobserved
data, i.e.
P (R|Y, Z,Xobs, Xmis) = P (R) (2.4)
or R ⊥ Y, Z,Xobs, Xmis .
Data are MAR if the probability of being missing depends on the observed values
of data but not on the missing values:
P (R|Y, Z,Xobs, Xmis) = P (R|Y, Z,Xobs) (2.5)
i.e. R ⊥ Xmis|Y, Z,Xobs .
Finally, data are MNAR if the probability of being missing depends on the
unobserved data, after conditioning on the observed data:
R 6⊥ Xmis|Y, Z,Xobs . (2.6)
In other words, the probability of being missing depends on the missing value itself.
Information about the missingness mechanisms are an important factor when
considering whether an missing data method is appropriate for a particular dataset.
2.2.3 Methods to handle missing data
There has been much methodological research into missing data [44, 45, 49]. Com-
mon ad hoc methods for handling missing data include excluding patients with
missing data [50] or excluding variables with missing data [51]. Other simple meth-
ods include using missing indicators, and replacing missing observations with fixed
values [52]; imputing missing values with the mean of observed values [49]; or, in
the context of longitudinal studies, imputing missing values by carrying forward
the last observation observed [45]. Alternative methods include multiple imputa-
tion [44, 53], likelihood-based methods use models based on observed data [45] and
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inverse probability weighting [54]. Multiple imputation is an increasingly popular
approach to missing data, where missing values are imputed multiple times with
plausible values in order to create multiple `complete' imputed datasets, and results
from each dataset are combined using Rubin's Rules to obtain an overall treatment
effect estimate [20, 44]. Standard implementations of multiple imputation require
data to be MAR [44,49].
In the context of propensity scores, insights from the general methodological
research into missing data cannot directly be used because the aims of regression
modelling in propensity score analysis are different (i.e. to achieve balance rather
than to estimate parameters [46]) and so the assumptions underlying the validity
of missing data methods may be different. Thus a chosen missing data technique
may need either stronger SITA-type assumptions or assumptions regarding the miss-
ingness mechanism to ensure that using subsequent propensity score methods will
achieve balance between treatment groups and obtain valid inferences [51].
2.2.4 Common methods to handle missing confounder data
A common approach to dealing with missing confounders is complete record analysis
(CRA), also known as complete case analysis, where individuals with missing data
are discarded before analysis. This approach leads to loss of efficiency as information
individuals with partial information is discarded. Also, this approach often leads to
biased estimates of the treatment effect when missingness depends on both outcome
and treatment [50].
The missing indicator approach, a simple method for handling missing con-
founder data, adds a `missing' category to partially observed categorical confounders.
Equivalently, for continuous confounders, missing values are set to a fixed value, say
0, and both the confounder and its corresponding missing indicator are included
in the propensity score model. Although the missing indicator approach has been
suggested as a missing data method for propensity score analysis [25, 55], the use
of missing indicators is generally considered to be an ad hoc method [56, 57] that
yields biased results [58,59].
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A popular alternative for handling missing confounder data is multiple imputa-
tion. Similarly to dealing with missing data in general, multiple imputation imputes
missing covariates with plausible values several times by drawing from the predictive
distribution of the missing covariates given observed data, thus creating a number of
imputed datasets. The full analysis (estimation of the propensity score then estima-
tion of the treatment effect) is performed separately in each imputed dataset [60].
The results are then combined using Rubin's rules to obtain an overall estimate of
the treatment effect and standard error [20,44,60]. Multiple imputation is very pow-
erful but also can be fairly complex. Guidelines regarding optimal use of multiple
imputation in conjunction with propensity score analysis have been proposed [60,61].
Another method that has been proposed is the missingness pattern approach,
which incorporates information about the pattern of missing variables into the
propensity score. My thesis focuses on this method, which avoids discarding in-
formation on individuals with missing confounder data and is relatively simple to
understand.
2.2.5 Using missingness patterns to handle missing
confounder data in propensity score analysis
Rosenbaum and Rubin (1984) and D'Agostino and Rubin (2000) proposed a gen-
eralized propensity score that additionally took into account information on miss-
ingness [46, 62]. The generalized propensity score is defined as the probability of
being assigned to treatment Z, given the observed covariates Xobs and the missing
indicator [46]:
e∗(X) = P (Z = 1|Xobs, R),
where e∗(X) denotes the generalized propensity score variable.
Rosenbaum and Rubin (1984) proved that adjusting for the generalized propen-
sity score balances on average the observed covariates and the observed-data indi-
cator (but not the unobserved data) [62], i.e.
Xobs, R ⊥ Z|e∗.
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To estimate the generalized propensity scores, Rosenbaum and Rubin (1984)
suggested fitting regression models for e∗(X) in each missingness pattern. Once
the estimated scores have been obtained and collected into one variable, the usual
propensity score methods can be used for analysis.
D'Agostino and Rubin (2000) stated that, assuming P (Z|X, Y (0), Y (1), R) =
P (Z|Xobs, R), this missingness pattern approch (MPA) can obtain valid causal in-
ferences and provide unbiased estimates of the ATE [46]. However, no explicit proof
is provided.
Mattei (2009) instead give the following assumptions for valid inference from the
MPA [63]:
P (Z|X, Y (0), Y (1), R) = P (Z|X,R),
and either P (Z|X,R) = P (Z|Xobs, R),
or P (Y (0), Y (1)|X,R) = P (Y (0), Y (1)|Xobs, R).
An extension of the MPA, suggested by D'Agostino et al. [64], is to estimate the
propensity scores in each missingness pattern for all subjects with data observed for
that pattern, but only retaining the scores for subjects who actually had that specific
pattern. Consequently, some subjects are used more than once in the estimation
procedure. However, they do not take into account the resulting correlation in the
data at the analysis stage.
2.3 Causal diagrams
A variable is defined a confounder if it is a member of some set of variables that is
sufficient to control for confounding [39]. When considering what variables could be
confounders, it can be helpful to draw a causal diagram to visualise the assumptions
being made in a given setting. Causal diagrams are useful for making explicit the
assumptions about a scenario's underlying causal structure as well as identifying a
set of measured variables (if such a set exists) that would be sufficient to account
for confounding.
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2.3.1 Introduction to causal diagrams
Causal diagrams are a visual representation of the causal relationships between
variables in a scenario of interest and are a useful tool for assessing conditional
independence statements under an assumed causal structure [65].
In graphs, nodes represent variables and directed arrows indicate causal relation-
ships between variables. We can visualise direct and indirect relationships between
variables by considering paths. A path between two variables is a unbroken sequence
of arrows between the variables, irrespective of arrow direction. Different paths be-
tween treatment and outcome variables, for example, represent the different ways
that treatment is associated with outcome, either directly or via other variables. A
directed path is a path where each arrow is in the same direction. We can describe
relationships between variables on a path using the concept of descendants. If there
is a directed path P → M → Q, we say that M and Q are descendants of P .
Directed acyclic graphs are graphs where all arrows are directed and there are no
cycles, i.e. directed paths that start and finish at the same variable. Causal directed
acyclic graphs, also known as causal diagrams, are directed acyclic graphs which
include all variables that are associated with two or more variables already included
in the graph.
For illustration, we consider a simplified version of our cohort study, introduced
in Chapter 1, looking at the relationship between prescription of ACEI/ARBs and
risk of AKI, where baseline CKD stage is the sole confounder (Figure 2.1). In this
simplified example, we assume (temporarily for illustrative purposes) that baseline
CKD stage is fully observed.
An example of a path in Figure 2.1 is the sequence of arrows from baseline CKD
stage to ACEI/ARB prescription, and from ACEI/ARB prescription to AKI. As each
arrow in this path is following the same direction, this is a directed path between
baseline CKD stage and AKI. In this path, the ACEI/ARB node and the AKI node
are descendants of the baseline CKD stage node, and AKI is also a descendant of
ACEI/ARB.
In Figure 2.1, there are two paths between treatment and outcome: the direct
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Figure 2.1: A causal directed acyclic graph representing confounding of the relationship
between prescription of angiotensin-converting enzyme inhibitors or angiotensin receptor
blockers (ACEI/ARBs) and risk of acute kidney injury (AKI), by baseline chronic kidney
disease (CKD) stage. All variables are fully observed.
arrow from ACEI/ARB prescription to AKI (the causal effect of interest), and the
sequence of arrows from ACEI/ARB prescription to baseline CKD stage, and from
baseline CKD stage to AKI.
After creating a causal diagram that represents our scenario of interest, using
clinical knowledge of the scenario, we can determine whether conditional indepen-
dence statements hold in that causal diagram by applying the d-separation rule.
2.3.2 The d-separation rule
The d-separation rule determines if two sets of variables (say A and B) are inde-
pendent when conditioning on a third set of variables (C) under an assumed causal
structure [66]. In order to define the d-separation rule, we first define colliders and
blocked paths.
For a particular path in a graph, a variable which has two incoming arrows is
called a collider for that path. In Figure 2.1, the AKI node is a collider for the path
from baseline CKD stage to ACEI/ARB prescription via AKI (i.e. the two arrows
`collide' at the AKI node).
A path may be blocked in two ways [4,66]: either (i) the path contains a collider
that is not in the conditioning set, and does not have any descendants in the con-
ditioning set; or (ii) the path contains a non-collider that is in the conditioning set.
If a path from A to B is not blocked, we say that this path is open, in which case,
A and B are associated. We say that C `d-separates' A and B if every path from A
to B is blocked by C. If C d-separates A and B, then we have A ⊥ B|C, i.e. A is
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conditionally independent of B given C.
2.3.3 Extensions of causal diagrams
Causal diagrams represent relationships between observed variables. However, re-
searchers often need to assess assumptions involving potential outcomes, rather than
observed outcomes. For example, the SITA assumption involves Y (0) and Y (1) in-
stead of Y . In order to incorporate potential outcomes into causal diagrams, we
consider Richardson and Robin's single world intervention graphs [67] and Balke
and Pearl's twin networks [68].
2.3.3.1 Single world intervention graphs
A single world intervention graph is obtained from a causal directed acyclic graph
by `splitting' the treatment variable into two components, separating the random
variable Z from the possible fixed values z treatment can take (eg. 0 or 1 for a bi-
nary treatment variable) [67]. The random variable part keeps the arrows entering
the original variable and the fixed value part keeps the arrows leaving the original
variable. A new graph is constructed for each possible treatment value and descen-
dants of the fixed treatment part are relabelled to reflect the effect of that particular
treatment. For example, when z = 0, Y  a descendant of Z in the original causal
diagram  becomes Y (0) and when z = 1, Y = Y (1).
Returning to our simplified example in Figure 2.1, we can split the ACEI/ARB
prescription variable to obtain the two single world intervention graphs in Figure
2.2. In Figure 2.2a, the ACEI/ARB prescription variable has been split into two
hemispheres: the random hemisphere (ACEI/ARB) and the fixed hemisphere repre-
senting the fixed value of no prescription. For convenience we can represent all values
in a single world intervention template (SWIT), where instead of setting treatment
to one particular value, we fix treatment equal to some value z, where z may be any
possible treatment value. A SWIT for our simple fully observed example is given in
Figure 2.3.
The d-separation rule can be applied to SWITs [67]. For example, we can apply
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(a) (b)
Figure 2.2: The single world intervention graphs resulting from splitting the treatment
variable in the graph in Figure 2.1 and intervening to: (a) not prescribe ACEI/ARBs, and
(b) prescribe ACEI/ARBs, with all variables fully observed.
Figure 2.3: The single world intervention template resulting from splitting the treatment
variable in the graph in Figure 2.1 and intervening to set the ACEI/ARB variable equal
to z = 0, 1, where z = 1 represents treatment (prescription of ACEI/ARBs) and z = 0
represents control (no ACEI/ARB prescription). All variables are fully observed.
the d-separation rule to Figure 2.3 to determine if AKI(z) ⊥ ACEI/ARB | baseline
CKD stage for z = 0, 1. The SWIT in Figure 2.3 contains only one path from
ACEI/ARB prescription to AKI(z) via baseline CKD stage. Conditioning on base-
line CKD stage blocks this path (since it is not a collider). Since the confounder
d-separates the treatment and outcome, ACEI/ARB prescription is conditionally in-
dependent of the corresponding potential AKI outcome, given baseline CKD stage.
Note that we cannot actually assess the SITA assumption as previously defined, as
each graph includes only one of the two outcomes, whereas the SITA assumption
involves the joint distribution of Y (1) and Y (0)  we are considering a weaker
version of the SITA assumption:
Z ⊥ Y (z)|X for z = 0, 1. (2.7)
The SITA assumption implies our weaker version in equation (2.7), but the converse
is not true [26].
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2.3.3.2 Twin networks
Researchers may sometimes need to assess whether conditional independence state-
ments involving both observed and counterfactual values of a variable are satisfied
in a particular scenario. In order to do this, an alternative to SWITs called twin
networks can be used, as described by Balke and Pearl (1994) [68] and Shpitser and
Pearl (2007) [69]. In brief, a twin network can be constructed from a directed acyclic
graph, which involves real world variables and relationships, by adding counterparts
of variables and relationships in the counterfactual world where treatment has been
intervened upon to be set to some realisation of the random variable Z.
Figure 2.4: A simple twin network.
X: partially observed confounder. Z: observed treatment allocation. Y : observed out-
come. Y (z): potential outcome resulting from intervening to set treatment to value z. R:
observed missingness indicator (=1 if X observed, =0 if X is missing). R(z): potential
missingness indicator (=1 if X observed in counterfactual world, =0 if X is missing in
counterfactual world). eY : unobserved error term between Y and Y (z). eR: unobserved
error term between R and R(z).
Figure 2.4 gives an example of a twin network in a simple scenario with a single
partially observed confounder, where treatment has a causal effect on missingness
and there are no unobserved common causes with missingness and other variables.
We can determine apply the d-separation rule to twin networks in the same way as
SWITs, conditioning only on the variables in the conditioning set of the assumptions.
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2.4 The MPA in the literature
Before investigating the statistical properties of the MPA and providing practical
recommendations for its use, it is important to understand when and how researchers
currently use this approach. Therefore, I initially planned to perform a systematic
review of the literature to provide a description of the methods used by researchers
to address the issue of missing confounder data in epidemiological studies analysed
using propensity scores. Specific objectives were to:
• Estimate the proportion of papers reporting the use of the MPA  and alter-
native approaches for propensity score analysis when some confounders are
partially observed
• Assess whether the assumptions underlying the validity of the methods em-
ployed were explicitly stated, and their plausibility discussed
• Among papers reporting the use of the MPA, describe the implementation of
the method (e.g. standard vs D'Agostino's extension of the approach [64],
missingness patterns pooling [70]) and the method used to estimate the vari-
ance of the treatment effect.
However, a systematic review with a similar scope was published by Malla et
al. [71] in the Journal of Comparative Effectiveness Research while I was at the
screening stage. To avoid duplication, it has been decided not to perform the sys-
tematic review, but the protocol and the search algorithm are detailed in Appendix
B together with the results of the screening strategy.
Malla et al. screened Embase (OvidSP) and Medline (OvidSP) to retrieve pub-
lications using propensity score methods in comparative effectiveness research be-
tween 1 January 2007 and 30 June 2017. Of the 167 papers included in their system-
atic review, 118 (71%) retrospectively analysed routine datasets, which emphasises
the importance of the development of guidance for handling missing data in this
setting.
Although missing data are almost systematic in routinely collected data, only
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86 articles (51%) provided information about how missing data were handled, and
62 (37%) reported the amount of missing data. Among papers reporting the use of
a missing data method, the most popular approach was complete record analysis
(n=53 (62%)), followed by multiple imputation (n=16 (19%)). These results were
expected given that complete record analysis is also the most common approach
to handle missing covariate data in multivariable regression. As for multiple im-
putation, it has been the focus of several methodological papers in the context of
propensity score analysis in the past few years [60, 61, 72], confirming an increasing
interest for this method.
The MPA was used in 3 articles only (3%) and the related missing indicator
approach was reported in 1 article. The remaining papers reported the use of a range
of single imputation methods. This distribution confirms the scarcity of studies using
the MPA in practice. Furthermore, the reasons for missingness were discussed in
12 papers, among which only 3 linked these reasons to the missingness mechanism.
This highlights a suboptimal reporting of missing data and missing data methods
for propensity score analysis, despite the availability of the STROBE guidelines
for the reporting of observational studies which includes specific items related to
missing data [73]. This could be explained by the difficulty to assess the assumptions
underlying the validity of the different approaches in real-life scenarios, especially
for the MPA, since its assumptions have not yet been explored in practice. Causal
diagrams could facilitate this investigation and encourage researchers to carefully
consider and report the reasons for missingness and the rationale for the choice of
the missing data methods.
42
Chapter 3
Understanding the assumptions
underlying the missingness pattern
approach
One potential explanation why the MPA is not often used by researchers is that
strategies for assessing assumptions underlying the MPA in practice have not been
discussed in prior literature. By using the causal diagrams introduced in Chapter 2
to visually represent scenarios of interest and the assumptions that we have made,
we can apply the d-separation rule to determine whether the MPA's assumptions
hold in a particular clinical scenario.
In this chapter, I explore the connections between the MPA and prior literature.
I then discuss how my use of causal diagrams evolved, driven by the nuances of the
MPA's assumptions.
3.1 Connections between the MPA's assumptions
and prior literature
In Chapter 2, our statement of the MPA's assumptions follows Mattei's statement
of assumptions sufficient for valid inference using the MPA [63]. Whereas Mattei
(2009) used conditional independence statements that hold jointly for the potential
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outcomes, we use weaker statements that hold separately for each potential outcome.
D'Agostino and Rubin (2000) instead asserted that, under the following assumption,
using generalized propensity scores can provide unbiased estimates of the ATE [46].
P (Z|X, Y (0), Y (1), R) = P (Z|Xobs, R) . (3.1)
We can also express Mattei's assumptions (i.e. the stronger versions of the
mSITA, CIT and CIO assumptions) using conditional probabilities:
strong mSITA: P (Z|X, Y (0), Y (1), R) = P (Z|X,R) (3.2)
CIT: P (Z|X,R) = P (Z|Xobs, R) (3.3)
strong CIO: P (Y (0), Y (1)|X,R) = P (Y (0), Y (1)|Xobs, R) (3.4)
Note that Mattei's `stronger' version of the CIT assumption (3.3) is the same as our
CIT assumption, since it does not involve potential outcomes.
Substituting the right-hand side of equation (3.3) into the right-hand side of
equation (3.2) gives the assumption in equation (3.1) as defined by D'Agostino and
Rubin [46]. Thus Mattei's statement of the mSITA and CIT assumption imply the
assumption given by D'Agostino and Rubin (2000).
Furthermore, assumptions (3.2) and (3.4) can hold whilst assumption (3.1) is
violated. Thus Mattei (2009) gives a wider set of assumptions than D'Agostino and
Rubin (2000) under which the MPA can give valid inference.
Other work exploring non-systematic monitoring of time-varying covariates [74,
75] suggest a version of the no unmeasured confounding assumption which, in the
single time-point exposure setting, can be written as:
Z ⊥ Y (z)|Xobs, R. (3.5)
If the D'Agostino and Rubin assumption (3.1) holds, then assumption (3.5) holds.
Furthermore, if either the mSITA and CIT assumptions hold, or the mSITA and
CIO assumptions hold, then assumption (3.5) holds. The mSITA, CIT and CIO
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assumptions can be seen as a wider set of assumptions under which variants of
missingness-pattern-type approaches can produce valid inference. All three sets of
assumptions seem likely to be satisfied in a setting where missing confounder values
are unavailable to the individual making the treatment decision and thus do not
affect treatment. However, only Mattei's statement of the assumptions, with CIT
and CIO as two separate sub-assumptions, makes it clear that there is another quite
different set of scenarios in which missingness-pattern-type methods may provide
valid inference.
3.2 Using weaker versions of the MPA's
assumptions
Mattei (2009) states three assumptions under which the MPA leads to valid infer-
ence [63]. I present weaker versions of these assumptions and prove that, under
these assumptions, the MPA still gives a consistent estimator of the ATE. The first
assumption is an extension of the SITA assumption (equation (2.1)), which I call the
Missingness Strongly Ignorable Treatment Assignment (mSITA) assumption due to
its similarities with the SITA assumption (equation (2.1)):
mSITA: Z ⊥ Y (z)|X,R for z = 0, 1. (3.6)
A key difference comparing assumption (3.6) with the weaker version of equation
(2.1) is the inclusion of information about the missingness pattern, represented by
R, in the conditioning set. We assume that SITA holds in the full data, thus this
assumption states that additionally conditioning on R does not introduce bias.
I call the two further assumptions [63]: the conditionally independent treatment
(CIT) assumption and the conditionally independent outcomes (CIO) assumption.
CIT: Z ⊥ Xmis|Xobs, R
CIO: Y (z) ⊥ Xmis|Xobs, R for z = 0, 1.
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If mSITA holds, and either CIT or CIO holds, then the MPA provides a consis-
tent estimate of the treatment effect. I refer to these assumptions as the `MPA's
assumptions'. To prove that the weaker versions of the MPA's assumptions lead
to a consistent estimator of the ATE, I first show that, under these assumptions,
E[(1− Z)Y/(1− e∗)] = E[Y (0)].
First, using the consistency assumption and conditioning on the missing indicator
and observed confounder values, we have that:
E
[
ZY
e∗
]
= E
[
ZY (1)
e∗
]
= E
[
E
[
ZY (1)
e∗
|Xobs, R
]]
= E
[
1
e∗
E
[
ZY (1)|Xobs, R
]]
. (3.8)
Switching briefly to summation notation:
E
[
ZY (1)|Xobs, R
]
=
∑
z
∑
y
zyP (Z = z|Xobs, R)P (Y (1) = y|Z,Xobs, R)
=
∑
z
∑
y
zyP (Z = z|Xobs, R)
∑
x
P (Y (1) = y,Xmis = x|Z,Xobs, R)
=
∑
z
∑
y
∑
x
zyP (Z = z|Xobs, R)P (Y (1) = y|Z,Xmis, Xobs, R)
× P (Xmis = x|Z,Xobs, R)
Using mSITA (Z ⊥ Y (z)|X,R for z = 0, 1) and CIT (Z ⊥ Xmis|Xobs, R), we
have that P (Y (1) = y|Z,Xmis, Xobs, R) = P (Y (1) = y|Xmis, Xobs, R) and P (Xmis =
x|Z,Xobs, R) = P (Xmis = x|Xobs, R) respectively. Hence:
E
[
ZY (1)|Xobs, R
]
=
∑
z
∑
y
∑
x
zyP (Z = z|Xobs, R)P (Y (1) = y|Xmis, Xobs, R)P (Xmis = x|Xobs, R)
=
∑
z
∑
y
zyP (Z = z|Xobs, R)
∑
x
P (Y (1) = y,Xmis = x|Xobs, R)
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=
∑
z
∑
y
zyP (Z = z|Xobs, R)P (Y (1) = y|Xobs, R)
=
∑
z
zP (Z = z|Xobs, R)
∑
y
yP (Y (1) = y|Xobs, R)
= E
[
Z|Xobs, R
]
E
[
Y (1)|Xobs, R
]
We can also show that E
[
ZY (1)|Xobs, R
]
= E
[
Z|Xobs, R
]
E
[
Y (1)|Xobs, R
]
using
mSITA with CIO (Y (z) ⊥ Xmis|Xobs, R for z = 0, 1):
E
[
ZY (1)|Xobs, R
]
=
∑
z
∑
y
zyP (Y (1) = y|Xobs, R)P (Z = z|Y (1), Xobs, R)
=
∑
z
∑
y
zyP (Y (1) = y|Xobs, R)
∑
x
P (Z = z,Xmis = x|Y (1), Xobs, R)
=
∑
z
∑
y
∑
x
zyP (Y (1) = y|Xobs, R)P (Z = z|Y (1), Xmis, Xobs, R)
× P (Xmis = x|Y (1), Xobs, R)
Under mSITA, P (Z = z|Y (1), Xmis, Xobs, R) = P (Z = z|Xmis, Xobs, R), and
under CIO, P (Xmis = x|Y (1), Xobs, R) = P (Xmis = x|Xobs, R). Hence:
E
[
ZY (1)|Xobs, R
]
=
∑
z
∑
y
∑
x
zyP (Y (1) = y|Xobs, R)P (Z = z|Xmis, Xobs, R)P (Xmis = x|Xobs, R)
=
∑
z
∑
y
zyP (Y (1) = y|Xobs, R)
∑
x
P (Z = z,Xmis = z|Xobs, R)
=
∑
z
∑
y
zyP (Y (1) = y|Xobs, R)P (Z = z|Xobs, R)
=
∑
z
zP (Z = z|Xobs, R)
∑
y
yP (Y (1) = y|Xobs, R)
= E
[
Z|Xobs, R
]
E
[
Y (1)|Xobs, R
]
Thus, the MPA's assumptions enable us to rewrite equation 3.8 as follows:
E
[
ZY
e∗
]
= E
[
1
e∗
E
[
Z|Xobs, R
]
E
[
Y (1)|Xobs, R
]]
.
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Since e∗ = E[Z|Xobs, R]:
E
[
ZY
e∗
]
= E
[
E
[
Y (1)|Xobs, R
]]
= E[Y (1)].
This proof is reproduced in Appendix A of the research paper pre-print in Chap-
ter 5.
It can similarly be shown that E[(1−Z)Y/(1− e∗)] = E[Y (0)] under the MPA's
assumptions.
3.2.1 The MPA's connection to Rubin's taxonomy of
missing data
The assumptions underlying the MPA are separate from Rubin's taxonomy of miss-
ing data (i.e. classification of missingness mechanisms into: missing completely at
random, missing at random, and missing not at random [20]) in the sense that clas-
sifying data according to Rubin's taxonomy does not give us any information as
to whether the MPA's assumptions would hold. For instance, one might intuitively
expect that if data are missing completely at random, the MPA's assumptions would
hold, as many missing data methods are appropriate under this assumption. How-
ever this is not true, as can be seen in the counterexample in Figure 3.1a where,
although the confounder data is missing completely at random since the observed-
confounder indicator (R) is not affected by any other variables, the MPA is not
appropriate because the confounder values directly affect both treatment and out-
come for patients with R = 0, violating both the CIT and CIO assumptions.
Conversely, one might expect that having confounder data missing not at random
would mean that the MPA is not appropriate. This is also not true, as can be seen
in the counterexample in Figure 3.1b. In this graph, missingness of the confounder
depends on the confounder itself and so data are missing not at random. Applying
d-separation to this scenario, we find that the mSITA assumption holds (since Z
and Y (z) are not associated given X and R) and that the CIT assumption holds
(since Z and Xmis are not associated given Xobs and R), and thus the MPA is
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(a) (b)
Figure 3.1: (a) An example of a single world intervention graph template, conditioning
on R = 0, under a missing completely at random mechanism. In this example, the MPA's
assumptions do not hold. (b) An example of a single world intervention graph template,
conditioning on R = 0, under a missing not at random mechanism. In this example, the
MPA's assumptions hold.
appropriate here. Despite the data being missing not at random, since the mSITA
and CIT assumptions hold here, the MPA is appropriate in this scenario. Thus,
classification of the missingness mechanism according to Rubin's taxonomy does
not provide information as to whether the MPA's assumptions will hold; instead,
the plausibility of the MPA's assumptions depends on which relationships between
variables exist in the subgroup of patients with missing confounder values.
3.3 The evolution of causal diagrams for assessing
the MPA's assumptions
In Section 2.3.3.1, we demonstrated how to apply d-separation in a simple single
world intervention template (SWIT) representing a simplified version of the mo-
tivating example with a single fully observed confounder, baseline chronic kidney
disease (CKD) stage (Figure 2.3). We now consider the situation where baseline
CKD stage is partially observed, letting RCKD denote the corresponding missing
indicator variable.
By simply incorporating RCKD as another variable in the SWIT, we obtain
the SWIT in Figure 3.2, which additionally assumes that RCKD is associated with
ACEI/ARB prescription via an unobserved common cause (denoted U). Applying
d-separation to this template will allow us to assess the mSITA assumption, i.e.
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Figure 3.2: Extension of the single world intervention template in Figure 2.3 where the
missingness of baseline chronic kidney disease stage is associated with treatment. RCKD
denotes the missing indicator for baseline CKD stage. U denotes an unobserved common
cause of RCKD and treatment. z = 0, 1, where z = 1 represents prescription of ACEI/ARBs
and z = 0 represents no ACEI/ARB prescription.
ACEI/ARB: angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, AKI:
acute kidney injury. CKD: chronic kidney disease.
to determine whether  after conditioning on baseline CKD stage and RCKD 
ACEI/ARB prescription and AKI(z) are conditionally independent (for z = 0, 1).
Since the only path from ACEI/ARB to AKI(z) in Figure 3.2 is blocked by baseline
CKD stage and RCKD, the mSITA assumption holds.
However, we cannot use the SWIT in Figure 3.2 to check whether the CIT and
CIO assumptions hold, as these assumptions involve the observed and missing values
of the confounder separately. Indeed, a necessary condition for one of the CIT and
CIO assumptions to hold is that baseline CKD stage is a confounder only when it is
observed, and so relationships between confounder values and treatment or outcome
must differ depending on whether the confounder values are observed or missing.
We considered two strategies to be able to assess the CIT and CIO assumptions
in SWITs. We initially split the confounder node into two separate nodes: a node
representing the observed baseline CKD stage values and a node representing the
missing baseline CKD stage values. Our second strategy was to construct a SWIT
restricted to the missingness pattern for the subgroup of patients with missing values.
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Figure 3.3: Extension of the single world intervention template in Figure 3.2 where
the missingness of baseline CKD stage is associated with treatment, modified to separate
the observed and missing components of baseline CKD stage. RCKD denotes the missing
indicator for baseline CKD stage. U denotes an unobserved common cause of measurement
of baseline CKD stage (i.e. RCKD) and treatment. z = 0, 1, where z = 1 represents
prescription of ACEI/ARBs and z = 0 represents no ACEI/ARB prescription. Bold arrows
indicate deterministic relationships.
ACEI/ARB: angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, AKI:
acute kidney injury. CKD: chronic kidney disease.
3.3.1 SWITs with separate confounder nodes
Our first strategy incorporated the observed and missing baseline CKD stage values
separately into the SWIT, using bold arrows to represent their deterministic relation-
ships with the full baseline CKD stage variable and RCKD. For example, the bold
arrows in Figure 3.3 indicate that the variables representing observed and missing
values are each fully determined by RCKD and the baseline CKD stage variable by
construction. Figure 3.3 also encodes the assumption that the missing values of base-
line CKD stage do not affect prescription of ACEI/ARBs (represented by the absence
of an arrow from the missing baseline CKD stage node to the ACEI/ARB node).
This seems plausible as when baseline CKD stage is not available to the General
Practitioner, it cannot be used to decide whether or not to prescribe ACEI/ARBs.
We also assume that the missing values of baseline CKD stage directly affect risk of
AKI (represented by the presence of an arrow from the missing baseline CKD stage
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node to the AKI node) since baseline CKD stage is associated with risk of kidney
disease, whether it is observed or missing.
When using SWITs with separate confounder nodes, the presence of determin-
istic relationships means that extra conditional independencies hold that are not
implied by the graph. Thus d-separation is not complete: d-separation does not
identify all possible conditional independencies [67, 76]. In our simplified example,
this means that if, for instance, we determine that treatment and the missing con-
founder values are not d-separated in the SWIT (given the observed confounder
values and the observed-confounder indicator), then we would conclude that CIT
does not hold. However, lack of completeness implies the CIT assumption might
still hold. Consequently, caution must be exercised when we do not find that a
particular conditional independence holds, and we must consider the deterministic
relationships and clinical knowledge to decide if the assumption truly does or does
not hold.
Figure 3.4: Extension of the single world intervention template in Figure 3.2 where
the missingness of baseline CKD stage is associated with treatment, restricted to the
missingness pattern with missing baseline CKD stage values (i.e. RCKD = 0). U denotes
an unobserved common cause of measurement of baseline CKD stage (i.e. RCKD) and
treatment. z = 0, 1, where z = 1 represents prescription of ACEI/ARBs and z = 0
represents no ACEI/ARB prescription.
ACEI/ARB: angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, AKI:
acute kidney injury. CKD: chronic kidney disease.
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3.3.2 SWITs by missingness pattern
In order to avoid the difficulties in applying d-separation to SWITs with determinis-
tic arrows, we developed an alternative strategy for constructing SWITs to be used
for assessing the CIT and CIO assumptions. Instead of splitting the confounder
node, we constructed a SWIT for the subgroup of patients with missing confounder
values (i.e. for the missingness pattern R = 0), using a square node to denote re-
striction to this missingness pattern (Figure 3.4).
We can apply the d-separation rule to this modified SWIT in the same way
as a normal SWIT. This will allow us to assess the CIT and CIO assumptions.
To explain this, we can rewrite the CIT and CIO assumptions separately for each
missingness pattern in a simple situation with a single partially observed confounder
X. For the subgroup of patients with X observed, the CIT and CIO assumptions,
Z ⊥ ∅|X,R = 1, and Y (z) ⊥ ∅|Xobs, R = 1, respectively, are trivially true because
Xmis is empty (= ∅) given R = 1. In the subgroup of patients with X missing, the
assumptions become: Z ⊥ X|R = 0, and Y (z) ⊥ X|R = 0, respectively. Thus, we
can construct SWITs restricted to the missingness pattern R = 0 in order to assess
the CIT and CIO assumptions under an assumed causal structure.
In Figure 3.4, the only path connecting Z and X passes through Y (z), a collider
on the path; thus applying the d-separation rule shows that Z and X are condition-
ally independent (in the subgroup with R = 0). Hence the CIT assumption holds.
However, the CIO assumption does not hold as there is a direct arrow from X to
Y (z). Thus, in this example, the mSITA and CIT assumptions hold and hence the
MPA can obtain valid inference.
We have demonstrated how to construct SWITs for a given scenario and applied
the d-separation rule to the SWITs to determine whether the mSITA, CIT and
CIO assumptions were plausible. We now develop guidance to investigate when the
MPA's underlying assumptions hold.
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Chapter 4
Guidance for assessing the
assumptions underlying the
missingness pattern approach
A key purpose of this thesis was to create guidance for assessing the assumptions
under which valid inference can be obtained from missing confounder methods in-
corporating missingness information. In this section, I discuss the process of devel-
oping this guidance. We have developed guidance for researchers seeking to decide
whether the MPA's assumptions are plausible in a particular clinical setting, and
thus whether the MPA is an appropriate method for dealing with missing confounder
data in the setting of interest. We developed our guidance by considering a variety of
scenarios and applying d-separation to SWITs representing each of these scenarios.
Initially, we developed a framework in the form of a decision-tree (Figure 4.1).
The intended purpose of this framework was to elucidate the clinical assumptions
underlying the validity of the MPA. In this early framework, we considered the
temporal order of the missingness relative to the confounder, treatment and outcome
variables, however, we found that this was too restrictive. Our current guidance,
given in a step-by-step format, instead focuses on considering the plausibility of
key violations and constructing a causal diagram to help assess the validity of the
assumptions. We will first describe the development of the decision-tree framework.
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Figure 4.1: Framework to decide if the missingness pattern approach (MPA) is appropri-
ate when treatment allocation and outcome are fully observed and there is one partially
observed confounder.
mSITA: missingness strongly ignorable treatment allocation assumption. CIT: condition-
ally independent treatment assumption. CIO: conditionally independent outcomes as-
sumption.
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4.1 Development of the early framework for
investigating the MPA's assumptions in
practice
Our initial attempts to develop guidance were restricted to settings with a fully
observed binary treatment, a fully observed outcome and a single partially observed
confounder.
In these initial explorations, to assess the mSITA assumption, we applied d-
separation to conventional SWITs. In order to assess the CIT and CIO assumptions,
we applied d-separation to our modified SWITs which incorporated the observed and
missing parts of the confounder separately and thus involve deterministic relation-
ships.
We considered a variety of scenarios to allow us to produce general conclusions
about when the MPA's underlying assumptions can be expected to hold. In order
to achieve this, we considered three key issues, namely: (i) relationships between
missing confounder values and treatment or outcome, (ii) temporal order of variables,
and (iii) relationships between missingness and confounder, treatment or outcome.
4.1.1 Relationships between missing confounder values and
treatment or outcome
Recall that, in order for at least one of the CIT and CIO assumptions to hold, we
require X to be a confounder only when it is observed. Thus, for the MPA to be an
appropriate method, relationships between confounder values and either treatment
or outcome must differ depending on whether the confounder values are observed or
missing.
4.1.2 Temporal order of variables
A requirement for treatment to have a causal effect on outcome is that treatment
temporally precedes outcome [34]. We have also been implicitly assuming that our
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confounders precede treatment. We now consider where missingness appears in this
temporal order.
Missingness is often considered to be external to the causal structure, i.e. the
relationships between confounders, treatment and outcome are the same whether or
not the values of these variables are measured. However, as previously mentioned, for
the CIT or CIO assumptions to hold we require that relationships between treatment
or outcome with confounder values must differ depending on missingness. We assume
that: for the relationship between treatment and confounder values to differ by
missingness, R must occur temporally prior to Z, and for the relationships between
outcome and confounder values to differ by missingness, R must occur prior to Y (z).
Thus, we assume that R always occurs temporally before Y (z).
Furthermore, we assume that R occurs after X, since a patient's stage of CKD
at the baseline visit exists prior to the assessment of that stage being made (or not
made).
4.1.3 Relationships between missingness and confounder,
treatment or outcome
Missingness can be associated with values of the confounder, treatment and outcome.
When missingness is considered to be external to the causal structure, such associa-
tion is thought to arise either through the variables directly causing the missingness,
or via shared common causes of missingness and the variables under study. In our
case, as discussed above, missingness is part of the causal structure and can affect
the values of, and the relationships between, study variables. This creates a third
possibility: that association arises due to missingness affecting confounder, treat-
ment or outcome values. Thus the way in which the association between missingness
and study variables arises can impact on the validity of the MPA's assumptions.
There are three ways in which associations between missingness and treatment
may arise. First, missingness has a direct effect on treatment (when missingness
occurs temporally prior to treatment). Second, treatment has a direct effect on
missingness (when treatment precedes missingness). Third, treatment and missing-
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ness share a common cause.
There are two ways in which associations may arise between missingness and
confounder values (under our assumption that R occurs temporally after X). First,
the confounder values have a direct effect on missingness. Second, X and R share a
common cause.
There are two ways in which associations may arise between missingness and
outcome (under our assumption that missingness temporally precedes outcome).
First, missingness has a direct effect on outcome. Second, missingness and outcome
share a common cause.
Hence we need to carefully consider the relationships between missingness and
each of the confounder, treatment and outcome when deciding whether the MPA's
assumptions seem plausible.
4.1.4 Application of the early framework to the illustrative
example
To demonstrate how the framework can be used in practice, we now apply the
framework in Figure 4.1 to the cohort study described in Section 1.1.
Given observed confounders, is missingness associated with
both treatment and outcome?
The first decision in the framework is to decide whether or not missingness is as-
sociated with both treatment and outcome, given observed confounders. In other
words, to decide if we expect the missingness reason to have unobserved common
causes with each of treatment and outcome.
CKD stage: Missingness in baseline CKD stage is more likely for patients ex-
pected to have a higher risk of kidney disease due to age, chronic comorbidities
or prescription of medicines that may interfere with renal function. Whilst these
risk factors are associated with missingness and treatment or outcome, they are
already captured and accounted for in the electronic health records. So with re-
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spect to baseline CKD stage, it seems plausible that missingness is not associated
with both treatment and outcome, given observed confounders.
Ethnicity: With respect to ethnicity, missingness may be caused by service-level
factors such as the circumstances at the time patients are admitted [13]. We
believe that these factors are unlikely to also be determinants of treatment or
risk factors for AKI, and so it seems plausible that missingness of ethnicity is not
associated with both treatment and outcome.
Thus we can follow the No arrow from the first yellow decision box in Figure 4.1,
finding that mSITA is expected to hold for our case study.
When does confounder missingness occur?
CKD stage: CKD stage, a measure of kidney function, was defined at baseline,
i.e. prior to treatment by definition.
Ethnicity: Ethnicity is also recorded (or not recorded) before treatment is allo-
cated, for example when patients register at a general practice.
So we follow the Before treatment allocation arrow to the red decision box.
Do missing confounder values directly affect treatment
allocation?
CKD stage: If baseline CKD stage is not available, this unobserved information
cannot be used to determine the General Practitioner's treatment decision whether
or not to prescribe ACEI/ARBs.
Ethnicity: If the General Practitioner believes that ethnicity is important, it is
more likely to be recorded.
It seems plausible that baseline CKD stage and ethnicity affect treatment allocation
only when they are measured and so we follow the No arrow in the decision-tree
to the left-hand blue decision box.
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Do missing confounder values directly affect outcome?
CKD stage: Baseline CKD stage (whether observed or missing) is associated
with risk of kidney disease.
Since at least one of the confounders affect outcome even when not measured, we
follow the Yes arrow from the left-hand blue decision box and we find that here,
we do not expect the CIO to hold.
Given observed confounders, is missingness associated with
both confounder and treatment allocation?
Again, we expect that common causes of missingness and prescription of ACEI/ARBs
are already accounted for in our analysis and thus we follow the No arrow from the
lowest yellow decision box, finding that we expect that the CIT assumption holds.
Result of applying the framework to the cohort study: Based on the as-
sumptions regarding the clinical scenario described above, we conclude that it is
plausible that (although the CIO assumption does not hold) the mSITA and CIT
assumptions hold and thus the MPA is appropriate.
4.2 Current guidance for assessing the MPA's
assumptions in practice
In our early guidance, we considered the temporal order of the missingness relative
to the confounder, treatment and outcome variables, considering settings where
missingness occurs after confounder and before outcome. However, this was too
restrictive and did not allow for scenarios where data is collected retrospectively but
the reason for missingness affected treatment assignment and/or outcome. Another
limitation of the early framework was ambiguity in Figure 4.1 regarding the text
descriptions of violations that could occur. This early guidance was developed using
single world intervention graph templates where the confounder node is split into
its observed and missing components.
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When developing our current guidance, we decided against using graphs with
separate missing and observed confounder nodes, in order to avoid difficulties when
applying the d-separation rule in the presence of deterministic relationships, and
chose to use graphs which condition on missingness pattern. This change in the type
of causal diagram used to develop guidance lead to a change in the presentation of
the guidelines, resulting in a step-by-step format. In our current guidance, we forego
the temporal restriction, and focus on considering the plausibility of key violations
and constructing causal diagrams to help assess the validity of the assumptions.
We also endeavoured to provide clearer explanations of violations, aided by causal
diagrams. This guidance is given in the Chapter 5 pre-print, in Section 5.9.
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5.1 Overview of the research paper pre-print:
Propensity scores using missingness pattern
information: a practical guide
In the following research paper pre-print, we explore assumptions under which the
MPA can obtain valid inference. After introducing the MPA and the method's
underlying assumptions, we discuss the plausibility of the CIT and CIO assumptions
using two illustrative examples. The first example describes a clinical scenario where
the CIT assumption seems plausible, whilst the second considers a scenario where
the CIO assumption seems plausible. We describe how we can use causal diagrams to
assess the plausibility of the MPA's assumptions and provide guidance for assessing
these assumptions in a given clinical setting. We then illustrate this guidance in
detail using our motivating study.
5.2 Abstract
Electronic health records are a valuable data source for investigating health-related
questions, and propensity score analysis has become an increasingly popular ap-
proach to address confounding bias in such investigations. However, because elec-
tronic health records are typically routinely recorded as part of standard clinical
care, there are often missing values, particularly for potential confounders. In our
motivating study  using electronic health records to investigate the effect of renin-
angiotensin system blockers on the risk of acute kidney injury  two key confounders,
ethnicity and chronic kidney disease stage, have 59% and 53% missing data, respec-
tively.
The missingness pattern approach (MPA), a variant of the missing indicator ap-
proach, has been proposed as a method for handling partially observed confounders
in propensity score analysis. In the MPA, propensity scores are estimated sepa-
rately for each missingness pattern present in the data. Although the assumptions
underlying the validity of the MPA are stated in the literature, it can be difficult in
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practice to assess their plausibility.
In this paper, we explore the MPA's underlying assumptions by using causal
diagrams to assess their plausibility in a range of simple scenarios, drawing general
conclusions about situations in which they are likely to be violated. We present a
framework providing practical guidance for assessing whether the MPA's assump-
tions are plausible in a particular setting and thus deciding when the MPA is appro-
priate. We apply our framework to our motivating study, showing that the MPA's
underlying assumptions appear reasonable, and we demonstrate the application of
MPA to this study.
5.3 Introduction
Observational data are an important source of information for investigating the effect
of treatments or interventions on health outcomes. In observational data, confound-
ing is often an issue, as characteristics of treated patients can systematically differ
from those of untreated patients. Propensity score methods aim to take account
of confounding by achieving balance of patient characteristics across the treatment
groups being compared. [33] However, observational studies may suffer from large
amounts of missing data, which can lead to biased treatment effect estimates if the
missing data are not handled appropriately. [50] We focus on scenarios where the
outcome and treatment of interest are fully observed, but data are missing on po-
tential confounders. This is a common occurrence, for example, in studies using
electronic health record data and insurance claims data, where prescriptions and di-
agnoses tend to be well recorded but potential confounders, such as smoking status,
may be less well recorded. [7]
The `missingness pattern' approach (MPA) is a way of handling missing con-
founder data that has been proposed in propensity score analysis. [46,62] It accounts
for missing data by incorporating information about which confounders are missing
into the estimation of the propensity score itself. [46, 62] Despite being easy to im-
plement, the MPA has not been widely used in practice. This might be explained
by the lack of guidance about its use in the literature. In particular, while the
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assumptions required for the validity of the MPA have been described formally in
terms of conditional independence, [46, 62, 63] how these mathematical statements
relate to real clinical scenarios remains unclear. Our aim is therefore to investigate
the assumptions underlying the MPA in order to provide practical guidance for re-
searchers about how to identify whether these assumptions hold in a given clinical
scenario.
We start by introducing our motivating example which investigates the asso-
ciation between renin-angiotensin system drugs and risk of acute kidney injury in
Section 5.4. We review propensity score methods for complete data (Section 5.5)
and approaches to handle missing confounder data in propensity score analysis, with
a particular focus on the MPA and the related missing indicator approach (Section
5.6). We discuss the plausibility of the assumptions underlying the MPA in Sec-
tion 5.7. We use causal diagrams to evaluate the assumptions in Section 5.8 and
present a framework giving practical guidance for assessing these assumptions in
Section 5.9. We illustrate our results on our motivating example (Section 5.10) and
conclude with a discussion (Section 5.11).
5.4 Motivating Example
We consider data from a cohort study using electronic health records to investi-
gate the association between use of angiotensin-converting enzyme inhibitors or
angiotensin receptor blockers (ACEI/ARBs) and risk of acute kidney injury (AKI)
in new users of antihypertensive drugs. [11]
Data were obtained from the UK Clinical Practice Research Datalink linked to
the Hospital Episode Statistics database for adults who were new users of antihyper-
tensive drugs between 1997-2014. Follow-up began at the first prescription of any of
the antihypertensive drugs: ACEI/ARBs, beta blockers, calcium channel blockers
or diuretics. Our treatment of interest is ACEI/ARB prescription at the start of
follow-up, and the outcome is AKI within 5 years. Potential confounders considered
are: gender; age; ethnicity; prescription of other antihypertensive drugs at start
of follow-up; and status of chronic comorbidities at start of follow-up, including
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Table 5.1: Patient characteristics by prescription of ACEI/ARBs
Baseline Prescribed ACEI/ARB
Characteristic Yes (n (%)) No (n (%))
(Total = 159,389) (Total = 411,197)
Age (years) 18 to 42 16,616 (10.4%) 94,265 (22.9%)
43 to 53 39,541 (24.8%) 77,224 (18.8%)
54 to 62 36,325 (22.8%) 77,985 (19.0%)
63 to 71 30,667 (19.2%) 75,141 (18.3%)
≥ 72 36,240 (22.7%) 86,582 (21.1%)
Sex Female 62,652 (39.3%) 236,296 (57.5%)
Chronic ≤ Stage 2 88,826 (55.7%) 146,825 (35.7%)
Kidney Stage 3a 10,535 (6.6%) 15,489 (3.8%)
Disease Stage 3b 2,728 (1.7%) 3,127 (0.8%)
Stage Stage 4 457 (0.3%) 551 (0.1%)
Missing 56,843 (35.7%) 245,205 (59.6%)
Ethnicity White 63,791 (40.0%) 153,747 (37.4%)
South Asian 3,072 (1.9%) 4,734 (1.2%)
Black 1,065 (0.7%) 3,905 (0.9%)
Mixed 237 (0.1%) 681 (0.2%)
Other 814 (0.5%) 1,623 (0.4%)
Missing 90,410 (56.7%) 246,507 (59.9%)
Comorbidities:
Diabetes Mellitus Yes 44,727 (28.1%) 38,714 (9.4%)
Ischaemic Heart Disease Yes 42,214 (26.5%) 76,013 (18.5%)
Arrhythmia Yes 17,494 (11.0%) 39,094 (9.5%)
Cardiac Failure Yes 18,647 (11.7%) 13,074 (3.2%)
Hypertension Yes 124,340 (78.0%) 240,135 (58.4%)
Other anti-hypertensives:
Beta-blocker Yes 14,666 (9.2%) 205,156 (49.9%)
Calcium Channel Blocker Yes 3,501 (2.2%) 91,912 (22.4%)
Diuretic Yes 21,950 (13.8%) 129,582 (31.5%)
Abbreviations:
ACEI/ARBs: Angiotensin-converting enzyme inhibitors or angiotensin receptor
blockers
Diuretic: Thiazide diuretics, Loop diuretics or Potassium sparing diuretics
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chronic kidney disease (CKD) stage. Table 5.1 shows the baseline characteristics of
the cohort. Of the 570,586 patients included in the cohort, 159,389 (27.9%) were
prescribed an ACEI/ARB. Many characteristics are not balanced across the treat-
ment groups, indicating potential for confounding. Propensity score analysis is a
popular method for taking account of confounding in analysis of electronic health
records. However, two potential confounders have missing data: ethnicity (59.0%
missing) and baseline CKD stage (52.9% missing). Only 121,527 (21%) of patients
have complete data for both variables.
5.5 Propensity score methods for complete data
5.5.1 Notation and assumptions
Suppose we have a group of n patients, each with a row vector Xi of p confounders:
Xi = (Xi1, ..., Xip)
>, where Xij is the value of confounder j for patient i (i = 1, . . . , n
and j = 1, . . . , p). Throughout the paper, we will assume that in the full data (i.e.
with no missing confounder data) theXi are sufficient to control for confounding. [39]
In this paper, we restrict our attention to a binary treatment (or exposure) and a
binary outcome. Patient i receives either treatment Zi = 1 or control Zi = 0. Each
patient has two potential outcomes: Yi(1) denotes the outcome that would have
been observed for patient i if they had received treatment, and Yi(0) denotes the
outcome value that would have been observed if patient i had received control. [10]
Yi denotes the outcome value that was actually observed. Henceforth, we omit the i
and j subscripts where unambiguous. Our estimand is the average treatment effect
(ATE): E[Y (1)− Y (0)]. [25,26] While the odds ratio suffers from non-collapsibility,
the risk ratio does not and provides an alternative relative measure; results in this
paper follow similarly for this estimand.
To estimate the treatment effect we make four standard assumptions: consis-
tency, no interference, strongly ignorable treatment assignment (SITA), and posi-
tivity. Consistency states that, for a patient who receives a particular treatment
level z, their observed outcome Y is the corresponding potential outcome Y (z), irre-
69
spective of the way in which they were assigned to that treatment level. [31] Under
the assumption of no interference, the treatment received by one patient does not
affect the potential outcomes of another patient. [3335] SITA implies that there are
no unmeasured confounders and can be expressed as [23,33]:
SITA : Z ⊥ (Y (1), Y (0))|X. (5.1)
where ⊥ denotes independence. Finally, positivity states that, given their individual
characteristics, all patients have a non-zero probability of receiving either treatment
or control. [23, 37] Throughout this paper, we assume these four assumptions hold
for the complete data.
5.5.2 Propensity scores
The propensity score e(x) is the probability of receiving treatment, conditional on
observed confounders X [33]:
ei(xi) = P (Zi = 1|Xi = xi),
for patient i (i = 1, . . . , n) with a vector of confounder values Xi = xi. Under the
four assumptions described above, Rosenbaum and Rubin showed that at each value
of the propensity score the confounders X are balanced across treatment groups. [33]
Typically, propensity scores are unknown and must be estimated from the data,
often as the predictions, eˆi, from a logistic regression of treatment allocation on po-
tential confounders. [28] We use inverse probability of treatment weighting (IPTW),
which creates weights from the estimated propensity scores to construct `pseudo-
populations' [36] in which the distribution of observed confounders are balanced
across treatment groups, resulting in the following estimator [28]:
ÂTE =
(∑n
i=1
YiZi
eˆi∑n
i=1
Zi
eˆi
)
−
(∑n
i=1
Yi(1−Zi)
(1−eˆi)∑n
i=1
(1−Zi)
(1−eˆi)
)
. (5.2)
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5.6 Propensity score methods with missing
confounder data
In practice, observational studies can suffer from large amounts of missing data,
potentially leading to both loss of efficiency and biased estimates. [44] The magnitude
of bias will depend on the extent to which the probability of missing confounder
data is related to outcome and exposure. [44] The most common classification of
missingness mechanisms is Rubin's taxonomy, in which data are missing completely
at random (MCAR), missing at random (MAR) or missing not at random (MNAR).
[44,48] Under a MCAR mechanism, the probability of being missing does not depend
on the observed or missing data. Missing data are MAR when the probability of
being missing depends on observed data values but, given these, does not depend
on missing values. If the probability of being missing depends on the unobserved
values of data then data are MNAR.
The simplest way of handling missing confounder data in propensity score anal-
ysis is a complete records (or complete case) analysis, which restricts the analyses
to patients with full data on all variables. [50] This approach provides unbiased es-
timates of the conditional average treatment effect as long as missingness does not
depend on both the treatment and the outcome. [50]
The missing indicator approach is another simple method. For partially ob-
served categorical confounders, a `missing' category is added before including the
confounder in the propensity score model. For continuous confounders, missing
values are set to a particular value, say 0, and both the confounder and a missing
indicator (a variable indicating whether that variable is observed or not) are included
in the propensity score model. Applied to standard outcome regression models, this
approach induces bias in a number of scenarios [58, 59]; whether this is the case in
the propensity score context has been questioned. [64]
Multiple imputation is a popular alternative, involving imputing (i.e. filling in)
missing covariates with plausible values several times, by drawing from the predictive
distribution of the missing covariates given observed data, to create a number of
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`complete' imputed datasets. The full analysis (estimation of the propensity score
then estimation of the treatment effect) is performed separately in each imputed
dataset. The results are then combined using Rubin's rules to obtain an overall
estimate of the treatment effect and standard error. [20, 44] Guidelines regarding
optimal use of multiple imputation in conjunction with propensity score analysis
have been proposed. [60] Standard implementations of multiple imputation require
data to be missing at random. [44,49]
5.6.1 The Missingness Pattern Approach (MPA)
The Missingness Pattern Approach (MPA) [46,62] accounts for missing confounder
data by separating patients into subgroups according to the possible combinations
of confounders being observed or missing, i.e. the missingness patterns, and fitting
a different propensity score model to each pattern.
Let Rij be a missing indicator indicating whether the confounder j (j = 1, . . . , p)
for patient i (i = 1, . . . , n) is observed (Rij = 1) or not (Rij = 0). This allows us to
partition the values Xij (i = 1, . . . , n; j = 1, . . . , p) into two sets: the set of values
that are observed, Xobs, and the set of values that are missing, Xmis:
X = {Xobs, Xmis} where Xobs = {Xij|Rij = 1} and Xmis = {Xij|Rij = 0}. (5.3)
We will use Ri = (Ri1, ..., Rip) to refer to the vector of missing indicators for patient
i, omitting the subscript i where unambiguous.
The generalized propensity score, e∗(x), is defined as the probability of receiv-
ing treatment, conditional on both the observed confounder information and the
missingness pattern: e∗(x) = P (Z = 1|Xobs, R). This can be estimated by using
a different propensity score model for each missingness pattern, including only the
confounders observed in that pattern. For example, in a study with treatment and
outcome both fully observed and a single partially observed confounder X, there
are two missingness patterns: X is either observed or missing. For patients with X
observed, the propensity score model would include X, whilst the propensity score
model for patients with X missing would include only a constant term. The gener-
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alised propensity score can then be used in the same way as the standard propensity
score, [62] eg. by substituting in equation (5.2) to estimate the ATE.
5.6.1.1 Assumptions of the Missingness Pattern Approach
Three assumptions under which the MPA leads to valid inference are given by Mat-
tei. [63] We present slightly weaker versions of these assumptions, under which the
MPA still gives a consistent estimator of the ATE (proof in Supplementary Ma-
terial: Section A). The first assumption is an extension of the SITA assumption
(equation (5.1)), which we call the Missingness Strongly Ignorable Treatment As-
signment (mSITA) assumption due to its similarities with the SITA assumption
(equation (5.1)):
mSITA: Z ⊥ Y (z)|X,R for z = 0, 1. (5.4)
A key difference with equation (5.1) is the inclusion of information about the miss-
ingness pattern, represented by R, in the conditioning set. We assume that SITA
holds in the full data, thus this assumption states that additionally conditioning on
R does not introduce bias.
We call the two further assumptions [63]: the conditionally independent treat-
ment (CIT) assumption and the conditionally independent outcomes (CIO) assump-
tion.
CIT: Z ⊥ Xmis|Xobs, R (5.5a)
CIO: Y (z) ⊥ Xmis|Xobs, R for z = 0, 1. (5.5b)
If mSITA holds, and either CIT or CIO holds, then the MPA provides a consistent
estimate of the treatment effect. We loosely term these the `MPA's assumptions'.
We note that the assumptions underlying the MPA are different to Rubin's tax-
onomy of missing data [20,45] in the sense that classifying data according to Rubin's
taxonomy does not provide any information as to whether the MPA's assumptions
would hold. Rather, the MPA's assumptions require the associations between vari-
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ables to differ across missingness patterns. It is possible for the MPA's assumptions
to hold when data are missing not at random; conversely data being missing com-
pletely at random does not guarantee the MPA's assumptions will hold.
How to assess the plausibility of the MPA's assumptions  and thus the validity
of the MPA itself  in a particular setting remains unclear.
5.6.1.2 Connections with the missing indicator approach
With a single partially observed confounder, the missing indicator approach can be
shown to be equivalent to the MPA (Supplementary Material: Section B). Thus the
missing indicator approach will provide a consistent estimator of the ATE if mSITA
and either CIT or CIO holds.
In a more complex scenario with one partially observed and one fully observed
confounder, the missing indicator approach is a simplified version of the MPA, ad-
ditionally imposing the assumption that the association between the fully observed
confounder and treatment is the same whether or not the other confounder is ob-
served (Supplementary Material: Section B). Therefore, the missing indicator ap-
proach relies on the same assumptions as the MPA, and additionally requires no
effect modification of the fully observed confounder(s) by the missingness patterns.
5.7 Plausibility of the CIT and CIO assumptions
The MPA provides valid inference if either CIT or CIO holds (equation (5.5)), in
addition to the mSITA assumption. The plausibility of these assumptions in real-life
settings will therefore determine how useful the MPA is as a missing data approach.
We have assumed that in the full dataX is a confounder, and so is associated with
both treatment and outcome. The CIT assumption requires that the confounder-
treatment relationship is absent in the subset of patients with X unmeasured, whilst
the CIO assumption requires that the confounder-outcome relationship is absent in
patients with X unmeasured. Thus, if either the CIT or CIO assumption holds,
X does not confound the relationship between treatment and outcome when it is
missing (i.e. X is not associated with both treatment and outcome in the subset of
74
patients missing X). Informally, we refer to this property as X being a confounder
only when it is observed.
The key point to consider is that the CIT and CIO assumptions are not about the
missingness mechanisms that drive the missing data, as much as which relationships
between variables exist in the subgroup of patients with missing confounder values.
5.7.1 The CIT assumption: an illustrative example
Consider a simplified version of our motivating example, investigating the effect of
prescribing ACEI/ARBs on the risk of AKI.
Underlying kidney function prior to ACEI/ARB prescription is a likely con-
founder: kidney function is a known risk factor for AKI and is likely to influence
whether ACEI/ARBs are prescribed. Kidney function is classified into the stage of
chronic kidney disease (CKD), via a serum creatinine blood test. Where a clini-
cian ordered a kidney function test prior to the prescribing decision, it is reasonable
to assume that the information regarding CKD stage contributed to that decision.
Where CKD stage was unavailable to the clinician, arguably it is unlikely to have
influenced the prescribing decision.
In this simplified example, underlying CKD stage is always a risk factor for
the outcome but is plausibly only associated with treatment allocation when it is
measured. Thus, CIT holds; baseline CKD stage is only a confounder when it is
observed.
5.7.2 The CIO assumption: an illustrative example
Suppose we were interested in estimating the effect of exposure to farming in early life
on subsequent development of asthma. Childhood exposures to domestic allergens,
e.g. dust mites, are potential confounders. Such domestic allergens may be measured
by health visitors. Suppose that the relationship between dust mites and asthma
has a threshold effect, i.e. an association is seen only once a certain concentration
of dust mites is present.
Since health visitors do not collect information for the purposes of research, they
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might plausibly record information more thoroughly for households where there were
concerns about the child's environment. Missing data for dust mites would therefore
be more likely to occur in households with little evidence of dust mites, and less likely
in households with a high concentration.
In this example, concentration of dust mites may be associated with subsequent
asthma only in households where dust mite concentration was recorded. In this case,
CIO holds; dust mite concentration is a confounder only when measured.
5.8 Detecting and dealing with violations of the
MPA's assumptions
The mSITA, CIT and CIO assumptions are statements of conditional independence.
In this section, we describe how causal diagrams can be used to assess conditional
independence statements. We demonstrate the use of causal diagrams in a simple
scenario in order to draw some general conclusions about situations in which the
MPA's assumptions are likely to be violated.
5.8.1 Causal diagrams
Causal diagrams, or directed acyclic graphs, are a useful tool for assessing conditional
independencies under an assumed causal structure. Because the assumptions of the
MPA involve the potential, rather than observed, outcomes we turn to a specific
type of causal diagram: Single World Intervention Templates (SWITs). [67]
SWITs are standard directed acyclic graphs which have been adapted to show
potential, instead of observed, outcomes. This involves `splitting' the treatment
node into two halves; the first represents the observed treatment Z, and the second
represents an `intervened-on value', z. Determinants of observed treatment affect
the first half (i.e. incoming arrows go into the Z half), and effects of treatment
are determined by the second (i.e. outcoming arrows leave from the z half). A
consequence of this splitting is that variables affected by treatment now become
potential rather than observed variables.
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Figure 5.1: A single world intervention template showing a scenario in which the mSITA
assumption is violated.
X: confounder. Z: treatment. Y (z): potential outcome resulting from intervening to
set Z equal to a particular value z. R: missing indicator (=1 if X observed, =0 if X is
missing). UZ : unobserved common cause between R and Z. UY : unobserved common
cause between R and Y (z).
Figure 5.1 shows a simple SWIT representing a typical confounding scenario
where the confounder X has a causal effect on the treatment and the outcome.
Additionally, this graph encodes the assumption that the missing indicator R (i.e.
whether or not the confounder is missing) is associated with the treatment and the
outcome, via shared common causes in both cases (denoted UZ and UY respectively).
In Figure 5.1, the outcome is affected by treatment so this SWIT includes the
potential outcome Y (z) rather than the observed outcome Y .
5.8.2 Assessing the MPA's assumptions using causal
diagrams
5.8.2.1 Assessing the mSITA assumption
Suppose Figure 5.1 depicts the true underlying causal structure which gave rise to
our study data. With a single partially observed confounder, the mSITA assumption
states that Z ⊥ Y (z)|X,R. By applying d-separation to Figure 5.1 (as described in
Supplementary Material: Section C), we find that the path from Z to Y (z) through
R is open after conditioning on X and R, thus Z is not conditionally independent
of Y (z) given X and R; mSITA is violated in this scenario.
For more complex causal diagrams, it may help to use software such as Dagitty
to assess which conditional independencies hold. [77] R code which uses Dagitty to
check the MPA's assumptions for the scenario shown in Figure 5.1 can be found in
77
Supplementary Material: Section F.
5.8.2.2 Assessing the CIT/CIO assumptions
The CIT and CIO assumptions state that Z ⊥ Xmis|Xobs, R, and Y (z) ⊥ Xmis|Xobs,
R, respectively. With a single confounder X, these assumptions are trivially true in
the subgroup of patients with X observed (because Xmis is empty given R = 1). In
the subgroup of patients with X missing, the assumptions become: Z ⊥ X|R = 0,
and Y (z) ⊥ X|R = 0, respectively.
Figure 5.2: A single world intervention template modified (from Figure 5.1) to assess
the CIT and CIO assumptions. The square box around R denotes the restriction of our
attention to the subgroup R = 0.
X: confounder. Z: treatment. Y (z): potential outcome resulting from intervening to
set Z equal to a particular value z. R: missing indicator (=1 if X observed, =0 if X is
missing). UZ : unobserved common cause between R and Z. UY : unobserved common
cause between R and Y (z).
A minimum condition for CIT or CIO to be satisfied is that X cannot be a
confounder when it is missing. Thus, for either of these assumptions to hold, there
must be grounds for believing that the causal relationships that generate confound-
ing bias in the full data are different in the subgroup with missing confounder values
(compared to the subgroup with observed confounder values). For example, in Fig-
ure 5.1, if we believe that all the arrows shown exist in the subgroup with missing
confounder values, then both CIT and CIO would be violated. In contrast, suppose
we believe that this diagram depicted the correct situation with full data, but we
believe that the arrow from the confounder to treatment did not exist when X was
missing. In this case, Figure 5.2 would depict the underlying causal structure for
the subgroup with X unmeasured.
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In Figure 5.2, the only path connecting Z and X passes through Y (z), a collider
on the path; thus applying the d-separation rule shows that Z and X are condition-
ally independent (in the subgroup with R = 0). Here, CIT holds. Because there is
a direct arrow from X to Y (z), however, CIO does not hold.
5.8.3 Key violations of the MPA's assumptions
In this section, we use causal diagrams to explore when the MPA's assumptions are
violated in a range of simple settings.
Scenarios considered: We consider scenarios where the outcome Y and treat-
ment Z are fully observed. Initially, we focus on simple scenarios with a single par-
tially observed confounder, X. Subsequently we extend this to consider scenarios
with an additional, fully observed confounder, C. We consider all combinations of
the scenarios discussed below, omitting those which give rise to cycles (i.e. we do
not allow scenarios where a variable has a causal effect on itself).
Relationships between the confounder, treatment, and outcome: We
consider causal structures where the relationships between the confounder X and
the treatment and outcome are either a direct causal relationship (e.g. X causes
treatment), or via shared unmeasured common causes (e.g. a third factor causes
both X and treatment). The relationship between the confounder and the treatment
is allowed to differ depending on whether the confounder is observed or missing;
specifically, this relationship is allowed to be absent when R = 0. Similarly, the
presence or absence of the relationship between the confounder and outcome is
allowed to depend on R. This allows for X to be a confounder only when observed,
as discussed in the previous section.
Missingness mechanisms: For each of the confounder, treatment and out-
come, we considered: no relationship with the missing indicator, a causal effect on
the missing indicator, the missing indicator has a causal effect on the variable, or
an unobserved common cause with the missing indicator (allowing scenarios where
one or more variables have both a direct causal relationship and a common cause
with the missing indicator).
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When a variable has a causal effect on the outcome, we assume that this effect
operates on the potential outcome rather than the observed (e.g. X causes Y (z)
rather than X causing Y ). Conversely, in the case where outcome is a cause of
missingness, we have chosen to allow the observed outcome to cause missingness (Y
causes R) rather than the potential outcome, since this is arguably more plausible
in real data.
Assessment of assumptions: In each setting, we draw the appropriate causal
diagram and assess the assumptions by applying d-separation to the causal diagram
overall, and to the modified causal diagram restricted to the subgroup with X miss-
ing.
In some scenarios, a slightly more complex route must be taken to assess the
conditional independencies involved in the MPA's assumptions. If the treatment or
outcome is a cause of missingness then the relevant SWIT contains R(z), the `poten-
tial' missingness after intervening on treatment, rather than the observed pattern of
missingness. Thus we can no longer use this graph to assess the relevant assump-
tions. In these cases we turn to twin networks [68, 69] (Supplementary Material:
Section D).
5.8.3.1 Key violations of the mSITA assumption
In the scenarios we considered, most violations of mSITA occurred via collider bias
on R. In order for this type of violation to occur, there needs to be a path from
Z to R and a path from Y (z) to R, each ending with arrows pointing towards R.
These violations operate via a cause of R. We let UX represent common causes of
missingness and the confounder, UZ represent common causes of missingness and
the treatment, and UY represent common causes of missingness and the outcome.
The different `Z-to-R' and `R-to-Y' patterns that could occur are summarised in
Figure 5.3. If one (or more) of each of these two patterns occurs then mSITA will
be violated. For example, Figure 5.1 shows the violation which arises when both
the indirect `Z-to-R' pattern and the indirect `R-to-Y' pattern occur (both patterns
in the second row of Figure 5.3).
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Figure 5.3: Summary of violations of the mSITA assumption. If one of the `Z-to-R'
patterns and one of the `R-to-Y' patterns occurs in the causal diagram representing the
study in question then the mSITA assumption will be violated.
a Also a violation if this occurs with additional `R-to-Y patterns' shown in Supplementary
Material: Section E; b Sufficient condition on its own, without a `Z-to-R pattern'.
X: partially observed confounder. C: fully observed confounder. Z: treatment. Y (z):
potential outcome resulting from intervening to set Z equal to a particular value z. Y :
observed outcome. R: missing indicator (=1 if X observed, =0 if X is missing). Ust:
unobserved common cause between two variables s and t. Us: unobserved common cause
between R and another variable s.
A key result in Figure 5.3 is that when treatment and missingness are associ-
ated via shared common causes, and outcome and missingness are associated via
(different) shared common causes, then mSITA is violated (as shown in Figure 5.1).
So the MPA cannot be used in scenarios where there are unmeasured determinants
of confounder missingness which are also associated with the treatment and the
potential outcomes.
Another important result in Figure 5.3 is that if the outcome has a causal effect
on confounder missingness, i.e. if Y → R, then mSITA is violated without the
need for any `Z-to-R' patterns. So the MPA cannot be used in scenarios where
outcome affects whether or not confounder values are missing. For instance, in
our AKI example, suppose that more efforts were made to track down historical
laboratory measures of eGFR for patients who were diagnosed with AKI, then this
would immediately violate mSITA.
A third important result is that when treatment causes missingness, and miss-
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ingness in turn has a causal effect on the potential outcomes, mSITA is violated
(see footnote a in Figure 5.3), although whether this is likely to occur in practice is
unclear.
5.8.3.2 Handling violations of the mSITA assumption
All violations of mSITA, other than those involving the treatment or the outcome
causing missingness of the confounder, operate via a cause of R. Suppose it were
possible to measure all such factors which determine whether or not the confounder
is measured (although this may be difficult in practice). We could define a new set
of confounders X˜ = {X,UX , UZ , UY } (or, where there is an additional fully observed
confounder C, X˜ = {X,C, UX , UC , UZ , UY }). Including this new set of confounders
in the propensity score model, and thus the conditioning set for mSITA, removes the
violation of this assumption. In most cases, measuring a subset of these variables
will suffice. For example, in Figure 5.1, if UZ could be measured and included in the
propensity score model, the mSITA assumption would become: Z ⊥ Y (z)|X,R,UZ ,
which is satisfied in Figure 5.1.
5.8.3.3 Key violations of the CIT and CIO assumptions
Figure 5.4 summarises the possible violations of CIT and CIO, which fall into two
broad groups: (A) violations related to X being a confounder when it is missing,
and (B) violations due to collider bias via R.
Since mSITA is always violated if outcome causes missingness, some CIT/CIO
violations involving Y → R are shown only in Supplementary Material: Section E,
along with a few additional violations involving Z → R.
Group (A) violations in Figure 5.4 relate to X being a confounder only when
observed, in the sense that if one of the CIT group (A) violations or one of the
CIO group (A) violations held, X would be a confounder when missing. For these
violations, X has been replaced by Xmis to emphasise the fact that we need to focus
on relationships that exist in the subgroup of patients with a missing confounder
value when assessing this assumption.
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Figure 5.4: Summary of violations of the CIT and CIO assumptions. If one or more of the
six sets of conditions on the left hand side appear in the relevant causal diagram (modified
to reflect relationships in the subgroup with X unobserved i.e. restricted to R = 0), the
CIT is violated. Similarly, if any of the six sets of conditions on the right hand side occur
then CIO is violated. Additional violations involving Y → R and Z → R can be found in
Supplementary Material: Section E.
X: partially observed confounder. C: fully observed confounder. Z: treatment. Y (z):
potential outcome resulting from intervening to set Z equal to a particular value z. Y :
observed outcome. R: missing indicator (=1 if X observed, =0 if X is missing). Ust:
unobserved common cause between two variables s and t. Us: unobserved common cause
between R and another variable s.
In contrast, Group (B) violations relate to collider bias induced by conditioning
on R.
5.8.3.4 Handling violations of the CIT and CIO assumptions
As with violations of the mSITA assumption, many of the violations of the CIT and
CIO assumptions  specifically those belonging to Group (B)  can be removed
by measuring and conditioning on causes of R. However, if either (i) both the
confounder and the treatment cause the missingness, or (ii) both the confounder
and outcome cause the missingness, then CIT or CIO are violated, respectively; no
conditioning can remove these violations.
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5.9 Practical guide to assessing the mSITA, CIT
and CIO assumptions
In order to decide if the MPA's assumptions hold in a particular clinical setting,
the first, most important step, is to assess whether it is plausible for the partially
observed confounder to be a confounder only when observed.
Second, key scenarios in which the MPA's assumptions do not hold, as identified
in the previous section, should be carefully considered using substantive knowledge
to ensure these do not apply in the setting at hand. These are: (I) outcome affects
missingness of the confounder; (II) outcome and missingness have shared unmea-
sured common causes, and treatment and missingness have shared common causes;
or (III) the confounder and treatment both affect missingness of the confounder and
the confounder is associated with outcome in the subgroup with X missing.
Third, a causal diagram should be constructed, reflecting what is believed to
be the underlying clinical structure. As with any causal diagram, any variable 
measured or unmeasured  which may have a causal effect on two or more variables
in the causal diagram must also be included. Missing indicators for the partially
observed confounders should be included in the causal diagram at this stage. When
there are multiple partially observed confounders, the causal diagram will include
one missing indicator per partially observed confounder.
Fourth, the causal diagram should be converted into a SWIT or a twin network,
as appropriate. Once the SWIT or twin network has been created, d-separation can
be applied to determine whether mSITA holds.
To assess CIT and CIO, the SWIT or twin network should be modified to reflect
the relationship thought to be absent in the subgroup of patients with missing
confounder values (i.e. remove the arrows which reflect the assumption that the
confounder is only a confounder when observed). In this modified diagram, the
d-separation rule can be again applied to assess CIT and CIO.
Supplementary Material: Section F provides R code to assess the mSITA, CIT
and CIO assumptions for Figure 5.1, and for the causal diagram associated with our
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more complex motivating example.
When there are multiple partially observed confounders, we advise constructing
modified diagrams for each missingness pattern with missing values and then apply-
ing the d-separation rule to each diagram to assess the CIT and CIO assumptions
for that particular missingness pattern. An assumption holds only if it holds for
each missingness pattern.
5.9.1 Assessing the validity of the assumptions in the
motivating example
5.9.1.1 Confounders only when observed
For the MPA's assumptions to hold in the motivating example, we have to believe
that the two partially-missing confounders  ethnicity and baseline chronic kidney
disease (CKD) stage  act as confounders only when observed. If baseline CKD
stage is not available, this unobserved information cannot be used to determine the
General Practitioner's treatment decision whether or not to prescribe ACEI/ARBs.
In practice, CKD stage may be recorded in a part of the patient record that the
General Practitioner is aware of but researchers using CPRD data cannot access
(e.g. letters from secondary care). However, this is likely to reflect advanced CKD
for only a small proportion of the whole study population. So in general, it seems
plausible that baseline CKD stage affects the clinician's prescribing decision only
when recorded.
The National Institute for Health and Care Excellence antihypertensive prescrib-
ing guidelines (which include ACEI/ARBs) offer different recommendations depend-
ing on ethnicity. [78] So, it is plausible that, if a clinician chooses to prescribe or not
prescribe an ACEI/ARB based on an individual's ethnicity, they would ensure that
the individual's ethnicity was recorded.
Therefore, the CIT assumption may be reasonable for this scenario. Conversely,
both baseline CKD stage and ethnicity are risk factors for AKI, whether measured
or not. Thus the CIO assumption is not plausible here.
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5.9.1.2 Checking plausibility of key violations
We also need grounds to believe that the three key scenarios listed above do not
apply in this setting. Scenarios (I) and (III) rely on either outcome or treatment
affecting missingness of the confounders. As CKD stage was defined at baseline,
missingness of baseline CKD stage precedes treatment and, as a result, outcome.
It also seems plausible that missingness of ethnicity occurs prior to treatment and
outcome. Hence we believe that these scenarios do not apply here.
Scenario (II) is when outcome and missingness have shared unmeasured common
causes, and treatment and missingness have shared common causes. Baseline CKD
stage is more likely to be recorded for patients expected to have a higher risk of
kidney disease due to age or chronic comorbidities (eg. hypertension, diabetes) or
due to other signs that the patient has poor kidney function (i.e. CKD itself may
affect the chance of the clinician measuring CKD stage). Whilst these risk factors are
associated with missingness and treatment or outcome, they are already captured
in the electronic health records.
With respect to ethnicity, patients who are hospitalised are more likely to have
ethnicity recorded (due to linkage of primary and secondary care data). Missingness
of ethnicity may be caused by service-level factors such as level of administrative
support at the time patients are admitted to hospital. It seems unlikely that these
factors are also determinants of treatments previously prescribed in primary care or
whether patients develop acute illnesses that require admission to hospital. Since
we believe that any relevant common causes are measured, scenario (II) does not
apply in our setting.
After considering the three key scenarios mentioned above, in which the MPA's
assumptions do not hold, we have found that these do not seem plausible in our
motivating example. Having ruled out these violations, we proceed to the next step
of our framework: to develop a causal diagram.
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Ace
Age
Aki
Arr
Car
Ckd
Diab
Eth
Hosp
Hyp
Ihd
Rckd
Reth
Sex
Slf
U
ace
Figure 5.5: A single world intervention template for the motivating example.
Eth: Ethnicity. Ckd: Baseline chronic kidney disease. Hyp: Hypertension. Diab: Diabetes
mellitus. Arr: Arrhythmia. Car: Cardiac failure. Ihd: Ischaemic heart disease. Ace:
Prescription of ACE/ARBs (treatment). ace: intervened-on version of exposure. Aki:
Acute kidney injury (outcome). Rckd: Missingness of Ckd. Reth: Missingness of Eth.
Hosp: Hospitalisation. Slf: Service-level factors. U: unmeasured factor.
5.9.1.3 Developing a causal diagram
Figure 5.5 shows the single world intervention template (SWIT) developed for this
example. This causal diagram encodes the investigators' assumptions that age, sex
and ethnicity each affect both treatment and outcome. Age and sex affect the
risk of developing diabetes, CKD, ischaemic heart disease, cardiac failure, arrhyth-
mia and hypertension. Note that the treatment node, representing prescription of
ACEI/ARBs, has been split into two: `Ace' and `ace', with the former represent-
ing the observed treatment and the latter representing the intervened-on treatment.
Thus patient factors affect `Ace' but not `ace', and only `ace' affects subsequent AKI.
5.9.1.4 Assessing the mSITA assumption
The mSITA assumption, for the motivating example, says that: Z ⊥ Y (z)|Rckd,
Reth, Ckd, Eth, V , where Z represents ACEI/ARB prescription; Y (z) the potential
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outcome (AKI status that would be observed if the patient were prescribed level z
of ACEI/ARB); V represents the confounders age, sex, diabetes, ischaemic heart
disease, cardiac failure, arrhythmia and hypertension; Reth and Rckd are missing in-
dicators for ethnicity and baseline CKD stage; and Ckd and Eth are the confounders
CKD stage and ethnicity, respectively.
The d-separation rule can be applied to the SWIT in Figure 5.5, to assess whether
this conditional independence holds under the causal assumptions encoded in the
diagram (example code in Supplementary Material: Section F.2). In this case, the
conditional independence statement is true; mSITA holds under the assumed causal
diagram.
5.9.1.5 Assessing the CIT and CIO assumptions
We have already established that the CIO assumption does not hold in our moti-
vating example. The CIT assumption states that:
Z ⊥ (Ckd,Eth) | Rckd = 0, Reth = 0, V,
Z ⊥ Ckd | Rckd = 0, Reth = 1, Eth, V,
Z ⊥ Eth | Rckd = 1, Reth = 0, Ckd, V.
To assess the first of these, we create a modified version of Figure 5.5 which omits
the arrows that we do not think exist when both ethnicity and baseline CKD stage
are missing. So we remove the arrow from baseline CKD stage to ACEI/ARB
prescription, and we remove the arrow from ethnicity to ACEI/ARB prescription.
We then assess whether, after conditioning on the two missing indicators and
the fully observed confounders, the treatment is independent of both ethnicity and
baseline CKD stage, by applying the d-separation rule for each partially observed
confounder. In this case, the conditional independence holds (example code in Sup-
plementary Material: Section F.2).
This process is repeated in the two subgroups where only one of ethnicity and
baseline CKD stage is recorded, assessing the second and third independence state-
ments above in the appropriately modified causal diagrams. In each case, the rel-
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evant conditional independence holds. Thus, under the assumed causal diagram,
CIT holds.
If our causal diagram correctly represents the causal structure giving rise to our
study data, both mSITA and CIT hold. Under these two assumptions the MPA will
provide consistent estimates of the ATE.
5.10 Motivating example: applying the MPA
5.10.1 Methods: ACEI/ARBs and AKI
We estimated the effect of prescription of ACEI/ARBs on the incidence of AKI
within 5 years of follow-up as a risk difference, first with no adjustment for con-
founding, and then by using inverse probability of treatment weighting (IPTW). For
IPTW, we estimated propensity scores using logistic regression to model ACEI/ARB
prescription as a function of the covariates: age, sex, baseline CKD stage, ethnicity,
diabetes mellitus, ischaemic heart disease, arrhythmia, cardiac failure and hyper-
tension (including an interaction between age and ischaemic heart disease, and an
interaction between age and hypertension). We applied non-parametric bootstrap-
ping (500 replications of the combined process of propensity score estimation and
treatment effect estimation) to obtain Normal approximation 95% confidence inter-
vals.
To deal with missing data in baseline CKD stage and ethnicity, we applied com-
plete records analysis, the MPA, the missing indicator approach and multiple im-
putation. For the MPA, the propensity scores were estimated separately in the four
subgroups corresponding to whether or not baseline CKD stage and ethnicity were
measured. For the missing indicator approach, we added `missing' categories to each
of baseline CKD stage and ethnicity. For multiple imputation, 10 imputed datasets
were created using chained equations. The imputation model included AKI inci-
dence within 5 years, ACEI/ARB prescription and all covariates and interactions
included in the propensity score model. In each imputed dataset, propensity scores
were estimated and IPTW was used to obtain treatment effect estimates, which
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were then pooled using Rubin's rules. [60] To assess covariate balance, standardized
differences [25] were calculated in the original sample and after IPTW with each
analysis method used.
5.10.2 Results and discussion: ACEI/ARBs and AKI
The complete records analysis included 121, 527 patients with full data. All other
missing data methods included all 570, 586 patients. Using any of the analysis
methods with IPTW removes most of the imbalance present in the original dataset
(Table S1 in Supplementary Material: Section G).
Table 5.2: Estimated effects of ACEI/ARBs on AKI using inverse-probability of treat-
ment weighting (IPTW) to account for confounding.
Confounder Missing data Risk difference Normal-based
adjustment method (per 1000 people) bootstrap 95% CI
Crude None 13.30 (12.52, 14.08)
IPTW Complete Case Analysis 4.60 (2.76, 6.45)
IPTW Missingness Pattern Approach 5.96 (5.10, 6.82)
IPTW Missing Indicator Approach 5.93 (5.01, 6.85)
IPTW Multiple Imputation 6.17 (5.27, 7.07)∗
∗ Not bootstrapped; obtained by using Rubin's rules across 10 imputed datasets.
Estimates of the effect of ACEI/ARBs on AKI are shown in Table 5.2. All
missing data methods greatly reduce the crude estimate of effect, with complete
records analysis providing the smallest estimate and multiple imputation providing
the estimate closest to the crude analysis. The MPA and missing indicator approach
produce almost identical results, estimating that patients prescribed ACEI/ARBs
had 6 additional cases of AKI within 5 years, per 1000 people, with a 95% confidence
interval of (5,7), compared to patients who were not prescribed ACEI/ARBs.
We expect the MPA estimate to be consistent since  as discussed  the mSITA
and CIT assumptions appear plausible here. Conversely, the missing at random as-
sumption underlying our application of multiple imputation is questionable. Base-
line CKD stage is more likely to be recorded for patients with a lower level of kidney
function (e.g. if they are ill or have more risk factors for kidney disease that have led
to testing) [79] and therefore baseline CKD stage may be MNAR. However, since
factors related to a lower level of kidney function are likely already captured in the
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observed data, the departure from the MAR assumption may be small. This may
explain why multiple imputation and the MPA provide fairly similar estimates in
this example, with multiple imputation giving an estimate closer to the crude es-
timate. Alternatively, having similar results may be due to misspecification of the
parametric models or because ethnicity and baseline CKD stage may not be strong
confounders.
In terms of precision, the complete records analysis has a very wide confidence
interval, in contrast to the other missing data methods which all produce much
narrower confidence intervals. This loss in precision, due to the exclusion of a large
portion of the data, is recovered by the MPA, the missing indicator approach and
multiple imputation.
5.11 Discussion
We have explored the three assumptions under which the missingness pattern ap-
proach to dealing with missing counfounders in propensity score analysis provides
valid inference. We have described how d-separation can be applied to a causal
diagram to assess the MPA's assumptions in a given setting and provided a frame-
work and detailed example to allow researchers to ensure the appropriateness of this
method in practice.
The key assumption required by the MPA is that the confounder acts as a con-
founder only when observed. Thus for the MPA to be an appropriate method to
use, we must believe that the relationships between treatment, outcome, and con-
founder are different in the subgroup with the confounder unmeasured. While this
assumption will be plausible only in specific scenarios, one setting where it may
have broad applicability is in the area of electronic health record research. In such
studies, missing confounder information reflects information that the clinician did
not have when making prescribing decisions, thus the assumption that the missing
values did not affect prescribing may well be reasonable.
If this key assumption is thought to be satisfied, careful consideration is required
to ensure that the remaining assumptions of the MPA are satisfied. In particular, the
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assumptions do not hold in the following scenarios: (i) where the outcome affects
missingness of the confounder; (ii) where outcome and missingness have shared
unmeasured common causes, and treatment and missingness have shared common
causes; and (iii) where a partially-missing confounder and treatment both affect
missingness of the confounder and the confounder is thought to be associated with
outcome whether or not it is measured. We note that the scenario where the outcome
affects the missingness of the confounder also gives biased estimates of the treatment
effect when using complete records analysis [50]; multiple imputation can be used
to deal with such scenarios if data are missing at random.
We also found that many violations of the MPA's assumptions can be dealt with
by recording, and including in the analysis, auxiliary variables that are predictors of
confounder missingness. Thus, although measuring such variables may be difficult
in practice, careful consideration of the process by which data become missing is
essential.
Our results demonstrate that classification of the missingness mechanism accord-
ing to Rubin's taxonomy does not provide information as to whether the MPA's
assumptions will hold. Unlike most missing data methods, for example, data being
missing completely at random does not guarantee that the assumptions of the MPA
are satisfied: the underlying relationships between the partially missing confounder
and either the treatment or outcome (or both) would need to differ according to
whether or not the confounder was missing. Also, if a confounder is missing not at
random, but the confounder does not confound the treatment-outcome relationship
when missing, the MPA's assumptions may hold.
The missing indicator approach is a popular and easy method to deal with miss-
ing confounder data. [57, 58] However, it is believed to be an `ad hoc' method [57]
that produces biased results. [58] Although the missing indicator approach is indeed
biased under standard missing at random assumptions, [58] our results show that
in the propensity score context, the missing indicator approach is a simplified ver-
sion of the MPA, and hence requires the same assumptions for valid results, along
with additional assumptions about interaction terms in the propensity score model.
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Our work, therefore, allows researchers to use the missing indicator approach in a
principled way.
There are several advantages to using the MPA, or the simpler missing indicator
approach, when dealing with partially observed confounders in propensity score
analysis. First, the method itself is simple to comprehend and easy to implement.
Second, in contrast to complete records analysis, the MPA retains all patients in the
analysis. Third, the MPA may be appropriate in some situations where multiple
imputation is not, as the MPA does not require the missing at random assumption
to hold.
A limitation of the MPA is that we require sufficient sample size in each missing-
ness pattern in order to be able to estimate propensity scores. This is of particular
concern when there are many missingness patterns, a scenario to which the MPA is
not currently easily extendable. Qu and Lipkovich (2009) suggested a pattern pool-
ing algorithm [70] to ensure sufficient sample size when estimating propensity scores
when there are a large number of missingness patterns. Further work is needed to
explore the performance of their algorithm in a range of scenarios. An extension
to the MPA was proposed by D'Agostino et al. [64] They suggested that in each
missingness pattern, propensity scores should be estimated in the wider group of
all subjects with observed data for the relevant confounders, retaining estimated
propensity scores only for those who actually observed that particular pattern. Fur-
ther work is required to compare this extension with the original MPA, and to
investigate how to account for the correlation induced by this method.
In scenarios with a large number of confounders, causal diagrams may be pro-
hibitively complex to construct. An alternative strategy could be to perform sensi-
tivity analyses to assess the extent of the violation that would be required to change
the study's conclusions. However, further work is required to determine how best
to implement such sensitivity analyses.
We have concentrated on scenarios where treatment and outcome are both fully
observed. A hybrid method, combining the MPA and multiple imputation, was
proposed by Qu and Lipkovich, [70] and studied by Seaman and White. [80]
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The MPA is simple and easy to implement, and may be useful in settings where
other missing confounder data methods are not appropriate. We believe that this
approach will be particularly useful in areas using routinely collected data, partic-
ularly electronic health record research. We have produced practical guidance for
researchers to decide whether the underlying assumptions of the MPA are plausibly
satisfied in a particular clinical setting.
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Supplementary material
In Section A, we prove that the missingness pattern approach (MPA) gives a con-
sistent estimator of the average treatment effect under weaker versions of Mattei's
assumptions, [63] referred to in the main text as the mSITA, CIT and CIO assump-
tions. In Section B, we explore the connection between the MPA and the missing
indicator approach by comparing propensity score models for the two approaches.
Section C describes the d-separation rule. Section D gives a brief overview of twin
networks. In Section E, we present additional violations of the MPA's assumptions.
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In Section F, we provide R code for assessing the MPA's assumptions in a simple
example and in our motivating example. Section G gives standardized differences
for our motivating example.
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A Validity of the MPA
In this appendix, we demonstrate that E
[
ZY
e∗
]
= E[Y (1)] under the weaker versions
of the assumptions presented in the text.
First, using the consistency assumption and rearranging, we have that:
E
[
ZY
e∗
]
= E
[
ZY (1)
e∗
]
= E
[
E
[
ZY (1)
e∗
|Xobs, R
]]
= E
[
1
e∗
E
[
ZY (1)|Xobs, R
]]
, (5.6)
where e∗ = E[Z|Xobs, R].
Switching briefly to summation notation:
E
[
ZY (1)|Xobs, R
]
=
∑∑
zyP (Z|Xobs, R)P (Y (1)|Z,Xobs, R)
=
∑∑
zyP (Z|Xobs, R)
∑
P (Y (1), Xmis|Z,Xobs, R)
=
∑∑∑
zyP (Z|Xobs, R)P (Y (1)|Z,Xmis, Xobs, R)P (Xmis|Z,Xobs, R)
Using mSITA (Z ⊥ Y (z)|X,R for z = 0, 1) and CIT (Z ⊥ Xmis|Xobs, R), we have:
E
[
ZY (1)|Xobs, R
]
=
∑∑∑
zyP (Z|Xobs, R)P (Y (1)|Xmis, Xobs, R)P (Xmis|Xobs, R)
=
∑∑
zyP (Z|Xobs, R)
∑
P (Y (1), Xmis|Xobs, R)
=
∑∑
zyP (Z|Xobs, R)P (Y (1)|Xobs, R)
= E
[
Z|Xobs, R
]
E
[
Y (1)|Xobs, R
]
We can also show that E
[
ZY (1)|Xobs, R
]
= E
[
Z|Xobs, R
]
E
[
Y (1)|Xobs, R
]
using
mSITA with CIO (Y (z) ⊥ Xmis|Xobs, R for z = 0, 1) in a similar manner. Thus, we
can rewrite equation 5.6 as follows:
E
[
ZY
e∗
]
= E
[
1
e∗
E
[
Z|Xobs, R
]
E
[
Y (1)|Xobs, R
]]
.
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Since e∗ = E[Z|Xobs, R]:
E
[
ZY
e∗
]
= E
[
E
[
Y (1)|Xobs, R
]]
= E[Y (1)].
Similarly, we can show that E[(1− Z)Y/(1− e∗)] = E[Y (0)].
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B The connection between the missingness pattern
approach and the missing indicator approach
In this appendix, we consider the propensity score models for the MPA and the
missing indicator approach to explore the connection between these approaches.
In a scenario with a single partially observed confounder X, the propensity score
model for the MPA can be written as:
logit(P (Z = 1)) =
 α1 + β1X if R = 1α0 if R = 0
with some parameters α1, β1, α0.
Defining a new variable X∗ which takes the value X if observed, and 0 otherwise,
this can be rewritten as:
logit(P (Z = 1)) = α0 + β1X
∗R + (α1 − α0)R.
If X is binary, this is equivalent to creating a third category for X representing
the missing values. If X is continuous, this sets missing values to 0 and adds an
indicator variable for missing observations. This is exactly the missing indicator
approach. If X were categorical, this could be extended to show that the MPA is
similarly equivalent to adding a `missing' category.
In a scenario with one partially observed confounder X, and one fully observed
confounder C, the propensity score for the MPA can be written as:
logit(P (Z = 1)) =
 α1 + β1X+ γ1C if R = 1α0 + β1X+ γ0C if R = 0
= α0 + β1X
∗R + (α1 − α0)R + γ0C + (γ1 − γ0)CR
with some parameters α1, β1, γ1, α0, γ0.
98
In contrast, the propensity score model for the missing indicator approach is:
logit(P (Z = 1)) = α + βX∗R + ηR + γC
with parameters α, β, η, γ.
This is the MPA model, constraining γ1 to be equal to γ0, i.e. the missing indica-
tor model additionally assumes there are no CR interactions in the true propensity
score model.
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C The d-separation rule
The d-separation rule, proposed within the context of directed acyclic graphs [66]
and extended to SWITs, [67] determines whether a particular conditional depen-
dency holds or not, under an assumed causal structure. Broadly speaking, asso-
ciation is transmitted through series of arrows  paths  in the assumed causal
diagram. [4] A particular path will transmit association between the nodes at either
end unless it contains a `collider': a node which  in that path  has two incoming
arrows. In Figure 5.1, the path Z ← X → Y (z) will transmit association between
Z and Y (z), but the path Z ← UZ → R ← UY → Y (z) will not because R is a
collider in this path. Conditioning on a non-collider blocks associations through a
specific path. Conversely, conditioning on a collider removes the blockage through
that collider thereby allowing association to be transmitted. Introducing bias by
conditioning on a collider is often termed collider bias. [81]
The d-separation rule states that two variables in the assumed causal diagram
are conditionally independent given a set of variables V if for each path connecting
the two variables: (i) the path contains two arrows which collide at a node in the
path, and that node is neither in V , nor a cause of a variable in V ; or (ii) the path
has a non-collider which is in V . [4, 66]
In Figure 5.1, there are two paths between Z and Y (z): Z ← X → Y (z), and
Z ← UZ → R ← UY → Y (z). If the conditioning set is V = {X}, then Z and
Y (z) are conditionally independent given V . This is because the first path contains
a non-collider (X) which is in V (condition (ii)) and the second contains a collider
(R) which is not in V (condition (i)). In contrast, Z and Y (z) are not conditionally
independent given V = {X,R}, because the second path then contains a collider
(i.e. R) which is in V , and neither X nor R is a non-collider in this path.
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Figure 5.6: A simple example of a twin network.
X: partially observed confounder. Z: observed treatment allocation. Y : observed out-
come. Y (z): potential outcome resulting from intervening to set treatment to value z.
R: observed missing indicator (=1 if X observed, =0 if X is missing). R(z): potential
missing indicator (=1 if X observed in counterfactual world, =0 if X is missing in coun-
terfactual world). eY : unobserved error term between Y and Y (z). eR: unobserved error
term between R and R(z).
D Twin networks
When considering scenarios in which treatment, or the outcome, has a causal effect
on missingness, by construction, the SWITs now include R(z) instead of R. This
means that the SWIT can no longer be used to test the MPA's assumptions. Instead,
we can construct twin networks to check such scenarios, as described by Balke and
Pearl, [68] and Shpitser and Pearl. [69]
Briefly, a twin network can be constructed from a directed acyclic graph, which
involves real world variables and relationships, by adding counterparts of variables
and relationships in the counterfactual world where treatment has been intervened
upon to be set to some realisation of the random variable Z.
For example, Figure 5.6 shows a simple twin network of a scenario where the
confounder X has a causal effect on both treatment and outcome, treatment has
a causal effect on outcome, and outcome has a causal effect on missingness of the
confounder. The `real world' is shown by Z, Y , and R. The nodes z, Y (z), and
R(z) show the counterfactual world  what would occur if we set treatment to
value z. The observed outcome Y and potential outcome Y (z) are connected by an
unobserved error term eY . Similarly, the observed missing indicator R and potential
missing indicator R(z) are connected by an unobserved error term eR. Because X
has a causal effect on outcome, it also has a causal effect on the potential outcome.
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It does not, however, affect the intervened-on value of treatment, z.
To assess mSITA in Figure 5.6, we need to assess whether Z ⊥ Y (z)|R,X.
Conditioning on X blocks the confounding pathway between Z and Y (z). There is
a closed path Z → Y ← eY → Y (z), blocked because Y is a collider on this path.
However, conditioning on R opens this path, because conditioning on a descendant
of a collider (i.e. something affected by the collider) has a similar, but weaker, effect
as conditioning on the collider itself. Thus the path Z → Y ← eY → Y (z) is open,
after conditioning on R, so the mSITA assumption may not be appropriate here. 1
Dagitty can be used to assess the assumptions in twin networks, just as for
SWITs.
1As d-separation for twin networks is not complete, [67] caution should be used in considering
the plausibility of results that suggest two variables are not d-separated.
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E Additional violations of assumptions
Figure 5.7 summarises additional violations of the MPA's assumptions.
Figure 5.7: Summary of additional violations of the mSITA, CIT and CIO assumptions.
X: partially observed confounder. Xmis: unobserved confounder values. C: fully observed
confounder. Z: treatment. Y (z): potential outcome resulting from intervening to set
Z equal to a particular value z. Y : observed outcome. R: missing indicator (=1 if X
observed, =0 if X is missing). Ust: unobserved common cause between two variables s and
t. Us: unobserved common cause between R and another variable s.
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F Using Dagitty to assess the MPA's assumptions
F.1 Simple example: R code to use Dagitty to assess the
MPA's assumptions
Run in R 3.4.0, [82] the R code below reads in our causal diagram for Figure 5.1
and uses d-separation to assess the mSITA, CIT and CIO assumptions. [77]
### R CODE TO USE DAGITTY: SIMPLE EXAMPLE
install.packages("dagitty")
library("dagitty")
############################
# Load DAG into Dagitty #
############################
# X partially observed confounder
# R observed covariate indicator: =1 if X observed, =0 otherwise.
# Z treatment allocation (fully observed)
# Yz potential outcome that would be observed when Z=z
# U_Y unobserved common cause of R and Y
# U_Z unobserved common cause of R and Z
g1 <- dagitty( 'dag {
z -> Yz
Z <- X -> Yz
R <- U_Z -> Z
R <- U_Y -> Yz
}')
coordinates( g1 ) <-
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list( x=c(Z=1, z=1.2, X=2, Yz=3, R=2, U_Z=1.2, U_Y=2.8),
y=c(Z=3, z=3, X=2, Yz=3, R=1, U_Z=1.7, U_Y=1.7) )
plot( g1 )
### Assess mSITA assumption:
### - Is Z indep of Yz given R, X, and z?
### (note: we add z to the conditioning set because we are using
### a SWIG)
# List all paths between Z and Yz
paths( g1, "Z", "Yz", c("R","X","z") )
# Check whether mSITA holds
dseparated( g1, "Z", "Yz", c("R","X", "z") )
# Check whether mSITA holds if U_Y were also measured and
# included in the confounder set
dseparated( g1, "Z", "Yz", c("R","X", "z", "U_Y") )
#########################################
# DAG for subgroup with X unmeasured #
#########################################
### Suppose we believe that X does not affect Z when unmeasured
### R is now written R0 as shorthand for "R=0"
g2 <- dagitty( 'dag {
z -> Yz
X -> Yz
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R0 <- U_Z -> Z
R0 <- U_Y -> Yz
}')
coordinates( g2 ) <-
list( x=c(Z=1, z=1.2, X=2, Yz=3, R0=2, U_Z=1.2, U_Y=2.8),
y=c(Z=3, z=3, X=2, Yz=3, R0=1, U_Z=1.7, U_Y=1.7) )
plot( g2 )
### Assess CIT assumption:
### - Is Z indep of X given R=0 (and z)?
### (note: we add z to the conditioning set because we are using
### a SWIG)
dseparated( g2, "Z", "X", c("R0", "z") )
paths( g2, "Z", "X", c("R0","z"))
### Assess CIO assumption:
### - Is Yz indep of X given R=0 (and z)?
### (note: we add z to the conditioning set because we are using
### a SWIG)
dseparated( g2, "Yz", "X", c("R0", "z") )
paths( g2, "Yz", "X", c("R0","z"))
F.2 Motivating example: R code to use Dagitty to assess
the MPA's assumptions
Figure 5.5 shows the causal diagram which represents what the investigators believe
to represent the underlying causal structure giving rise to the data. The R code
below reads in our causal diagram for our motivating example and uses d-separation
to assess the mSITA, CIT and CIO assumptions.
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### R CODE TO USE DAGITTY: MOTIVATING EXAMPLE
#install.packages("dagitty")
library("dagitty")
############################
# Load DAG into Dagitty #
############################
# Outcome and treatment:
# Aki Acute Kidney Injury (outcome)
# Ace ACE/ARB (treatment)
# ace Intervened-on ACE/ARB (intervened-on treatment)
# Partially observed confounders and missing indicators:
# Eth Ethnicity (partially observed confounder)
# Ckd Baseline CKD (partially observed confounder)
# Reth Missingness of ethnicity
# Rckd Missingness of baseline CKD
# Determinants of missing data:
# Slf Service-level factors determining whether or not ethnicity
# is measured
# Hosp Hospitalisation
# Fully observed confounders:
# Age
# Sex
# Hyp Hypertension
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# Diab Diabetes
# Arr Arrhythmia
# Car Cardiac failure
# Ihd Ischaemic heart disease
# Unmeasured factors:
# U (e.g. frailty)
### Draw DAG ###
g1 <- dagitty( 'dag {
Age -> Hyp Age -> Diab Age -> Ckd Age -> Arr Age -> Car Age -> Ihd
Sex -> Hyp Sex -> Diab Sex -> Ckd Sex -> Arr Sex -> Car Sex -> Ihd
Reth <- Eth Reth <- Slf Reth <- Hosp
Rckd <- Hyp Rckd<- Ckd Rckd <- Diab Rckd <- Age
Diab -> Ckd Ihd -> Ckd Car -> Ckd
Eth -> Arr Ihd -> Arr Arr -> Car Hyp -> Car Ihd -> Car
U -> Ckd U -> Hyp U -> Diab U -> Hosp U -> Ihd U-> Arr
Hyp -> Ace Sex -> Ace Diab -> Ace Eth -> Ace Ckd -> Ace Car -> Ace
Ihd -> Ace
Age -> Aki Eth -> Aki Sex -> Aki Diab -> Aki Ckd -> Aki U -> Aki
Car -> Aki
ace -> Aki
}')
coordinates( g1 ) <-
list( x=c(Age=1, Sex=1, Eth=1, Ace=6, ace=6.5, Aki=10,
Arr=5, Car=3.25, Ihd=5,
Reth=9, Slf=8, Hosp=8, Hyp=3.25, Ckd=4, Diab=4, Rckd=5, U=1.5),
y=c(Age=3, Sex=5, Eth=8, Ace=4.75, ace=4.75, Aki=5,
Arr=7, Car=6.75, Ihd=6,
Reth=7.5, Slf=8, Hosp=7, Hyp=2, Ckd=3, Diab=4, Rckd=2, U=6) )
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plot( g1 )
#############################
# Check mSITA assumption #
#############################
### mSITA assumption:
### Is Z indep of Yz given R, X, and z?
### Here: Is Ace indep of Aki given Rckd, Reth, Ckd, Eth, ...
### ...Age, Sex, Hyp, Diab, Arr, Car, Ihd and ace?
###
# List all paths between Z and Yz
paths( g1, "Ace", "Aki", c("Rckd", "Reth","Ckd", "Eth",
"Age", "Sex", "Hyp", "Diab",
"Arr", "Car", "Ihd", "ace") )
# Check whether mSITA holds
dseparated( g1, "Ace", "Aki", c("Rckd", "Reth","Ckd", "Eth",
"Age", "Sex", "Hyp", "Diab",
"Arr", "Car", "Ihd", "ace") )
#########################################################
# DAG for subgroup with CKD and ethnicity unmeasured #
#########################################################
### Suppose we believe that:
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### Ckd does not affect prescription of ACE when unmeasured
### Eth does not affect prescription of ACE when unmeasured
### Draw DAG (group with neither ethnicity nor ckd measured) ###
g2 <- dagitty( 'dag {
Age -> Hyp Age -> Diab Age -> Ckd Age -> Arr Age -> Car Age -> Ihd
Sex -> Hyp Sex -> Diab Sex -> Ckd Sex -> Arr Sex -> Car Sex -> Ihd
Reth <- Eth Reth <- Slf Reth <- Hosp
Rckd <- Hyp Rckd<- Ckd Rckd <- Diab Rckd <- Age
Diab -> Ckd Ihd -> Ckd Car -> Ckd
Eth -> Arr Ihd -> Arr Arr -> Car Hyp -> Car Ihd -> Car
U -> Ckd U -> Hyp U -> Diab U -> Hosp U -> Ihd U-> Arr
Hyp -> Ace Sex -> Ace Diab -> Ace Car -> Ace Ihd -> Ace
Age -> Aki Eth -> Aki Sex -> Aki Diab -> Aki Ckd -> Aki U -> Aki
Car -> Aki
ace -> Aki
}')
coordinates( g2 ) <-
list( x=c(Age=1, Sex=1, Eth=1, Ace=6, ace=6.5, Aki=10,
Arr=5, Car=3.25, Ihd=5,
Reth=9, Slf=8, Hosp=8, Hyp=3.25, Ckd=4, Diab=4, Rckd=5, U=1.5),
y=c(Age=3, Sex=5, Eth=8, Ace=4.75, ace=4.75, Aki=5,
Arr=7, Car=6.75, Ihd=6,
Reth=7.5, Slf=8, Hosp=7, Hyp=2, Ckd=3, Diab=4, Rckd=2, U=6) )
plot( g2 )
###############################
# Check CIT/CIO assumption #
###############################
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### CIT assumption:
### Is Z indep of X given R=0 (and z)?
### Here: is Ace indep of Ckd given Rckd=0 and Reth=0, conditional
### on: Age, Sex, Hyp, Diab (and ace)?
### Here: is Ace indep of Eth given Rckd=0 and Reth=0, conditional
### on: Age, Sex, Hyp, Diab (and ace)?
# Check whether CIT holds
dseparated( g2, "Ace", "Ckd", c("Rckd", "Reth",
"Age", "Sex", "Hyp", "Diab",
"Arr", "Car", "Ihd", "ace") )
dseparated( g2, "Ace", "Eth", c("Rckd", "Reth",
"Age", "Sex", "Hyp", "Diab",
"Arr", "Car", "Ihd", "ace") )
### CIO assumption:
### Is Yz indep of X given R=0 (and z)?
### Here: is Aki indep of Ckd given Rckd=0 and Reth=0, conditional
### on: Age, Sex, Hyp, Diab (and ace)?
### Here: is Aki indep of Eth given Rckd=0 and Reth=0, conditional
### on: Age, Sex, Hyp, Diab (and ace)?
# Check whether CIO holds
dseparated( g2, "Aki", "Ckd", c("Rckd", "Reth",
"Age", "Sex", "Hyp", "Diab",
"Arr", "Car", "Ihd", "ace") )
dseparated( g2, "Aki", "Eth", c("Rckd", "Reth",
"Age", "Sex", "Hyp", "Diab",
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"Arr", "Car", "Ihd", "ace") )
### Use similar steps to check CIT/CIO in other missingness pattern
### subgroups
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G Balance of confounders in motivating example
In Table 5.3, we present standardized differences [25] calculated to assess the balance
of confounders in our motivating example.
Table 5.3: Standardised mean differences of confounders, before and after inverse prob-
ability of treatment weighting for complete records analysis (CRA), missingness pattern
approach (MPA), missing indicator approach (MIndA), and multiple imputation (MI).
A standardized difference greater than 10% indicates imbalance for that variable.
(∗ Standardized differences for multiple imputation were averaged over 10 imputed
datasets.)
Percentage standardized differences (absolute values)
In original After After After After
Covariate sample CRA MPA MIndA MI∗
Age (years) 18 to 42
43 to 53 14.64 1.33 0.49 0.36 0.26
54 to 62 9.42 1.64 1.51 1.45 2.26
63 to 71 2.48 2.17 2.11 1.98 2.93
≥ 72 4.07 2.25 3.70 3.60 4.81
Sex Female 36.95 1.92 4.44 4.99 4.66
Chronic ≤ Stage 2
Kidney Stage 3a 12.84 1.77 1.13 1.08 1.27
Disease Stage 3b 8.62 0.07 0.35 0.38 4.56
Stage 4 3.33 0.32 0.19 0.16 1.19
Ethnicity White
South Asian 6.31 0.38 0.65 0.65 7.63
Black 3.14 3.75 3.75 4.22 8.30
Mixed 1.73 0.56 0.69 0.84 4.25
Other 0.43 0.42 <0.01 0.01 1.12
Diabetes Mellitus 49.21 0.43 2.70 2.01 3.06
Ischaemic Heart Disease 19.25 2.52 2.83 2.28 6.00
Arrhythmia 4.84 0.68 2.16 3.07 2.04
Cardiac Failure 32.90 1.75 0.02 0.03 0.19
Hypertension 43.08 5.74 7.85 7.88 10.93
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Chapter 6
Variance estimation for the
missingness pattern approach
6.1 The theory of M-estimation
M-estimation provides a generalisable theory to obtain the large-sample variance for
estimators that can be written as the solution to a set of estimating equations [83].
Suppose the observed data for individual i are Yi, and the data are independent
and identically distributed according to distribution function F . A M-estimator is
the solution, θˆ, to the estimating equations
n∑
i=1
ψ(Yi, θ) = 0.
So θˆ is defined as the value that solves:
n∑
i=1
ψ(Yi, θˆ) = 0.
The true value of the parameter, θ0, is defined by
EF [ψ(Y, θ0)] =
∫
φ(y, θ0)dF (y) = 0.
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Then the large-sample approximate distribution of the estimator θˆ is:
θˆ ∼MVN
(
θ0,
V (θ0)
n
)
, as n→∞
where
V (θ0) = A(θ0)
−1B(θ0){A(θ0)−1}T
with
A(θ0) = E
[
− ∂
∂θT
ψ(Y1, θ0)
]
, B(θ0) = E[ψ(Y1, θ0)ψ(Y1, θ0)
T ].
To obtain an estimate of the variance, the matrices A(θ0) and B(θ0) can be
replaced by sample estimates of the relevant quantities, i.e..
Aˆ(θ0) = − 1
n
n∑
i=1
∂
∂θT
ψ(Yi, θˆ), Bˆ(θ0) =
1
n
n∑
i=1
ψ(Yi, θˆ)ψ(Yi, θˆ)
T .
6.2 Estimating the variance of the IPTW
estimator with MPA for a partially missing
confounder
This chapter considers a simplified setting with a single potential confounder, X,
which is partially observed. The variable R indicates whether the confounder is
observed (R = 1) or missing (R = 0).
6.2.1 The IPTW estimator with MPA as an M-estimator
If the propensity scores were given by pii for individual i, then the two means which
are contrasted to give the IPTW treatment effect estimator can be written as the
solution to the estimating equations
n∑
i=1
vi = 0
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where
vi =
 (Yi − µ1)Zipi−1i
(Yi − µ0)(1− Zi)(1− pii)−1

The treatment effect estimate is given by µˆ1 − µˆ0.
In fact, the propensity scores are themselves estimated, often via a logistic re-
gression model for the treatment with the potential confounders as explanatory
variables. Thus
n∑
i=1
wi = 0
where, letting xi = (1, Xi)
T , and using expit(.) to denote the function expit(x) =
exp(x)/(1 + exp(x)), we have
wi =
Rixi(Zi − expit(λTxi))
(1−Ri)(Zi − expit(ζ))

Putting these two estimation steps together, the two estimated means are ob-
tained by solving the estimating equations
n∑
i=1
ui = 0
where
ui =

(Yi − µ1)Zipii(Ri, Xi, λ, ζ)−1
(Yi − µ0)(1− Zi)(1− pii(Ri, Xi, λ, ζ))−1
Rixi(Zi − expit(λTxi))
(1−Ri)(Zi − expit(ζ))

with
pii(Ri, Xi, λ, ζ) = Ri × expit(λTxi) + (1−Ri)× expit(ζ)
The parameter being estimated by solving the set of estimating equations is
θ = (µ1, µ0, λ
T , ζ)T , and the parameter of interest  the estimated treatment effect
 is given by δ = µ1 − µ0.
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6.2.2 Large sample variance
Partitioning the matrix B into four components, corresponding to the four compo-
nents of u, we can write
B(θ0) =

b11 0 b13 b14
0 b22 b23 b24
bT13 b
T
23 b33 0
bT14 b
T
24 0 b44

where the zeros arise from multiplying Z and (1− Z) or R and (1−R).
The matrix A can also be partitioned in a similar manner:
A(θ0) =
(
−E
[
∂u
∂µ1
]
,−E
[
∂u
∂µ0
]
,−E
[
∂u
∂λT
]
,−E
[
∂u
∂ζ
])
giving
A(θ0) =

a11 0 a13 a14
0 a22 a23 a24
0 0 a33 0
0 0 0 a44

where the zeros arise from differentiating with respect to a parameter not appearing
in the relevant part of the estimating equation.
The inverse matrix is given by
A(θ0)
−1 =

a−111 0 −a13a−111 a−133 −a14a−111 a−144
0 a−122 −a23a−122 a−133 −a24a−122 a−144
0 0 a−133 0
0 0 0 a−144

The large-sample approximate variance of the estimator θˆ = (µˆ1, µˆ0, λˆ
T , ζˆ)T , is
given by: V ar(θˆ) = A(θ0)
−1B(θ0){A(θ0)−1}T . The variance of the treatment effect
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estimator δˆ = µˆ1 − µˆ0 is given by
V ar(δˆ) = V ar(µˆ1) + V ar(µˆ0)− 2Cov(µˆ1, µˆ0)
Thus, to obtain an estimator for the variance, the following steps must be fol-
lowed:
• Obtain sample estimates of the individual components of the matrices B and
A
• Multiply out the matrices Aˆ(θˆ)−1Bˆ(θˆ){Aˆ(θˆ)−1}T
• Extract the variances nV̂ ar(µˆ1) and nV̂ ar(µˆ0), as the (1, 1) and (2, 2) entries
of the matrix obtained. Similarly, extract Ĉov(µˆ1, µˆ0) as the (1, 2) component
of the matrix obtained.
• Substitute into the equation to obtain V̂ ar(δˆ)
6.2.3 Estimating the matrix B
The components of this matrix can be estimated by:
bˆ11 =
1
n
n∑
i=1
(Y − µˆ1)2Zipˆi−2i
bˆ22 =
1
n
n∑
i=1
(Y − µˆ0)2(1− Zi)(1− pˆii)−2
bˆ13 =
1
n
n∑
i=1
{Rixi(Yi − µˆ1)Zi(1− expit(λˆTxi))}pˆi−1i
bˆ14 =
1
n
n∑
i=1
{(1−Ri)(Yi − µˆ1)Zi(1− expit(ζˆ))}pˆi−1i
bˆ23 = − 1
n
n∑
i=1
{Rixi(Yi − µˆ0)(1− Zi)expit(λˆTxi)}(1− pˆii)−1
bˆ24 = − 1
n
n∑
i=1
{(1−Ri)xi(Yi − µˆ0)(1− Zi)expit(ζˆ)}(1− pˆii)−1
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bˆ33 =
1
n
n∑
i=1
Rixix
T
i (Zi − expit(λˆTxi))
bˆ44 =
1
n
n∑
i=1
(1−Ri)(Zi − expit(ζˆ))
with
pˆii = Ri × expit(λˆTxi) + (1−Ri)× expit(ζˆ)
6.2.4 Estimating the matrix A
The components of the matrix A can be estimated as follows:
aˆ11 = − 1
n
n∑
i=1
∂
∂µ1
{(Yi − µ1)Zipii(Ri, Xi, λ, ζ)−1} = 1
n
n∑
i=1
Zi
pˆii
Similarly,
aˆ22 =
1
n
n∑
i=1
(1− Zi)
(1− pˆii)
And
aˆ33 = − 1
n
n∑
i=1
∂
∂λT
{Rixi(Zi − expit(λTxi))}
= − 1
n
n∑
i=1
Rixix
T
i expit(λ
Txi)(1− expit(λTxi))
Similarly,
aˆ44 = − 1
n
n∑
i=1
(1−Ri)expit(ζ)(1− expit(ζ))
We also have
aˆ13 =
1
n
n∑
i=1
Rix
T
i (Yi − µˆ1)Zipˆi−1i (1− pˆii)
aˆ23 = − 1
n
n∑
i=1
Rix
T
i (Yi − µˆ0)(1− Zi)pˆii(1− pˆii)−1
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aˆ14 =
1
n
n∑
i=1
Ri(Yi − µˆ1)Zi(1−Ri)pˆi−1i (1− pˆii)
aˆ24 =
1
n
n∑
i=1
Ri(Yi − µˆ0)(1− Zi)(1−Ri)pˆii(1− pˆii)−1
6.3 Plans to evaluate and extend the variance
formula
Further work will involve simulation studies, including a single partially observed
confounder, in order to assess how well the large-sample variance formula performs
in finite  particularly in small  sample sizes.
The variance formula above is immediately extendable to the case with multi-
ple confounders, in the simplified setting where confounders are either all missing
simultaneously or all observed. Future work will extend the variance formula to
the case where multiple confounders are partially missing and others fully observed,
with all possible combinations of the partially missing confounders being missing or
observed.
In this latter scenario, sparsity of data patterns mean that some sort of `pattern
pooling' is likely to be required, whereby similar patterns of missingness are grouped
together. This will enable estimation of the propensity score within each of the larger
missingness patterns.
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Chapter 7
The connection between the
missingness pattern approach and
the missing indicator approach
7.1 The MPA's connection to the missing
indicator approach in propensity score analysis
The missing indicator approach (MIA) is a simple missing data method where all
missing values are set to a particular value, say 0, and a missingness indicator is
included in the analysis model. In our cohort study, this is equivalent to adding
an `absent' category to baseline CKD stage for patients with missing data for this
confounder.
In a scenario with a single partially observed confounder, it can be seen that
the MIA is equivalent to the MPA. With a single partially observed confounder, the
propensity score model for the MPA can be written as:
logit(P (Z = 1)) =
 α
1 + β1X if R = 1
α0 if R = 0
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with coefficients α0, α1, β1. This can be rewritten as:
logit(P (Z = 1)) = (α1 + β1X)R + α0(1−R),
which is equivalent to the propensity score model for the MIA.
Since the MPA and MIA are equivalent in this simple scenario with a single
partially observed confounder, it is clear that the MIA also requires the mSITA
assumption and at least one of the CIT and CIO assumptions to hold.
In order to see if this equivalency can be extended to more complex scenarios,
we now consider the scenario with one partially observed confounder and one fully
observed confounder, C.
The propensity score model for the MIA is now:
logit(P (Z = 1)) = α + βXR + ηR + γC,
with coefficients α, β, η, γ.
The propensity score model for the MPA can be written as follows:
logit(P (Z = 1)) =
 α
1 + β1X+ γ1C if R = 1
α0 + β1X+ γ0C if R = 0
with coefficients α0, α1, β1, γ0, γ1. This can be rewritten as:
logit(P (Z = 1)) = (α1 + β1X + γ1C)R + (α0 + γ0C)(1−R)
= α0 + β1XR + (α1 − α0)R + γ0C + (γ1 − γ0)CR.
In this more complex scenario, we find that the models for the MIA and the
MPA are not equivalent, as there is an additional term for the interaction between
C and R. Hence, the MIA can be seen to be a simplified version of the MPA, where
the effect of the fully observed confounder on treatment is assumed to be the same
for all missingness patterns (i.e. the coefficient for the interaction term is zero).
Before using the MIA in practice, in addition to considering the plausibility of the
MPA's assumptions, researchers also need to check the assumption that there are no
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interactions between fully observed confounders and the missing indicator. Unlike
the mSITA, CIT and CIO assumptions, this interaction assumption can be assessed
in the data at hand, and the propensity score model adapted as necessary to ensure
correct specification.
7.2 How MIA relates to MPA with multiple
partially observed confounders
Let Z denote treatment allocation and X, W denote two partially observed con-
founders with corresponding missing indicators RX and RW . We define X
∗, which
takes the value X if X is observed and 0 otherwise, and similarly define W ∗.
With two partially observed confounders, the propensity score for the MPA can
be written as
logit(P (Z = 1)) =

α00 if RX = 0 & RW = 0
α10 + β10X if RX = 1 & RW = 0
α01 + γ01W if RX = 0 & RW = 1
α11 + β11X + γ11W if RX = 1 & RW = 1
= α00 + (α10 − α00)RX + (α01 − α00)RW
+ (α00 − α10 − α01 + α11)RXRW + β10X∗RXγ01W ∗RW
+ (β11 − β10)X∗RXRW + (γ11 − γ01)W ∗RXRW .
In contrast, the propensity score model for the MIA is:
logit(P (Z = 1)) = α + βX∗RX + γW ∗RW + δRX + ηRW .
This is the MPA model, where the coefficents for terms involving interactions be-
tween missing indicators are zero. So, in general, the missing indicator method is a
simplification of the MPA, which makes additional assumptions about the absence
of interactions between the missingness indicator(s) and other fully-observed con-
founders. These additional assumptions can be assessed in the data by testing for
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interactions in the propensity score model.
7.3 Motivation for extending from propensity
score analysis to outcome regression
When investigating the missingness pattern approach (MPA), I found that, with a
single partially observed confounder, the MPA was equivalent to the missing indica-
tor approach (MIA), and thus the MIA would provide unbiased estimates under the
mSITA assumption and either the CIT or the CIO assumption. With an additional
fully observed confounder, I showed that the MIA is a simplification of the MPA,
with the additional assumption that the propensity score model is correctly speci-
fied. In particular, the MIA as typically applied implicitly assumes the absence of
interactions in the true propensity score model between the missing indicator and
the fully observed confounder, i.e. the effect of the fully observed confounder on
treatment does not vary by missingness pattern.
So, in the propensity score context, the MIA can provide unbiased estimates
under certain assumptions. Indeed, the use of missing indicators has been rec-
ommended by Stuart (2010) for use in propensity score analysis [55] and also by
Hernán et al. (2009) and Kreif et al. (2018) in the context of non-systematic mon-
itoring of covariates in settings with time-varying treatments [74, 75]. However, in
the context of outcome regression, the MIA is often considered to be an ad hoc
approach [56, 57] that gives biased results [58, 59]. The purpose of this chapter is
to investigate whether our finding that the MIA can provide unbiased estimates
extends to the context of outcome regression.
In order to investigate whether our work in the propensity score context can be
extended to outcome regression, we must first consider how these contexts differ
from each other. Although in both cases the aim is to remove confounding bias,
in propensity score analysis, we wish to model the relationship between covariates
and the treatment, whilst in outcome regression, we wish to model the relationship
between covariates and the outcome. Thus the MIA (or other methods to handle
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partially observed confounders) would be applied differently for each context: in
the propensity score context, the MIA is applied when modelling the covariate-
treatment relationship, whereas for outcome regression, the MIA would be used in
the outcome model. Consequently, when extending the MIA to outcome regression,
instead of assuming correct specification of the propensity score model, the analogous
assumption would be that the outcome model is correctly specified. In particular,
we might expect that that the effect of fully observed confounders on the outcome
does not vary by missingness pattern.
7.3.1 Relating our findings to previous literature
I prove that the MIA gives unbiased treatment effect estimates in outcome regression
when (i) the mSITA assumption holds, (ii) either the CIT or the CIO assumption
holds, and (iii) the outcome model is correctly specified. Details are given in the
MIA research paper pre-print (Chapter 8).
Jones assumed that the true model for the outcome Y was a linear regression
model with two covariates X1, X2 and an independent normal error term , where
Y and X1 are assumed to be fully observed and X2 may be partially observed [59].
Jones (1996) proved that the MIA for outcome regression gives biased least squares
estimators and noted that the least squares estimators are unbiased when (i) the
proportion of individuals with missing data is zero, or (ii) the sample covariance of
X1 and X2 for individuals missing X2 is zero.
As our interest lies in estimating the effect of treatment, we will henceforth
replace Jones'sX1 with the treatment allocation variable Z andX2 with our notation
for a partially observed covariate: X. So, Jones's work suggests that the least square
estimator for the treatment effect is unbiased when the sample covariance of Z and
X for individuals missing X is zero. We prove below that if the CIT assumption
holds, this sample covariance is indeed zero, and thus the least square estimator for
the treatment effect is unbiased. Furthermore, if the true outcome model resembles
a parametric model corresponding to the MIA, then the CIO assumption holds, and
it is simple to show that the least squares estimator is unbiased.
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Suppose that the true data generation model for outcome Y is:
Yi = β0 + β1Zi + β2Xi + i,
for i = 1, ..., n patients, where Z denotes treatment allocation, X is a single partially
observed confounder, and  is an independent normal error term. Suppose further
that the true data generation model for Z is:
Zi = γ0 + γ1XiRi + γ2(1−Ri), i = 1, ..., n (7.1)
where R denotes the missing indicator. Under the model in equation (7.1), the CIT
assumption holds (Z ⊥ X|R = 0).
The sample covariance of Z and X for patients missing X is defined as:
S = [n(1− R¯)]−1
∑
(1−Ri)(Zi − Z¯m)(Xi − X¯m) (7.2)
where R¯ = n−1
∑
Ri and V¯
m = [n(1− R¯)]−1∑(1−Ri)Vi for V = Z,X.
Under the model in equation (7.1),
Z¯m = [n(1− R¯)]−1
∑
(1−Ri)
(
γ0 + γ1XiRi + γ2(1−Ri)
)
.
Since the missing indicator is binary, we can rewrite this as:
Z¯m = [n(1− R¯)]−1
∑(
γ0(1−Ri) + γ2(1−Ri)
)
.
By cancelling, we get Z¯m = γ0 + γ2. Substituting this expression and equation (7.1)
into equation (7.2):
S = [n(1− R¯)]−1
∑
(1−Ri)
(
γ0 + γ1XiRi + γ2(1−Ri)− γ0 − γ2
)
(Xi − X¯m).
= [n(1− R¯)]−1
∑(
γ1XiRi(1−Ri)− γ2Ri(1−Ri)
)
(Xi − X¯m)
= 0.
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Hence, if the CIT assumption holds, the sample covariance of Z and X for
patients missing X is zero. Thus, the least square estimator for the treatment effect
is unbiased [59].
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8.1 Overview of the research paper pre-print:
Estimating treatment effects with partially
observed covariates using outcome regression
with missing indicators
In the following research paper pre-print, we extend the MIA from propensity score
analysis to the context of outcome regression. After introducing the MIA and the
method's underlying assumptions, we prove that the MIA gives unbiased treatment
effect estimates when the mSITA assumption holds, either the CIT or the CIO
assumption holds, and the outcome model is correctly specified. We show how this
finding is compatible with previous work by Jones (1996) which found that the MIA
generally gives biased estimates in outcome regression [59], and highlight additional
interesting results. In addition, we use simulation studies to explore the extent
of bias when the MIA's assumptions are violated. We then illustrate the MIA in
outcome regression with a cohort study using electronic health records.
8.2 Abstract
Missing data is a common issue in research using observational studies to investigate
the effect of treatments on health outcomes. When missingness occurs only in the
covariates, a simple approach is to use missing indicators to handle the partially
observed covariates. The missing indicator approach has been criticised for giving
biased results in outcome regression. However, recent papers have suggested that
the missing indicator approach can provide unbiased results in propensity score anal-
ysis under certain assumptions. We consider assumptions under which the missing
indicator approach can provide valid inferences, namely: (1) no unmeasured con-
founding within missingness patterns; either (2a) covariate values of patients with
missing data were conditionally independent of treatment; or (2b) these values were
conditionally independent of outcome; and (3) the outcome model is correctly spec-
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ified: specifically, the true outcome model does not include interactions between
missing indicators and fully observed covariates. We prove that, under the assump-
tions above, the missing indicator approach with outcome regression can provide
unbiased estimates of the average treatment effect. We use a simulation study to
investigate the extent of bias in estimates of the treatment effect when the assump-
tions are violated and we illustrate our findings using data from electronic health
records. In conclusion, the missing indicator approach can provide valid inferences
for outcome regression, but the plausibility of its assumptions must first be consid-
ered carefully.
8.3 Introduction
Observational studies are a valuable source of information for research investigating
the efficacy and safety of treatments in practice. We focus on scenarios where we
want to estimate the effect of treatment on a health outcome. However, a common
challenge when using observational data is how to deal with missing data. If not
handled appropriately, missing data can lead to bias and a loss of efficiency [50].
When using observational data for research, missing data is often an issue in variables
that may be considered as potential confounders, such as smoking status or ethnicity.
The simplest approach for handling partially observed covariates is complete
record analysis (also called complete case analysis), where patients with missing
data are excluded from analysis. Although complete record analysis can provide
unbiased results [50], this approach will typically lead to a loss of efficiency due to
the exclusion of information. Furthermore, if patients with complete records are not
representative of the population of interest, results from a complete record analysis
may not be generalizable to the population of interest [45, 84].
A popular alternative missing data method is multiple imputation, where missing
values are imputed multiple times with plausible values in order to create multiple
`complete' imputed datasets. After analysing each dataset, the results are com-
bined using Rubin's Rules to obtain an overall treatment effect estimate [20, 44].
Although multiple imputation is very powerful, it can be fairly complex and stan-
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dard implementation requires the assumption that data are missing at random (i.e.
the probability of being missing depends on observed data and, given these, does
not depend on unobserved data) [44,48]. The plausibility of the missing at random
assumption should be considered when implementing multiple imputation [49]. In
addition, imputing missing values in standard multiple imputation relies on para-
metric assumptions [45], the plausibility of which should also be considered [85].
Another simple way of dealing with partially observed covariates is to use missing
indicators  variables which indicate whether the covariate is missing or observed.
For a continuous covariate, missing observations are replaced with a fixed value, say
0, and a missing indicator is added to the analysis model, alongside the continuous
variable. For a categorical covariate, the missing indicator approach is equivalent to
adding a `missing' category to the variable.
The use of missing indicators to handle missing covariates in outcome regression
has been criticised in the literature for being ad hoc [56,57], and for giving biased
results [58, 59]. However, the missing indicator approach is often used to deal with
missing covariates [52] and has been recommended as a missing data method for
propensity score analysis [55]. Related methods, incorporating the last-observation-
carried-forward approach, have been studied in the context of non-systematic mon-
itoring of covariates in settings with time-varying treatments [74,75]. Furthermore,
our recent work in the propensity score context suggests that the missing indicator
approach can provide unbiased estimates under certain assumptions [86]. In propen-
sity score analysis, we want to model the relationship between the covariates and
the treatment, whereas in outcome regression, we wish to model the relationship
between the covariates and the outcome. So, we need to investigate whether the
validity of our findings in the propensity score context also holds for outcome re-
gression. Therefore, in this paper we consider whether our work can be extended to
the context of outcome regression.
We begin in Section 8.4 by describing the basic principles of the missing indicator
approach and the assumptions underlying its validity. In Section 8.5, we prove that
the missing indicator approach can give unbiased estimates of the treatment effect in
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outcome regression and show how our work fits in with the literature. In Section 8.6,
we explore the extent of bias in the estimation of the treatment effect when these
assumptions are violated. In Section 8.7, we apply the missing indicator approach
in multivariable outcome regression to an illustrative example. We conclude with a
discussion in Section 8.8.
8.4 Background
8.4.1 Notation and potential outcome framework
Let Z be a binary variable indicating treatment allocation (or exposure status, etc.
depending on context) and let Y represent the observed outcome variable. In this
paper, we will concentrate on missing data in covariates and assume that treatment
Z and outcome Y are fully observed, as the missing indicator method does not
accommodate missing data on the outcome or exposure.
To enable us to describe the assumptions underlying the missing indicator ap-
proach, we refer to the potential outcome framework, developed by Rubin (1974),
for causal inference from observational data. We let Y (z) represent the potential
outcome that would be observed if Z was set equal to the value z (z = 0, 1).
We focus on a scenario with two confounders: a fully observed confounder C
and a partially observed confounder X. The missing indicator R equals 1 if X is
observed, and R = 0 if X is missing.
The confounder values can be partitioned as {Xobs, Xmis}, where Xobs is the set
of X values that are observed and Xmis is the set of missing X values (i.e. Xmis
contains the true unobserved X values). For each patient with R = 1, Xobs is equal
to X and Xmis is empty. For each patient with R = 0, Xmis = X and Xobs is empty.
Additionally, we define X∗ = X when R = 1, and X∗ = 0 when R = 0. Note that
an alternative approach would be to define Xobs instead as RX (which is equivalent
to X∗) and Xmis as (1− R)X. However, for the purposes of this paper, we use the
Xobs and Xmis notation, following the literature on which our theory builds [46,63].
Our estimand of interest is the average treatment effect (ATE): E[Y (1)]−E[Y (0)].
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To estimate the treatment effect, we make the following standard assumptions for
causal inference with complete data: strongly ignorable treatment allocation (SITA),
no interference, consistency, and positivity.
The SITA assumption  an important assumption in causal inference using
observational data  is that there is no unmeasured confounding [33]. In a scenario
with two confounders, C and X, the SITA assumption can be written as:
Z ⊥ Y (1), Y (0)|C,X. (8.1)
Under the assumption of no interference, the treatment status of one patient does
not affect the potential outcomes of another patient [31,34]. Assuming consistency,
the observed outcome of a patient is equal to the potential outcome corresponding
to the treatment they actually received, i.e. if Z = z then Y = Y (z) [31]. Finally,
under positivity, all patients have a non-zero probability of being assigned to each
value of treatment, given their characteristics [31, 37]
8.4.2 The missing indicator approach
The missing indicator approach is a simple method of dealing with partially observed
covariates. When using outcome regression, the missing indicator approach allows
patients with missing data to be used for the estimation of the treatment effect on
the outcome, given covariates.
For a continuous partially observed covariate, the missing indicator approach in
outcome regression replaces missing covariate values with some fixed value: the same
value (for example, 0) is used for all participants with that covariate missing. Both
the modified covariate and the missing indicator R are then included in the analysis
model. For a categorical partially observed covariate, the missing indicator approach
is equivalent to adding a `missing' category to the variable. The regression coefficient
for treatment can then be used to obtain an estimate of the treatment effect using
appropriate transformations (eg. the identity function for linear regression).
For example, using the missing indicator approach for linear regression, the anal-
ysis model is E[Y ] = α0 + α1Z + α2C + α3X
∗ + α4R, where X∗ = X when R = 1,
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and X∗ = 0 when R = 0, and where α1 is the regresssion coefficient corresponding
to our estimate of the ATE.
We note that, in the propensity score context, the missing indicator approach
allows patients with missing data to contribute to the estimation of the propensity
score (i.e. the probability of receiving treatment, given patient characteristics). So,
missing indicators are included in the propensity score model, rather than the out-
come model (which only includes treatment allocation and the propensity score as
covariates).
8.4.2.1 Assumptions underlying the missing indicator approach
Our recent work in the context of propensity score analysis has shown that the
missing indicator approach relies on four assumptions [86]. In this paper, we extend
this work by investigating whether these four assumptions also underlie the validity
of the missing indicator approach in outcome regression, in order to understand
when this approach is appropriate in practice.
The first assumption is that there is no unmeasured confounding within missing-
ness patterns, i.e. within each subgroup of patients who have information recorded
on the same variables [63]. We call this the missingness Strongly Ignorable Treat-
ment Allocation (mSITA) assumption, due to the similarity to the SITA assumption
(equation (8.1)). Mathematically:
mSITA: Z ⊥ Y (z)|C,X,R for z = 0, 1. (8.2)
We call the second and third assumptions the Conditionally Independent Treat-
ment (CIT) assumption and the Conditionally Independent Outcomes (CIO) as-
sumption, respectively. The CIT assumption is that missing confounder values are
conditionally independent of treatment, given the observed confounder values and
the missing indicator, while the CIO assumption is that missing confounder values
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are conditionally independent of the potential outcomes [63].
CIT: Z ⊥ Xmis|C,Xobs, R. (8.3a)
CIO: Y (z) ⊥ Xmis|C,Xobs, R for z = 0, 1. (8.3b)
Note that in scenarios with partially observed confounders, the mSITA, CIT and
CIO assumptions replace the SITA assumption with respect to identification of the
causal estimand.
The fourth assumption in the propensity score context is that the propensity
score model is correctly specified; in particular, we assume that the true propensity
score model does not include an interaction between the missing indicator R and
the fully observed confounder C (CR interaction). In other words, the effect of the
fully observed confounder on treatment allocation is assumed to be the same for all
missingness patterns.
The analogue assumption for outcome regression is that the outcome model is
correctly specified and, in particular, the true outcome model does not include a
CR interaction. The plausibility of this correct specification assumption is context-
dependent and can be assessed in the data at hand, allowing the possibility of
adapting the model in order to ensure the outcome model is correctly specified.
We can obtain valid inferences from the missing indicator approach in propensity
score analysis under the following sufficient assumptions: (i) the mSITA assumption
holds; (ii) either the CIT or the CIO assumption holds; and (iii) the propensity
score model is correctly specified [86]. In this paper, we extend this work to the
outcome regression context, demonstrating in Section 8.5 that we can use the missing
indicator approach with outcome regression to obtain valid inferences under the
following assumptions: (i) the mSITA assumption holds; (ii) either the CIT or the
CIO assumption holds; and (iii) the outcome model is correctly specified.
137
8.4.2.2 Plausibility of the assumptions underlying the missing
indicator approach
In missing data methodology, when deciding if a particular method is appropriate, it
is important to consider the way in which data becomes missing, i.e. the missingness
mechanism. Rubin's taxonomy [20] is commonly used to classify data as being
missing completely at random, missing at random, or missing not at random [44,45].
The plausibility of the assumptions in Section 8.4.2.1 rely instead on the under-
lying structure of the data (i.e. the causal associations between variables), rather
than the missingness mechanisms [86]. For example, the CIT and CIO assump-
tions together mean that the partially observed confounder does not confound the
relationship between treatment and outcome when it is missing [86]. So, either the
confounder-treatment relationship is absent in individuals who have missing con-
founder values or the confounder-outcome relationship is absent in individuals who
have missing confounder values. Hence, key violations of the CIT or CIO assump-
tions occur when the missing confounder values affect treatment allocation or the
outcome, respectively.
If we believe that the SITA assumption (i.e. no unmeasured confounding) holds
in full data, then the mSITA assumption says that additionally conditioning on
missingness patterns does not introduce bias. One key way in which this can be
violated is when there are: shared unmeasured common causes between outcome and
missingness, and unmeasured common causes between treatment and missingness.
This is an example of M-bias, which has been discussed extensively in the literature
[4, 81].
The correct specification assumption would be violated if the effects of fully
observed confounders on the outcome varied by missingness pattern. Unlike this
parametric assumption, which can be tested in the data, the mSITA, CIT and CIO
assumptions are not testable. Instead, researchers should use substantive knowledge
of the given clinical setting to determine the plausibility of the mSITA, CIT and
CIO assumptions.
The first step to assess the plausibility of these assumptions would be to consider
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Figure 8.1: A causal diagram for a simple scenario with a partially observed confounder
X and a fully observed confounder C, incorporating the missing indicator R. Y (z) is the
potential outcome resulting from intervening to set treatment Z to a particular value z.
whether it is clinically plausible that X is only a confounder when it is observed.
If so, and if key violations of the assumptions can be ruled out, then researchers
can construct a causal diagram to represent the underlying structural assumptions
for the given clinical setting [86]. This causal diagram should include the missing
indicator R. The next step is to convert this causal diagram to incorporate potential
outcomes [6769]. Then, the d-separation rule  which determines whether variables
are conditionally independent given a set of other variables [66,67]  can be applied
to the causal diagram to assess whether the mSITA assumption holds. In order to
assess the CIT and CIO assumptions, the causal diagram should be restricted to
patients with R = 0 and modified to reflect why it is plausible that X is only a
confounder when it is observed [86]. The d-separation rule can then be applied to
this final causal diagram to assess the CIT and CIO assumptions.
For example, consider a simple scenario with a partially observed confounder X
and a fully observed confounder C, where C also has causal effects on both X and
R. Further suppose that the X-Z relationship is absent in patients with missing X
values. Hence, it is plausible that X is only a confounder when it is observed. Figure
8.1 shows a causal diagram representing this scenario, constructed in the form of
a single world intervention graph in order to incorporate potential outcomes [67].
Applying the d-separation rule to Figure 8.1, as previously described [67, 86], we
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Figure 8.2: A causal diagram for a simple scenario with a partially observed confounder
X and a fully observed confounder C, modified to assess the CIT and CIO assumptions.
The square box around R = 0 indicates restriction to individuals with missing X values.
Y (z) is the potential outcome resulting from intervening to set treatment Z to a particular
value z.
find that Z is conditionally independent of Y (z) given C, X and R. Hence, the
mSITA assumption holds in this example. In order to be able to assess the CIT
and CIO assumptions, we modify Figure 8.1, by restricting to patients with R = 0
and removing the arrow from X to Z in order to encode the assumption that the
X-Z relationship is absent in patients with R = 0. Figure 8.2 shows this modified
causal diagram. Applying the d-separation rule to this diagram, we find that the
CIT assumption holds and that the CIO assumption is violated. Hence, in this
scenario, the mSITA and CIT assumptions hold and the missing indicator approach
is considered appropriate.
When there are multiple partially observed confounders, R becomes a vector of
the missing indicators, whilst Xobs now represents all of the sets of observed con-
founder values and Xmis represents all sets of missing confounder values. Assuming
that the missingness of these confounders are not associated with each other or with
the other confounders, we can assess the CIT and CIO assumptions for each con-
founder separately, but whilst conditioning on all sets of observed confounder values
and all fully observed confounders. An assumption only holds if it holds for every
confounder. Issues may arise if the missing indicator of one confounder changes
the missing values of another confounder; however, this seems unlikely. For com-
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plex scenarios, we recommend constructing a causal diagram that incorporates all
relevant substantive knowledge and a missing indicator for each partially observed
confounder, and then using software such as Dagitty [77] to assess the plausibility
of the assumptions.
8.5 Unbiased estimation of the average treatment
effect
In this section we prove that, under the four assumptions given in Section 8.4.2.1,
the missing indicator approach in outcome regression can give an unbiased estimate
of the average treatment effect (ATE). We also explore how this result relates to the
findings in the literature that the missing indicator approach gives biased results [59],
and how the assumptions relate to prior literature.
The target estimand is: ATE = E[Y (1)]− E[Y (0)]. We can rewrite this as:
ATE = E
[
E
(
Y (1)|C,Xobs, R
)− E(Y (0)|C,Xobs, R)],
which can then be written as:
ATE =
∑[∑
yP
(
Y (1) = y|C,Xobs, R
)−∑ yP(Y (0) = y|C,Xobs, R)]. (8.4)
Below in Section 8.5.1, we show that if the mSITA assumption holds and either
the CIT assumption or the CIO assumption holds, then:
E[Y (z)|C,Xobs, R] = E[Y (z)|Z,C,Xobs, R] (for z = 0, 1). (8.5)
Hence, we can rewrite equation (8.4) as:
ATE =
∑[∑
yP
(
Y (1) = y|Z,C,Xobs, R
)−∑ yP(Y (0) = y|Z,C,Xobs, R)]
= E
[
E
(
Y (1)|Z,C,Xobs, R
)− E(Y (0)|Z,C,Xobs, R)].
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Under the consistency assumption (Section 8.4.1), this is:
ATE = E
[
E
(
Y |Z = 1, C,Xobs, R
)− E(Y |Z = 0, C,Xobs, R)]. (8.6)
So, we can model the relationship between the outcome and C,Xobs, R in each
of the two treatment groups and  assuming that the outcome model is correctly
specified  we can substitute estimates of the conditional expectations in equation
(8.6) to obtain an unbiased estimate of the ATE. Thus, under the assumptions
given in Section 8.4.2.1, we can get an unbiased estimate of the treatment effect by
modelling the relationship between outcome and treatment, given confounders and
the missing indicator.
The missing indicator approach suggests a particular parametric specification of
the outcome model, at this stage. In particular, missing indicators are added as
main effects only, thereby encoding the assumption that there are no interactions
between the missing indicators and fully observed confounders. These parametric
modelling assumptions can be assessed using the data at hand, although it is unclear
whether such checks are common in practice.
8.5.1 Proof of equation (8.5)
We first suppose the mSITA and CIT assumptions hold (equations (8.2) and (8.3a),
respectively). For z = 0, 1, we can write E[Y (z)|C,Xobs, R] (from equation (8.5)) in
summation notation:
∑
yP
(
Y (z) = y|C,Xobs, R
)
=
∑∑
yP
(
Y (z) = y,Xmis|C,Xobs, R
)
=
∑∑
yP
(
Y (z) = y|Xmis, C,Xobs, R
)
P(Xmis|C,Xobs, R). (8.7)
Under the mSITA assumption, the first probability in equation (8.7) can be
written as P
(
Y (z) = y|Z,Xmis, C,Xobs, R
)
, and under the CIT assumption, the
second probability can be written as P(Xmis|Z,C,Xobs, R). So, for z = 0, 1, equation
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(8.7) becomes:
∑∑
yP
(
Y (z) = y|Z,Xmis, C,Xobs, R
)
P(Xmis|Z,C,Xobs, R)
=
∑∑
yP
(
Y (z) = y,Xmis|Z,C,Xobs, R
)
=
∑
yP
(
Y (z) = y|Z,C,Xobs, R
)
.
Alternatively, if the mSITA and CIO assumptions (equations (8.2) and (8.3b))
hold, for z = 0, 1, we write:
∑
yP
(
Y (z) = y|C,Xobs, R
)
=
∑
y
P
(
Y (z) = y|C,Xobs, R
)
P
(
Z|C,Xobs, R
) ∑P(Z,Xmis|C,Xobs, R),
(8.8)
where the denominator is strictly positive under the positivity assumption.
Now, we can write:
∑
P
(
Z,Xmis|C,Xobs, R
)
=
∑
P
(
Z|Xmis, C,Xobs, R
)
P
(
Xmis|C,Xobs, R
)
. (8.9)
Under the mSITA assumption, the first probability in equation (8.9) can be
written as P
(
Z|Y (z) = y,Xmis, C,Xobs, R
)
, and under the CIO assumption, the
second probability can be written as P(Xmis|Y (z) = y, C,Xobs, R). So, for z = 0, 1,
equation (8.9) becomes:
∑
P
(
Z,Xmis|C,Xobs, R
)
=
∑
P
(
Z|Y (z) = y,Xmis, C,Xobs, R
)
× P(Xmis|Y (z) = y, C,Xobs, R)
=
∑
P
(
Z,Xmis|Y (z) = y, C,Xobs, R
)
= P
(
Z|Y (z) = y, C,Xobs, R
)
.
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Hence, we can write equation (8.8) as:
∑
y
P
(
Y (z) = y|C,Xobs, R
)
P
(
Z|C,Xobs, R
) P(Z|Y (z) = y, C,Xobs, R)
=
∑
y
P
(
Y (z) = y, Z|C,Xobs, R
)
P
(
Z|C,Xobs, R
)
=
∑
yP
(
Y (z) = y|Z,C,Xobs, R
)
.
8.5.2 Connections to prior work on the missing indicator
approach
Jones (1996) assumed that the true outcome model is a linear regression model with
a fully observed covariate Z, a single partially observed covariate X and independent
normal errors :
Y = β0 + β1Z + β2X + , (8.10)
where  is independent of (Z,X,R). Correspondingly, the missing indicator approach
can be represented mathematically as:
E[Y ] = γ0 + γ1Z + γ2X
∗ + γ3R. (8.11)
Jones (1996) showed that the least squares estimator of γ1 is biased for β1, noting
that the least squares estimator is unbiased when the sample covariance of Z and X,
for patients missing X, is zero. If the CIT assumption holds, this condition holds,
since treatment allocation is independent of the confounder for those patients with
missing confounder values.
The true outcome model assumed by Jones (1996) in equation (8.10) leads to
the CIO assumption being violated as the outcome is dependent on the missing con-
founder values. However, if the CIO assumption does hold, then the true outcome
model instead resembles the parametric model corresponding to the missing indica-
tor approach in equation (8.11) (i.e. the true model is Y = β0+β1Z+β2X
∗+β3R+),
and it is simple to show that the least squares estimator is unbiased.
Hence, our findings are compatible with Jones's findings (1996). We have addi-
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tionally shown that the missing indicator approach can give unbiased estimates when
the mSITA and CIO assumptions hold (regardless of whether the CIT assumption
additionally holds).
8.5.3 Connection to alternative statements of assumptions
in the literature
The missing indicator method has been recommended for propensity score anal-
ysis [55], based on work in relation to the missingness pattern approach within
propensity score analysis [46, 63]. This approach involves modelling the propensity
score separately for each pattern of missing confounder data and can be thought of
as a generalisation of the missing indicator method.
In Section 8.4.2.1, our statement of the mSITA, CIT and CIO assumptions fol-
lows Mattei (2009), who states assumptions sufficient for valid inference for the
missingness pattern approach. Our assumptions differ from Mattei (2009) in that
our version of the CIO assumption is slightly weaker, and requires the conditional
independence statement to hold separately for each potential outcome, rather than
jointly for the pair of potential outcomes as in the original presentation.
D'Agostino and Rubin (2000) instead provide the following assumption, sufficient
for valid inference in the missingness pattern approach:
Z ⊥ (Y (0), Y (1), Xmis)|Xobs, R. (8.12)
The mSITA and CIT assumptions imply that equation (8.12) holds. However,
mSITA and CIO can hold while equation (8.12) is violated. Thus Mattei (2009) gives
a wider set of assumptions under which the missingness pattern approach provides
valid inference.
There are strong connections between the missingness pattern approach and
other work exploring non-systematic monitoring of time-varying covariates [74, 75].
These papers suggest a version of the no unmeasured confounding assumption
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which, in the single time-point exposure setting, can be written as:
Z ⊥ Y (z)|Xobs, R. (8.13)
If the D'Agostino assumption holds, then assumption (8.13) holds. Further, if
either the mSITA and CIT assumptions hold, or the mSITA and CIO assumptions
hold, then assumption (8.13) holds. Compared to the D'Agostino assumption (8.12),
therefore, the mSITA, CIT and CIO assumptions can be seen as a wider set of as-
sumptions under which variants of missingness-pattern-type approaches can produce
valid inference.
Kreif et al. (2018) focus on the scenario where the partially missing (non-
systematically monitored) covariate is key to the treatment decision process and
thus when the clinician does not have this covariate information, they must rely
on the last measurement available. Therefore, in their setting  in contrast to our
scenario  the covariate always contributes to the treatment decision, whether as
an up-to-date measurement or as the last available measurement. However, both
settings lead to a causal structure which satisfies a CIT-type assumption.
Here, we assume that full-data inference is the goal, i.e. if we were able to obtain
full data then we would. Kreif et al. (2018), in contrast, treat the monitoring process
(which induces the missing covariate data) as an intrinsic part of the setting, and as
an attribute of interest in its own right. In particular, in time-varying settings the
optimal treatment combination may depend on the intended monitoring process.
This makes the inferential goals of Kreif et al. (2018) quite different to those laid
out in the current paper. In particular, the set of assumptions we focus on (mSITA,
CIT and CIO) require the investigator to consider the confounding structure in the
full data setting and how missingness arises in that setting (mSITA), and then to
subsequently explore how this structure may change when missing confounder values
are present (CIT/CIO). We have found this two-step process useful in considering
plausibility of assumptions in real-life settings.
All three sets of assumptions make it clear that they are likely to be satisfied in
a setting where missing confounder values are unavailable to the individual making
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the treatment decision and thus do not affect treatment. However, only the first
version, with CIT and CIO as two separate sub-assumptions, makes it clear that
there is another quite different set of scenarios in which missingness-pattern-type
methods may provide valid inference.
8.6 Simulation Study
In this simulation study, we explored the extent of the bias introduced into the
treatment effect estimation when each of the key assumptions is violated. Source
code to reproduce the results is available as Supporting Information on the journal's
web page (http://onlinelibrary.wiley.com/doi/xxx/suppinfo).
8.6.1 Data-generating mechanisms
We considered 81 data-generating mechanisms. For each, datasets of sample size
n = 500 were generated. The data-generating mechanisms differed according to
which of the assumptions hold. A factorial design was used to consider all possible
combinations of each assumption having no violation, a weak violation or a strong
violation.
We let UZ represent a common cause between treatment and the missing indica-
tor, UY represent a common cause between the outcome and the missing indicator,
and e represent error in the outcome regression model. We generated UZ , UY and e
from independent standard Normal distributions.
Two binary confounders X and C were generated using Binomial distributions:
X ∼ Bin(1, 0.67) and C ∼ Bin(1, 0.58). To create missing data in X, we generated
a missing indicator R ∼ Bin(1,P(R = 0)), where: logit(P(R = 0)) = −0.5 + 1.48 ·
UZ + 1.36 · UY .
We also generated a binary treatment allocation variable Z ∼ Bin(1,P(Z = 1)),
where:
logit(P(Z = 1)) = −1.2 + αUZ + 1.38XR + βX(1−R) + 2R + 1.69C.
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The observed proportion of treated patients varied between 62.2% and 86.2%, de-
pending on the data-generating mechanism. We generated a continuous outcome
using the regression model:
Y = 1− 2.35Z − 2.2αUY − 1.55XR + γX(1−R) + 1.8R− 1.7C + δCR + 3e.
where α ∈ {0, 0.125, 1.25}, β ∈ {0, 0.138, 1.38}, γ ∈ {0,−0.155,−1.55} and δ ∈
{0,−0.42,−4.2}. If α = 0, then the mSITA assumption holds. Similarly, if β = 0,
γ = 0, or δ = 0, then, respectively, the CIT assumption holds, the CIO assumption
holds, or the outcome model is correctly specified. For each parameter, the smaller
and larger non-zero values represent, respectively, a weak violation and a strong
violation of the corresponding assumption.
Data were simulated using Stata 14.2 with 5000 simulation repetitions per data-
generating mechanism.
8.6.2 Methods
Each simulated data set was analysed using the missing indicator approach with mul-
tivariable linear regression, by creating a new version of the partially observed binary
covariate with a third `missing' category. Our estimand is the average treatment ef-
fect, as estimated using the treatment coefficient from a linear regression model.
Our performance measure of interest is absolute bias of the ATE: 1
5000
∑5000
i=1 θˆi − θ,
where θˆi is the estimated treatment effect from the ith repetition, and θ is the true
treatment effect.
8.6.3 Results
In Figure 8.3, the left-hand panel presents the absolute bias in the estimated treat-
ment effect for eight scenarios, depicting all possible combinations of the mSITA,
CIT and CIO assumptions holding or not. The dark bars show scenarios where the
mSITA assumption (required for valid inference) holds. The light bars show scenar-
ios where it does not. As expected from our theory above, if the mSITA assumption
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Figure 8.3: Results from a simulation study showing the absolute bias in the estimated
treatment effect when using the missing indicator approach for multiple linear regression
under different data-generating mechanisms, which vary according to: (i) whether the
mSITA assumption holds; (ii) whether the CIT assumption holds; (iii) whether the CIO
assumption holds; and (iv) whether there is an interaction between the fully observed
confounder C and the missing indicator R in the true outcome model. True treatment
effect: −2.35. Sample size: n = 500. Number of replications: 5000.
is violated (light bars), bias is present. The four sets of bars show combinations
of the CIT and CIO assumptions holding or not, for scenarios where the mSITA
assumption holds (dark bars); bias is present only when both CIT and CIO are
violated. The right-hand panel of Figure 8.3 shows the same eight scenarios, but
with a violation of the parametric assumption: the outcome model fitted assumes
no interaction between the missingness indicator and the fully observed confounder
C, but in truth this interaction does exist. Violation of this parametric assumption
leads to bias in all eight scenarios.
Figure 8.4 shows a number of scenarios in which the outcome model is correctly
specified but the other three assumptions (mSITA, CIT and CIO) may be violated.
The three panels show  from left to right  increasing levels of violation of the
CIO assumption. Within the three panels, the three sets of bars show  from
left to right  increasing levels of violation of the CIT assumption. Within each
set of bars, the bars show  from left to right  increasing levels of violation of
the mSITA assumption. Large bias is seen when either a strong violation of the
mSITA assumption is present, or when strong violations of both the CIT and CIO
assumptions are present.
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Figure 8.4: Results from a simulation study showing the absolute bias in the estimated
treatment effect when using the missing indicator approach for multiple linear regression
under different data-generating mechanisms, which vary according to whether there is no
violation, a weak violation or a strong violation of: (i) the mSITA assumption, (ii) the
CIT assumption, and (iii) the CIO assumption. For all data-generating mechanisms, the
outcome model is correctly specified. True treatment effect: −2.35. Sample size: n = 500.
Number of replications: 5000.
Figure 8.5 shows the same scenarios as Figure 8.4, but with weak violations
of the parametric assumptions (weak CR interactions present but not included in
the fitted model) shown in the top panel, and strong violations of the parametric
assumptions shown in the bottom. Weak violations of the parametric assumptions
induced additional small amounts of bias compared to Figure 8.4. Strong violations
of the parametric assumptions induced large amounts of bias under most settings.
The missing indicator approach gives unbiased estimates of the treatment effect
when the mSITA assumption holds, the outcome model is correctly specified and
either one, or both, of the CIT and CIO assumptions hold. When both the CIT and
CIO assumptions are violated, the missing indicator approach gives biased results,
whether or not the other two assumptions hold. The worst bias occurs when both
the mSITA assumption and the correct specification assumption is violated and the
CIT assumption holds, whether or not the CIO assumption holds. In general, having
the mSITA assumption violated results in larger biases for the settings explored in
the simulation study. In addition, incorrectly specifying the outcome model, i.e.
failing to include an interaction between the fully observed confounder C and the
missing indicator R in the true outcome model, generally results in larger biases
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Figure 8.5: Results from a simulation study showing the absolute bias in the estimated
treatment effect when using the missing indicator approach for multiple linear regression
under different data-generating mechanisms, which vary according to whether there is no
violation, a weak violation or a strong violation of: (i) the mSITA assumption, (ii) the
CIT assumption, and (iii) the CIO assumption. For all data-generating mechanisms, the
true outcome model contains either a weak interaction (8.5a) or a strong interaction (8.5b)
between the fully observed confounder C and the missing indicator R. True treatment
effect: −2.35. Sample size: n = 500. Number of replications: 5000.
than when the outcome model is correctly specified.
When the outcome model is correctly specified, weak violations of the other
assumptions results in similar biases compared to when the assumptions hold (Fig-
ure 8.4). Similar results were found when considering data-generating mechanisms
where the true outcome model includes a weak CR interaction and when considering
data-generating mechanisms with a strong CR interaction (Figures 8.5a and 8.5b
respectively). In general, having a weak CR interaction resulted in similar or larger
biases compared to scenarios where the outcome model is correctly specified.
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8.7 Application to illustrative example
8.7.1 Study description
Our illustrative example is a cohort study using electronic health records data from
the UK Clinical Practice Research Datalink and the Hospital Episode Statistics [11].
The cohort study aimed to investigate the association between risk of acute kidney
injury (AKI) and use of angiotensin-converting enzyme inhibitors or angiotensin
receptor blockers (ACEI/ARBs), compared to other antihypertensive drugs. An
important covariate in the study was chronic kidney disease, which was categorised
into stages based on a continuous measure of kidney function called the estimated
glomerular filtration rate (eGFR). Lower values of eGFR indicate worse kidney
function.
Data were obtained for 570 586 new adult users of antihypertensive drugs be-
tween 1997 and 2014. Follow-up began at first prescription of ACEI/ARBs, beta
blockers, calcium channel blockers, or diuretics. The treatment of interest was pre-
scription of ACEI/ARBs. Our outcome of interest was kidney function within 2
months of first prescription of an antihypertensive drug, as measured using eGFR
[87]. Due to conditions of the data use agreement, we can no longer access the
eGFR data after treatment initiation, so we have simulated this variable, based on
observed relationships in prior studies (see Appendix for details). As a result, the
`true' treatment effect is known.
In this study there were a number of fully observed potential confounders: age,
sex, chronic comorbidities, other antihypertensive or diuretic drugs, and calendar
period. In addition, two potential confounders were partially observed: ethnicity,
which had 59.0% missing data; and baseline eGFR category, which had 52.9% miss-
ing data.
In this example, only 21% of patients had complete data for both ethnicity and
baseline eGFR category; the majority of patients records would be discarded, lead-
ing to a loss of efficiency, if complete record analysis was used for this example.
Furthermore, standard multiple imputation may not be appropriate since the miss-
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ing at random assumption is questionable: baseline eGFR category is more likely to
be measured for patients with worse kidney function. The assumptions underlying
the missing indicator approach seem reasonable in this context. First, the mSITA
assumption would be violated if there are any unobserved common causes between
missingness of baseline eGFR category and treatment allocation or the outcome.
In this example, it seems plausible that any such common causes, such as age or
chronic comorbidities, are measured and able to be included in the analysis model.
In addition, predictors of missingness in ethnicity seem unlikely to also be predictors
of prescription decisions. Thus the mSITA assumption seems plausible here.
Second, it is plausible to assume that information about a patient's baseline
eGFR category is unlikely to influence the clinician's decision to prescribe if this
information is not available to the clinician (eg. if a kidney function test had not been
ordered beforehand). In practice, proxy information about a patient's baseline eGFR
category may be available to the clinician (but not to researchers using electronic
health records). However, this is likely to reflect poor kidney function for only a
small proportion of the whole study population. In addition, it is plausible that a
clinician would ensure information on patient's ethnicity is recorded if they believe
that this information is an important factor in their decision whether or not to
prescribe ACEI/ARBs. Thus we believe that the CIT assumption is plausible.
Third, it seems plausible that the effect of the other fully observed risk factors
on AKI would not vary according to whether or not ethnicity and baseline eGFR
category were measured. Furthermore, this assumption can be tested in the data.
Fourth, the CIO assumption does not seem plausible in this context  since
baseline kidney function remains a risk factor for change in eGFR, whether or not
baseline eGFR category is measured. Since we can obtain valid inferences from
the missing indicator approach when just one of the CIT and CIO assumptions
hold (in addition to the mSITA and correct specification assumptions holding), the
CIO assumption being violated is not an issue here; the mSITA, CIT and correct
specification assumptions seem plausible and thus the missing indicator approach is
considered appropriate.
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8.7.2 Method
We applied linear regression, adjusted for ethnicity, baseline eGFR category and
fully observed confounders (age category, sex, chronic comorbidities, and calendar
period), to obtain estimates of the treatment effect comparing patients prescribed
ACEI/ARBs at start of follow-up time exposed to ACEI/ARBs versus patients not
prescribed ACEI/ARBs at baseline. To handle missing data in ethnicity and base-
line eGFR category, we applied complete record analysis and the missing indicator
approach. Analysis was conducted in Stata 14.2.
8.7.3 Results
Our results are given in Table 8.1. The missing indicator approach uses all miss-
ingness patterns; in addition to the 121 527 patients with complete data, 112 142
patients had missing data for baseline eGFR category, 147 011 have ethnicity miss-
ing, and 189 906 had missing data for both. Using the missing indicator approach,
the estimated treatment effect was closer to the true treatment effect than the esti-
mate from complete record analysis. In addition, the complete record analysis esti-
mate has a wider confidence interval due to the exclusion of over 75% of the patient
records. When interactions between the missing indicators and the fully observed
confounders are added into the regression model, the results do not change much
compared to the missing indicator approach (-0.6575, 95% CI: [-0.7509, -0.5640]),
and so there is no evidence of a violation of the parametric assumption.
Table 8.1: Estimated treatment effects (mean differences) and 95% confidence intervals
(CIs) using linear regression to compare the effect on (simulated) kidney function of being
prescribed ACEI/ARBs at start of follow-up versus not being prescribed ACEI/ARBs at
baseline. True treatment effect: -0.6831
Missing data method Treatment effect (95% CI) Number of
patients analysed
Complete record analysis −0.6150 (−0.7977,−0.4324) 121 527
Missing indicator approach −0.6496 (−0.7424,−0.5567) 570 586
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8.8 Discussion
In this paper, we have shown that the missing indicator approach in outcome regres-
sion is unbiased when (i) there is no unmeasured confounding within missingness
patterns; (ii) either confounder values of patients with missing data are condition-
ally independent of treatment assignment, or these missing confounder values are
conditionally independent of the outcome; and (iii) the effect of fully observed con-
founders on the outcome is the same for all missingness patterns. We have applied
the missing indicator approach to an illustrative example using routinely collected
data, a key area in which the method's underlying assumptions may be plausible [86].
An advantage of the missing indicator approach for outcome regression is that it
is easy to implement and, unlike complete record analysis, avoids discarding much
information when the proportion of missing data is large. In addition, the missing
indicator approach may be appropriate in situations where multiple imputation is
not, as the missing indicator approach does not rely on the conventional classifi-
cation of missingness mechanisms. Whereas standard implementation of multiple
imputation is guaranteed to be valid when data are missing at random, the CIT and
CIO assumptions are not about the missingness mechanism, but are rather about
whether the partially observed covariate confounds the relationship between treat-
ment and outcome when it is missing. When either the CIT or the CIO assumption
holds, the relationships between variables among patients with observed data are
not the same as those among patients with missing data, and so multiple imputa-
tion may not be appropriate. In contrast, the missing indicator approach may be
unbiased under missing not at random mechanisms, and biased under some missing
completely at random mechanisms.
The missing indicator approach has been criticised in the missing data method-
ology literature as being `ad hoc' [57] and biased [58, 59]. We have shown that the
missing indicator approach can give unbiased results under certain assumptions. Re-
searchers seeking to use the missing indicator approach should first consider whether
these assumptions seem plausible within the context of a given clinical setting, with
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the help of causal diagrams. In our simulation study, we considered scenarios with
a single partially observed variable. Our suggested approach to handling multiple
partially observed confounders within the missing indicator framework requires the
assumption that the missingness of one confounder does not affect the missing val-
ues of another confounder. In practice, researchers should carefully consider the
plausibility of such an assumption, in addition to considering the plausibility of
the mSITA, CIT, CIO, and correct specification assumptions. If the assumptions
underlying the missing indicator approach are found to not be appropriate, then
researchers should consider whether the assumptions underlying complete record
analysis or multiple imputation are more appropriate in the given scenario.
The missing indicator approach is a method for handling missing covariate data,
but cannot handle missing data on the outcome or treatment allocation. Further
work is required to extend the approach to handle other missing data, perhaps by
combining with other methods such as multiple imputation. Another limitation
of the missing indicator approach, in the context of propensity score analysis, is
that estimation issues may arise if there are many missingness patterns and some of
these patterns have low sample size. Qu and Lipkovich (2009) proposed a pattern-
pooling algorithm to ensure sufficient sample size for estimation in propensity score
analysis [70]. Further work is needed to explore the impact of low sample size in
missingness patterns in the context of outcome regression and whether this impact
can be alleviated by using pattern-pooling algorithms. A limitation of our simulation
study is that we did not assess the impact of changing the proportion of missing
data. However, when the assumptions do not hold, bias is expected to increase with
the proportion of missing data. Furthermore, in this paper, we have focused on
linear regression. We believe that our theoretical results can be extended to risk
difference estimation and Poisson regression; further work is required to confirm
this. Careful consideration would be required to translate these results to the odds
ratio setting due to non-collapsibility issues.
In conclusion, the missing indicator approach for outcome regression can be ap-
plied in a principled way and can give valid results under a particular set of assump-
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tions, but researchers must first consider whether these assumptions seem plausible
in the clinical setting of interest. We end by noting that standard application of
the missing indicator approach makes rather strong parametric assumptions about
absence of interactions between missing indicators and fully observed confounders;
we recommend that checking these assumptions in the data at hand should form
part of routine practice when applying this approach.
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Appendix
A. Simulating kidney function for the illustrative example
We simulated a continuous outcome Y = Xβ+e whereX denotes the design matrix,
β represents the vector of regression coefficients and e denotes the vector of error
terms, where e ∼ (0, 14.65). The design matrix contains the vector with all entries
equal to 1 and the following variables: prescription of ACEI/ARBs at baseline;
diabetes mellitus status at baseline; hypertension status at baseline; cardiac failure
status at baseline; arrhythmia status at baseline; ischaemic heart disease status
at baseline; sex; ageband at baseline; calendar period at baseline; ethnicity; and
baseline eGFR category. The regression coefficients are given in Table 8.2.
Table 8.2: Regression coefficients for using baseline characteristics to simulate an outcome
variable measuring kidney function within two months of prescription of antihypertensive
drugs. ACEI/ARBs: angiotensin-converting enzyme inhibitors or angiotensin receptor
blockers. eGFR: estimated glomerular filtration rate.
Coefficient Variable Coefficient Variable
-0.6831 ACEI/ARBs prescription 1.3974 calendar period 2001− 2004
0.4847 diabetes mellitus 2.7825 calendar period 2005− 2008
-5.5041 hypertension 4.2181 calendar period 2009− 2011
-1.9321 cardiac failure 4.9409 calendar period 2012− 2014
-1.6349 arrhythmia 4.1883 ethnicity recorded as south asian
-3.4547 ischaemic heart disease -2.6490 ethnicity recorded as black
-1.6717 female 2.7238 ethnicity recorded as other
-12.8473 45 ≤ age < 55 3.3971 ethnicity recorded as mixed
-17.6097 55 ≤ age < 60 0.1647 ethnicity missing
-20.0686 60 ≤ age < 65 -36.7126 baseline eGFR < 30
-22.1784 65 ≤ age < 70 -25.1941 30 ≤ baseline eGFR < 45
-24.1881 70 ≤ age < 75 -16.3931 45 ≤ baseline eGFR < 60
-26.5288 75 ≤ age < 85 -4.4043 baseline eGFR missing
-25.6283 age ≥ 85 94.0335 constant
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Chapter 9
Discussion
In this thesis, I have investigated missing data methods incorporating missingness
information to deal with partially observed confounder data when using causal in-
ference methods in observational studies. In particular, I have focused on the miss-
ingness pattern approach (MPA) for propensity score analysis, as well as the related
missing indicator approach for propensity score analysis and for outcome regression.
9.1 Objective 1: Exploring the assumptions of the
missingness pattern approach
The first objective of my thesis was to explore the assumptions under which the
MPA would provide valid inference, by: (i) investigating the connection between
the MPA and the conventional classification of missing data proposed by Rubin
(1976) [20], (ii) identifying settings where the assumptions are likely to be plausible,
and (iii) developing ways of assessing the assumptions.
Two methodological articles in the literature, D'Agostino and Rubin (2000)
and Mattei (2009), have proposed assumptions underlying the validity of the MPA
[46, 63]. However, the connection between these two sets of assumptions is unclear.
Nor is it clear how the assumptions relate to the conventional classification of miss-
ingness mechanisms proposed by Rubin [20,44] or how to assess whether or not the
assumptions hold.
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In this thesis, I have clarified the connection between the two sets of assump-
tions given in the literature, finding that the set of assumptions proposed by Mattei
(2009) [63] is a wider statement of the assumptions underlying the MPA than the
assumption stated by D'Agostino and Rubin (2000) [46]. Following Mattei's state-
ment of the assumptions sufficient for valid inference using the MPA [63], I have
stated weaker assumptions that hold separately for each potential outcome, rather
than holding jointly. I have proved that the MPA can obtain unbiased estimates of
the treatment effect under these weaker assumptions.
In addition, I have found that the assumptions underlying the MPA are separate
from the conventional classification of missingness mechanisms, as classifying missing
data according to Rubin's taxonomy is not informative with respect to assessing
plausibility of the MPA's assumptions.
In order to be able to assess the plausibility of the MPA's assumptions, I used
single world intervention graph templates (SWITs) incorporating the missing in-
dicator. I then adapted these causal diagrams in order to be able to assess the
CIT and CIO assumptions. My initial strategy was to construct SWITs where the
confounder node was split into two component parts: the observed confounder val-
ues and the missing confounder values. However, this strategy required the use of
deterministic arrows which meant that applying d-separation may not identify all
conditional independencies. Thus, I used an alternative strategy to modify SWITs
for use in assessing the CIT and CIO assumptions, where SWITs are constructed by
conditioning on missingness patterns, and d-separation is applied to the SWIT(s)
representing the pattern(s) with missing data.
9.2 Objective 2: Guidance for assessing the
assumptions underlying the missingness
pattern approach
The second objective of my thesis was to develop practical guidance for assessing
the MPA's assumptions in a given setting. Prior to this work, no guidance existed
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for how to assess the MPA's assumptions; this may be a major factor as to why the
MPA is not used much in practice.
In this thesis, I have used causal diagrams to explore when the MPA's assump-
tions are violated in a range of simple settings, by varying: the causal relationships
between confounders and treatment allocation, the causal relationships between con-
founders and outcome, and causal relationships with the missing indicator. I con-
sidered all combinations of the factors considered, applying d-separation to causal
diagrams representing each scenario and employing the use of twin networks when
treatment allocation or potential outcomes has a causal effect on the missing indi-
cator.
On the basis of the results, I have developed guidance for assessing the MPA's
assumptions. Initially, I developed the guidance in the form of a decision tree and
provided a worked example of how it could be used to assess the assumptions in set-
tings with a single partially observed confounder and restricted to certain temporal
assumptions.
I then developed more comprehensive guidance in a step-by-step format that
focuses on assessing the plausibility of possible violations and recommends the use
of causal diagrams to help assess the plausibility of the MPA's assumptions.
The step-by-step guidance for assessing the MPA's assumptions in practice be-
gins by considering whether or not it is plausible that the confounder with missing
data is only a confounder when observed. In other words, given that the observed
confounder values do indeed confound the relationship between treatment allocation
and the potential outcomes, either the missing confounder values have no effect on
treatment allocation or the missing confounder values have no effect on the potential
outcomes (or both). If it is decided that it is indeed plausible that the confounder is
only a confounder when it is observed, then the next step is to assess the plausibility
of key violations in the setting of interest. If it is considered plausible that these
violations are not present, then I recommend constructing a causal diagram where
possible and using the d-separation rule to assess the MPA's assumptions.
I have demonstrated the step-by-step guidance in a real-data example, discussing
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the clinical context of the example setting and showing how this information is
utilised when assessing the plausibility of the MPA's assumptions. In addition, I
have provided code for constructing causal diagrams and applying d-separation using
the DAGitty package in R, both for a general hypothetical example as well as for
the real world example.
9.3 Objective 3: The missing indicator approach
for propensity score analysis
My third thesis objective was to explore the relationship between the MPA and the
missing indicator approach in the context of propensity score analysis, in particular
investigating the implications of this relationship on the assumptions under which
the missing indicator approach can provide valid inference.
The missing indicator approach has been criticised in the missing data methodol-
ogy literature for being an `ad hoc' missing data method [56,57] that leads to biased
results in general [58, 59]. Whilst Stuart (2010) [55] and Williamson and Forbes
(2014) [25] have recommended the use of the missing indicator approach to handle
partially observed confounder data in propensity score analysis, no formal evidence
has been yet provided to support their recommendations. Despite this, incorporat-
ing missing indicators into regression models is a popular method in epidemiological
studies [52]. Indeed, my motivating example is from a pharmacoepidemiological
study using electronic health records that includes an `absent' category in the base-
line chronic kidney disease (CKD) stage variable. Baseline CKD stage is more likely
to be recorded for patients with poorer kidney function and so excluding patients
missing baseline CKD stage would induce selection bias. Hence my third thesis ob-
jective is to consider whether using missing indicators was an appropriate approach
to handing missing confounder data.
In this thesis, I have shown a clear mathematical connection between the be-
tween the MPA and the missing indicator approach, finding that the missing indi-
cator approach is a simplification of the MPA. I also demonstrated that the missing
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indicator approach can provide valid inference under the MPA's assumptions and an
additional parametric assumption that there are no interactions between fully ob-
served confounders and the missing indicator in the propensity score model. Hence,
I have shown that the missing indicator approach for dealing with partially observed
confounder data can provide valid inference and so enable researchers to use this
approach in a principled way.
9.4 Objective 4: The missing indicator approach
for outcome regression
My fourth thesis objective was to investigate the use of the missing indicator ap-
proach in the context of outcome regression. The general missing data methodology
literature consider the missing indicator approach to be `ad hoc' and unprincipled,
and recommend avoiding the approach, with some theoretical work [59] showing that
the approach is generally biased. Indeed, our result from Objective 3 showed that
the missing indicator approach can provide valid inference in the propensity score
context. The continued use of the missing indicator approach in outcome regression
settings, such as our motivating example encourages a further consideration of this
approach.
In this thesis, I have proved that the missing indicator approach can obtain valid
inference in the context of outcome regression under the MPA's assumptions and
further parametric assumptions. Furthermore, I have shown how this finding relates
to the results published by Jones (1996) [59].
In particular, although Jones ultimately concludes that the missing indicator
approach for outcome regression is generally biased, Jones notes situations where
the approach is unbiased, including scenarios where data are fully observed. I have
shown that the other situation highlighted by Jones corresponds to settings where
the MPA's assumptions  in particular the CIT assumption  hold. I have also
shown that the assumed true outcome model in Jones (1996) [59] precludes the CIO
assumption from being satisfied. If instead, the CIO assumption does hold, then
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the true outcome model incorporates the missing indicator as a covariate, and the
missing indicator approach can thus provide valid inference.
In addition, I have implemented a simulation study to explore the extent of bias
introduced in outcome regression when the assumptions underling the missing indi-
cator approach are violated, finding that weak violations of the assumptions may not
introduce substantial amounts of bias compared to strong violations. A key finding
from the simulation studies conducted during the PhD was that the conventional
approach of generating missing data after the main data generation of confounders,
treatment and outcome leads to violations of both the CIT and CIO assumptions,
and thus the MPA would generally yield biased results. Instead, I discovered that for
the CIT or CIO assumptions to be able to hold, the missingness generation must be
incorporated into the main data generation process: the missingness pattern must
be able to influence the treatment allocation and/or the potential outcomes.
9.5 Dissemination of my research so far
In this thesis, I have included two papers that have been developed over the course
of my PhD. The first paper, providing step-by-step guidance for assessing the MPA's
assumptions in propensity score analysis, has been resubmitted to Statistics in
Medicine after undergoing review and revisions based on the reviewers' comments.
The second paper, exploring the use of the missing indicator approach in the con-
text of outcome regression, has undergone revisions based on reviewer comments
and has been accepted by the Biometrical Journal pending further minor revisions.
Other dissemination efforts include presentations at two international conferences
and internal meetings throughout the PhD.
In March 2017, I presented a poster on the decision-tree guidance at a research
degree poster day at the London School of Hygiene and Tropical Medicine for a
general audience. I also presented this work in more detail at a meeting in May 2017
for researchers involved in missing data methodological research, and in July 2017
at the 38th Annual Conference of the International Society for Clinical Biostatistics
in Vigo, Spain.
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In August 2018 I presented preliminary work, on extending the work on the miss-
ing indicator approach being a principled approach for handling missing confounder
data in propensity score analysis to the context of outcome regression, at the Joint
International Society for Clinical Biostatistics and Australian Statistical Conference
2018 in Melbourne, Australia.
9.6 Further areas for research
During the course of my PhD, I have identified areas for further work. First, whilst
the MPA is a relatively simple method to implement compared to multiple impu-
tation, as the number of missingness patterns increases (and thus the number of
propensity models increases), implementation of the MPA in standard software may
become more complex. Further work would be required to write functions for imple-
menting the MPA in standard software such as Stata and R, including calculating
appropriate standard errors.
Another issue when dealing with a large number of missingness patterns is spar-
sity of data: some missingness patterns may be rare and thus lead to model es-
timation issues. Approaches for dealing with sparsity have been suggested in the
literature. D'Agostino et al. (2001) suggested a variation of the MPA where, in each
missingness pattern, propensity scores are estimated in the wider group of all pa-
tients with observed data for the relevant confounders but retaining the estimated
propensity scores only for those who actually had that missingness pattern [64].
However, this approach may lead to correlation issues as patients will be used in
multiple patterns. How to deal with this correlation in order to calculate appropriate
standard errors requires further consideration.
An alternative approach to dealing with sparse missingness patterns was sug-
gested by Qu and Lipkovich (2009). Their suggested approach was a pattern pooling
algorithm that groups `similar' missingness patterns using a distance metric in order
to obtain a set of pooled patterns that have a minimum sample size [70]. Further
work is required to investigate the performance of this algorithm in practice and to
compare pattern pooling to the D'Agostino modification of the MPA. Writing func-
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tions in standard software for implementing the pattern pooling algorithm would
also be a valuable contribution.
Qu and Lipkovich (2009) also proposed an approach that combines multiple
imputation and the MPA [70]. Seaman and White (2014) explored this approach
[80], but further consideration is required to investigate assumptions underlying the
method and their connections with the MPA's assumptions and Rubin's taxonomy.
It would be also interesting to explore the use of multiple imputation for dealing
with missing outcome or treatment allocation values with missingness pattern-type
approaches to deal with partially observed confounders, and other combinations of
missing data methods.
It is well known in the propensity score literature that propensity score analysis
is a two-stage process: the first stage estimates the propensity score and the second
stage uses this estimated propensity score in the estimation of the treatment effect
[25, 88]. Thus, when estimating the variance of the treatment effect estimate, if
the propensity score estimation stage is not taken into account, then the standard
error is likely to be conservative, with this loss of precision being a greater issue in
scenarios with a continuous outcome [25, 88]. Williamson et al. (2014) [88] have
derived a variance estimator for propensity score analysis in complete data. This
has not yet been extended to settings where the MPA is used to deal with multiple
missing confounders, and is a key area for further work.
The simulation studies in this thesis are relatively simple. Future work could
explore magnitudes of bias in realistic settings by using plasmode simulation studies.
Another opportunity for further work would be to extend the MPA to settings
with more than two treatment arms. In addition, it is not currently clear how to
assess balance after use of the MPA or missing indicator approach.
Future work could be to consider the use of the MPA when using alternative
methods of estimating the propensity score, such as classification trees, random
forests and generalised boosted modelling [40]. Using non-parametric approaches
to estimating the propensity score, would enable development of a parsimonious
version of the MPA model, including only necesssary interactions (as opposed to
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using the MPA-equivalent approach of including covariates, missing indicators and
all interactions between missing indicators and covariates).
Another key area for further research is how to perform sensitivity analyses for
violation of the MPA's assumptions in real-world data examples.
9.7 Implications for research
Researchers must carefully consider the assumptions underlying approaches for han-
dling missing confounder data in causal inference. If considering employing miss-
ingness pattern-type approaches, it is not enough to consider which missingness
mechanism seems most plausible. Researchers should carefully consider the plau-
sibility of the MPA's assumptions in the setting of interest prior to analysis. This
can be achieved by following the practical guidance developed over the course of
my PhD, in particular by: (i) considering the clinical context to assess whether it
is plausible that the confounder(s) with missing data is only a confounder when
observed, (ii) considering the key violations identified in the guidance, and (iii) con-
structing a causal diagram to represent the scenario of interest. The plausibility of
the MPA's assumptions should be considered prior to analysis to enable capture of
predictors of missingness that might have otherwise been completely unobserved.
Advantages of the MPA and the missing indicator approach are that they are
simple to understand and they retain all patients in the analysis whether or not
they have missing data. In addition, these approaches may be appropriate where
multiple imputation is not as they do not rely upon data being missing at random.
However, there are still some key areas of research that could be explored, including:
dealing with sparseness and settings with many missingness patterns; developing
ways to assess covariate balance after using missingness pattern-type approaches
in propensity score analysis; and investigating how to perform sensitivity analyses
for violations of the MPA's assumptions. Settings in which the missingness pattern
approach and the missing indicator approach are likely to be useful are studies
using routinely collected data such as electronic health records. In these settings,
whilst the CIO assumption may be less plausible, the CIT assumption is likely to be
167
plausible as making decisions about treatment allocation can only take into account
the information available.
The information available to the researcher using routinely collected data is in
general the same as the information that was available to the clinician making the
treatment decision. Thus, we believe it is plausible to assume that treatment al-
location is not associated with confounder information that is unavailable to the
researcher. Hence, research using electronic health records is a key area in which
the CIT assumption is likely to be plausible.
Furthermore, as studies using large health datasets become ever more popular
with the increasing popularity of big data, approaches using missingness patterns
to handle partially observed confounder data may be less computationally intensive
than multiple imputation.
9.8 Conclusion
Using missingness patterns to deal with missing confounder data is a simple alterna-
tive to conventional missing data methods which can provide valid inference under
certain assumptions. In this thesis, I have clarified the connection between the sets
of assumptions given in the literature and I have found that classifying missing
data according to Rubin's taxonomy is not informative with respect to assessing
plausibility of the assumptions underlying the missingness pattern approach. I have
provided guidance for assessing the plausibility of these assumptions in practice. I
have also shown that using missing indicators to deal with missing confounder data
is a simplified version of the missingness pattern approach, and thus is a principled
approach in propensity score analysis and outcome regression contexts.
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Appendix A
Ethics approval
In this appendix, I include:
• the cover letter and application for ethics approval from CPRD by an Inde-
pendent Scientific Advisory Committee
• the favourable ethics approval letter from CPRD
• the (redacted) application form for ethics approval from LSHTM
• the favourable ethics approval letter from LSHTM
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N.B. Any questionnaire for completion by patients must be approved by ISAC before circulation for 
completion.   
21. Does this study require contact with patients in order to collect a sample? 
 
Yes*   No   
 
* Please state what will be collected N/A   
22. Experience/expertise available  
 
Please complete the following questions to indicate the experience/expertise available within the team of researchers 
actively involved in the proposed research, including  analysis of data and interpretation of results 
 Previous GPRD/CPRD Studies  Publications using GPRD/CPRD data 
 
None      
1-3       
> 3       
          Yes                              No 
Is statistical expertise available within the research team?       
                           If yes, please outline level of experience   very experienced 
 
Is experience of handling large data sets (>1 million records)  
available within the research team?          
                           If yes, please outline level of experience   very experienced 
 
Is UK primary care experience available within the research team?       
                           If yes, please outline level of experience   very experienced 
23.  References relating to your study 
 
Please list up to 3 references (most relevant) relating to your proposed study. 
 
Tomlinson LA, Abel GA, Chaudhry AN, Tomson CR, Wilkinson IB, Roland MO, et al. ACE inhibitor and angiotensin receptor-II 
antagonist prescribing and hospital admissions with acute kidney injury: a longitudinal ecological study. PLoS One. 
2013;8(11):e78465.  
 
Lapi F, Azoulay L, Yin H, Nessim SJ, Suissa S. Concurrent use of diuretics, angiotensin converting enzyme inhibitors, and angiotensin 
receptor blockers with non-steroidal anti-inflammatory drugs and risk of acute kidney injury: nested case-control study. BMJ. 
2013;346–8525.  
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PROTOCOL CONTENT CHECKLIST 
In order to help ensure that protocols submitted for review contain adequate information for protocol 
evaluation, ISAC have produced instructions on the content of protocols for research using CPRD data. 
These instructions are available on the CPRD website (www.cprd.com/ISAC). All protocols using CPRD data 
which are submitted for review by ISAC must contain information on the areas detailed in the instructions.  
IF you do not feel that a specific area required by ISAC is relevant for your protocol, you will need to justify 
this decision to ISAC.  
 
Applicants must complete the checklist below to confirm that the protocol being submitted includes all the 
areas required by ISAC, or to provide justification where a required area is not considered to be relevant for 
a specific protocol.  Protocols will not be circulated to ISAC for review until the checklist has been completed 
by the applicant.  
 
Please note, your protocol will be returned to you if you do not complete this checklist, or if 
you answer ‘no’ and fail to include justification for the omission of any required area. 
 
 Included in 
protocol? 
 
Required area Yes No If no, reason for 
omission 
Lay Summary (max.200 words)         
Background         
Objective, specific aims and rationale         
Study Type 
Descriptive 
Hypothesis Generating 
Hypothesis Testing 
 
 
 
 
  
 
 
 
 
      
      
Study Design         
Sample size/power calculation  
(Please provide justification of  
sample size in the protocol) 
        
Study population  
(including estimate of expected number of  
relevant patients in the CPRD)  
 
 
 
 
 
      
Selection of comparison group(s) or controls         
Exposures, outcomes and covariates 
Exposures are clearly described  
Outcomes are clearly described 
 
 
 
 
 
 
      
      
Use of linked data  
(if applicable) 
        
Data/ Statistical Analysis Plan 
There is plan for addressing confounding  
There is a plan for addressing missing data 
 
 
 
 
 
 
      
      
Patient/ user group involvement †         
Limitations of the study design, data sources  
and analytic methods 
        
Plans for disseminating and communicating study 
results 
        
 
† It is expected that many studies will benefit from the involvement of patient or user groups 
in their planning and refinement, and/or in the interpretation of the results and plans for 
further work. This is particularly, but not exclusively true of studies with interests in the 
impact on quality of life.   Please indicate whether or not you intend to engage patients in any 
of the ways mentioned above. 
 
Voluntary registration of ISAC approved studies:  
Epidemiological studies are increasingly being included in registries of research around the world, including 
those primarily set up for clinical trials. To increase awareness amongst researchers of ongoing research, 
ISAC encourages voluntary registration of epidemiological research conducted using MHRA databases. This 
will not replace information on ISAC approved protocols that may be published in its summary minutes or 
annual report. It is for the applicant to determine the most appropriate registry for their study. Please 
inform the ISAC secretariat that you have registered a protocol and provide the location. 
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Study Protocol 
1. Title 
The incidence and mortality of acute kidney injury (AKI) associated with prescribing of ACE inhibitors 
and angiotensin-receptor blockers  
2. Lay Summary 
This study uses very large numbers of linked electronic health records to answer important questions 
about episodes of sudden decline in kidney function with the aim of preventing serious illness and 
death, and creating substantial savings for the NHS. A sudden decrease in kidney function or acute 
kidney injury (AKI) is common and associated with an increased risk of death, prolonged hospital stay 
and risk of permanent kidney failure. Rates of AKI are increasing and causing significant cost to the 
NHS. Some limited evidence suggests that AKI can occur as a side effect of angiotensin converting 
enzyme inhibitors (ACEI) and angiotensin-receptor blockers (ARBs), particularly when prescribed with 
water tablets (diuretics) and anti-inflammatory painkillers. ACEI and ARBs are commonly prescribed 
for conditions such as high blood pressure and heart problems. At present it is not known how 
common AKI is among people taking these drugs or whether there are any conditions (e.g. diabetes, 
existing kidney problems) that modify the risk. This is important because if it was understood who is 
likely to develop AKI and in what circumstances, strategies could be developed to prevent AKI.  
3. Objectives 
The overall aims of the project are to investigate the incidence and mortality of acute kidney injury 
(AKI) associated with prescribing of ACE inhibitors and angiotensin-receptor blockers, and other 
commonly prescribed antihypertensive drugs (calcium channel blockers, beta-blockers, and diuretics), 
and to investigate what chronic comorbidities are associated with the development of drug-
associated AKI. 
Specifically: 
1. To evaluate the validity of an operational case definition for AKI based on morbidity coding (from 
Read-coded primary care data and ICD-10 coded hospital data) and biochemical test results. 
2. To obtain estimates for the incidence of antihypertensive-associated AKI in the UK general 
population and investigate the variation in incidence over time. 
3. To explore differences in the rate of antihypertensive-associated AKI in different classes of 
antihypertensive drugs (ACEI/ARBs, beta-blockers, calcium channel blockers and diuretics). 
4. To determine which chronic comorbidities are associated with increased risk of drug-associated 
AKI. 
5. To determine rates of mortality, hyperkalaemia and dialysis following drug-associated AKI. 
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4. Background 
Acute kidney injury (AKI) is a sudden (within hours or days) decline in renal function. It is associated 
with increased mortality (1,2) and increased duration of hospital stay (3,4). AKI has been observed in 
15–20% of hospital admissions (2,5,6). It has been estimated that the annual cost of AKI inpatient care 
in England is £1.02 billion, a little over 1% of the NHS budget (4).  
AKI has been variably defined based on changes in serum creatinine and urine output (See Appendix 
1, Table A1.1). Estimates for annual AKI hospital incidence differ based on varying AKI definitions 
ranging from 1,811 per million population using the RIFLE criteria (Risk, Injury, Failure, Loss and End 
stage) (7), to 2,400 per million population using administrative coding (8) (13), and 15,325 per million 
population using the AKIN (Acute Kidney Injury Network) definition (2). 
Angiotensin converting enzyme inhibitors (ACEI) and angiotensin receptor blockers (ARB) are often 
used in the management of hypertension and cardiac failure. There is evidence that combinations of 
ACEI/ARBs, non-steroidal anti-inflammatory drugs, and diuretics may impair renal function (9–12). 
However, there is only limited evidence of an association between AKI and ACEI/ARBs alone (13,14). 
One study has suggested an increase in post-operative AKI in cardiovascular surgery patients taking 
ACEI/ARBs preoperatively (13). While other existing evidence for an association between AKI and 
ACEI/ARBs comes from an ecological study and is therefore limited by lack of patient level data (14). 
To reduce the potential adverse effects associated with ACEI/ARBs we need a better understanding of 
individual level risk factors for AKI associated with these drugs. 
Current consensus suggests that ACEI/ARBs should be withheld during acute illness, however the 
evidence supporting this is limited (15,16) (11,20). This is in part because observational studies on this 
topic are confounded by indication. The indications for ACEI/ARB prescription are themselves 
associated with increased risk of AKI. Therefore an observed increased incidence of AKI may reflect 
increasing prevalence of comorbidities rather than a causal effect of the drugs themselves.  
We aim to investigate the association between ACEI/ARBs and AKI (drug-associated AKI). We will 
calculate the incidence of AKI in those prescribed ACEI/ARBs and compare this to AKI incidence in a 
number of control groups. We have selected our control groups to avoid confounding by indication. In 
addition to a group of matched (age, gender and GP practice) controls with no prescriptions for 
medications with similar indications to those for ACEI/ARBs, we will also look at AKI incidence in those 
prescribed other classes of antihypertensive medications (i.e. drugs prescribed for indications similar 
to those for ACEI/ARBs). Our control groups will therefore be: i) those prescribed beta-blockers (BB); 
ii) those prescribed calcium channel blockers (CCBs); iii) those prescribed thiazide diuretics; and iv) an 
age, gender and GP practice matched control group not prescribed antihypertensives (ACEI/ARBs, 
BBs, CCBs or thiazide diuretics). We will investigate changes in AKI incidence rates over time, changes 
in AKI incidence when ACEI/ARBs are prescribed in drug combinations thought to be associated with 
impaired renal function (ACEI/ARB drugs plus other diuretics and non-steroidal anti-inflammatory 
drugs), and investigate the mortality, and rate of progression to end-stage renal disease (ESRD) in 
drug-associated AKI. 
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5. Study type 
This will primarily be a hypothesis testing study. The null hypothesis is that ACEI/ARBs do not increase 
the risk of AKI compared to other antihypertensive drugs. 
6. Study design 
This will be a new-user cohort study with time-updating exposure status, using CPRD data and linked 
HES data. 
7. Study population 
We will use data from general practices in CPRD that have consented to Hospital Episode Statistics 
(HES) data linkage. The study period will cover the period for which there is HES data linkage with the 
CPRD database; from April 1997 to March 2012. However, if an updated version of CPRD linked HES 
data becomes available at an appropriate point in the project timeline (i.e. before data extraction) we 
will use the most recent version of the linked data available, which will result in a later end to the 
study period and maximise follow-up time. 
We will retrieve data on all patients aged 18 or over who do not have end stage renal disease (ESRD), 
who have no record of a prescription for antihypertensive medication (ACEI/ARBs, beta-blockers, 
calcium channel blockers, or thiazide diuretics) within the 12 months prior to cohort entry, who have 
at least one serum creatinine result recorded at any time from 12 months prior to cohort entry 
onwards (in order to establish CKD status – see Section 10.4.2), and who have a new prescription for 
one or more of the following: i) ACEI/ARBs; ii) beta blockers (BB); iii) calcium channel blockers (CCB); 
or iv) thiazide diuretics, in addition to an age, sex and GP practice matched control group on none of 
these drugs.  
7.1 Cohort entry 
Cases (antihypertensive users) will enter the cohort at first prescription for an antihypertensive (new 
use of ACEI/ARB, BB, CCB, or thiazide diuretic). Controls will enter the cohort on the same date as 
their matched cases. Patients will be eligible for cohort entry from the latest of: i) one year after 
practice registration date; ii) date practice reached CPRD quality control standards; or iii) 18th 
birthday.  
We have chosen to use a new-user cohort (i.e. entry to cohort on new use of the drugs of interest). If 
we were to include existing users of these drugs, we would introduce adherence bias, since those 
who have remained on the drug will be systematically different to those who stop taking a drug after 
the first prescription due to early adverse effects. In addition we may miss important outcomes in 
those who entered the cohort who were already prescribed the drugs of interest. 
7.2 Cohort exit 
Individuals will be eligible until the first of: i) date of death; ii) patient transferred out of practice; iii) 
last data collection from the practice; or iv) ESRD diagnosis. 
ESRD will be defined based on hospital and primary care morbidity coding as: i) presence of an ESRD 
morbidity code; ii) a code for renal transplant; iii) a code for peritoneal dialysis; iv) two or more 
haemodialysis codes more than 90 days apart; v) stage 5 chronic kidney disease (CKD); or vi) stage 4 
CKD with a fistula (this suggests rapidly worsening renal function). 
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8. Outcome 
The primary outcome of interest will be AKI. AKI cases will be identified from three sources: i) primary 
care morbidity coding (Read-codes); ii) hospital admission morbidity coding (ICD-10 codes); and iii) 
biochemical results recorded in primary care health records. 
8.1 Morbidity codes 
Primary care (Read) and hospital (ICD-10) morbidity codes for AKI will be identified by a consensus 
exercise. A list of search terms to identify AKI will be developed using the Medline medical subject 
headings (MeSH) thesaurus (see Appendix 2, Table A2.1). These search terms will be applied in both 
Read and ICD-10 code browsers. We (Laurie Tomlinson (LT) and Kate Mansfield (KM)) will classify the 
two lists of codes (Read and ICD-10) returned by the search terms independently as either probably 
representing an episode of AKI or possibly identifying an episode of AKI. The code lists we generate 
will be compared and any disagreements discussed in order to generate one list of codes that 
definitely represent an AKI episode. A previous study has already investigated the positive predictive 
value of the ICD-10 code N17 in UK hospital admissions data for the KDIGO AKI definition and found it 
to be accurate for 95% of cases (17). 
Lists of Read and ICD-10 codes for AKI are provided in Appendix 2, Tables A2.3 and A2.4, and are 
illustrative of the final lists that will be generated from the more rigorous code list development 
process described above. 
8.2 Serum creatinine algorithm 
We have developed an algorithm to identify community cases of AKI based on changes in serum 
creatinine recorded in primary care health records. Our algorithm is based on the 2013 Association 
for Clinical Biochemistry and Laboratory Medicine (ACB) algorithm for AKI (18). The ACB algorithm 
was developed to generate e-alerts using electronic hospital lab data based on the KDIGO guidelines 
for AKI (19). Applying this unchanged to community data would be imprudent since the frequency of 
renal function testing in a hospital setting is likely to be quite different to that in primary care. 
Compared to a hospital setting, serial serum creatinine measurements in the community are likely to 
be separated by longer intervals. This increases the likelihood of misclassifying a gradual decline in 
renal function as AKI.  
To avoid this sort of misclassification, our algorithm for diagnosis of AKI in the community applies the 
ACB algorithm only in those recorded with morbidity codes for acute conditions likely to cause AKI 
(e.g. acute infections) but not sufficiently severe as to as to warrant immediate hospital admission. It 
is assumed that in severe acute conditions needing hospital admission (e.g. sepsis or gastrointestinal 
bleeding) if AKI occurs it will be recorded in hospital records and therefore picked up by ICD-10 coding 
in linked HES records. 
To be classified as having an episode of AKI based on changes in community serum creatinine 
measurements a patient must have: 
1. Baseline serum creatinine measurement: A minimum of one serum creatinine result prior to the 
recording of the index acute morbidity code in order to determine baseline serum creatinine. 
2. A primary care morbidity code for an acute condition that may precipitate AKI but does not 
necessarily require hospital admission. Operationalised as a Read code for gastroenteritis, urinary 
tract infection or lower respiratory tract infection (termed the index infection). 
3. A change in serum creatinine classified as AKI according to the ACB algorithm in the two weeks 
following the record of an acute morbidity code. The maximum interval of two weeks between 
acute morbidity coding and serum creatinine result has been chosen pragmatically to allow time 
for the practicalities of community blood testing. 
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4. If a hospital admission occurs within the two weeks following the index acute morbidity code 
then, to be defined as AKI, the recorded creatinine change must occur between the index 
infection morbidity code and up to and including the day of hospital admission. If a hospital 
admission is recorded between the index-infection morbidity code and the date of the change in 
creatinine, this will not be defined as AKI since we cannot assume that the index infection 
recorded in primary care is related to the change in creatinine. 
Codes for acute infections that may precipitate AKI (urinary tract infection, gastroenteritis and 
respiratory tract infection) will be identified using a similar consensus approach to that presented in 
the previous section on identifying morbidity codes for AKI (Section 8.1). 
To explore the validity of our AKI definition we will compare incidence rates calculated using our 
measures of AKI (using a combination of both morbidity coding and biochemical test results) with 
those from a study in the Canadian general population (8) and those from a recent study using 
secondary care biochemical data in East Kent (2). 
8.3 Secondary outcomes 
We will investigate mortality, hyperkalaemia and ESRD following AKI (addressing objective five: To 
determine rates of mortality, hyperkalaemia and dialysis following drug-associated AKI). We will 
investigate overall mortality and mortality at 0–3 months following the AKI episode, 4–6 months and 
7–12 months. Hyperkalaemia will be established using specific Read and ICD-10 morbidity codes and 
potassium levels ascertained in biochemical tests. ESRD will be defined using morbidity coding as 
above (see Section 7.2). 
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9. Exposure 
9.1 Exposure status 
In the main analysis the exposure of interest will be ACEI/ARB use. Patients prescribed ACEI/ARB may 
be at greater risk of the outcome (AKI) due to prescribing indication. The main analysis will therefore 
investigate how AKI incidence differs in those exposed to ACEI/ARBs compared to three other classes 
of antihypertensive drug (BB, CCB, and thiazide diuretics), in addition to a control group exposed to 
no antihypertensive medication. 
Prescriptions for each class of antihypertensive will be identified from coded primary care 
consultation data. Drugs are uniquely identified in CPRD using codes. We will identify both the generic 
and brand names of relevant drugs using the British National Formulary (BNF). The BNF is an 
authoritative guide to UK prescription drugs. We will use the drug names to create search terms to 
identify relevant drug codes in a data file containing codes for all the available prescription drugs. We 
will exclude drugs that are not taken orally from the list. A list of search terms for each class of 
antihypertensive is included in Appendix 2 (Table A2.2). 
A prescription does not necessarily mean that a patient has taken a drug. To indicate regular use of 
the drug one approach would be to develop an exposure measure based on continued repeat 
prescription. However, our primary outcome (AKI) is an acute event that may occur as an early 
adverse event following initiation of therapy. Our main analysis will therefore use time-updating 
exposure status where individuals can move between exposure groups based on changing 
prescriptions.  
For the main analysis, exposure status will be defined in two different ways: i) time exposed to a 
single class of antihypertensive drug; and ii) exposure defined by multiple binary indicator variables 
for each class of antihypertensive or control status. We will repeat the analysis using each exposure 
definition. We will also conduct a secondary analysis looking at combination antihypertensive therapy 
in individuals prescribed ACEIs or ARBs. 
9.1.1 Exposure to a single class of antihypertensive  
We will use time-updating variables to define time at risk to the different classes of drugs. Exposure 
will be defined in the following categories: 
i. Time when prescribed an ACE/ARB (no other class of antihypertensives prescribed) 
ii. Time when prescribed a BB (no other class of antihypertensives prescribed) 
iii. Time when prescribed a CCB (no other class of antihypertensives prescribed) 
iv. Time when prescribed a thiazide diuretic (no other class of antihypertensives prescribed) 
v. Time contributed by a random sample of patients not prescribed ACEI/ARBs, BBs, CCBs or thiazide 
diuretics. 
Figure 1 shows assignment of exposure status under four example scenarios. In scenario one the 
patient remains exposed to only one agent for the duration of the study. In scenario two, in the 
situation where a second antihypertensive is added, the patient is censored from follow-up (unless 
there is a further change in prescription resulting in prescription for a single agent). In scenario three, 
when a patient switches from one class of drug to a different class of drug, we account for a seven-
day wash-out period between prescriptions, therefore start of time-at-risk to the second drug is 
delayed for seven days to allow for the practicalities of prescription fulfilment. In scenario four, where 
an individual initially selected to be part of the control group is started on an antihypertensive, the 
patient is censored from follow-up as a control and begins to contribute follow-up tome to ACEI/ARB 
exposure. 
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Figure 1. Assignment of time-varying exposure status during follow-up using a single exposure variable 
under four example scenarios. 
 
 
 
9.1.2 Exposure defined by multiple binary indicators  
As a secondary analysis we will use an alternative definition for exposure status that will allow 
exposure to more than one class of antihypertensive at a time. Rather than a single variable 
representing time exposed to a single class of antihypertensive, we will use five time-updating, binary 
indicator variables to indicate exposure status. Each indicator variable will identify whether the 
associated period of time at risk was exposed (1) or unexposed (0) to a specific class of 
antihypertensive. Figure 2 illustrates the same four example scenarios shown in Figure 1 using 
multiple binary indicator variables rather than a single exposure variable. 
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Figure 2. Assignment of time-varying exposure status during follow-up using multiple binary indicator 
exposure variables under four example scenarios. 
  
183
  
14 ISAC v1.3-August 2017 
9.2 Control group 
The control group will be identified as a matched cohort. Controls will be individuals not prescribed 
one of the exposure drugs they will be matched on age, sex and GP practice, and will enter the cohort 
on the same day as a matched antihypertensive case. Controls will be matched to all cases entering 
the cohort who are prescribed one of the classes of antihypertensive to be investigated. We will 
select ten controls for each case (since we do not know whether potential controls are eligible for 
study inclusion, we will match a high number of controls to each case to allow for a proportion of 
matched controls being ineligible for inclusion). We will allow controls to be matched to more than 
one case (i.e. controls can be selected more than once – in order to maximise the possibility of 
matching cases that might occur less frequently within the dataset, for example, the very young and 
the very old).  
During follow-up, if a control is started on one of the drugs of interest, their follow-up will be 
censored (with respect to the control group) from this date and they will enter the exposed cohort. 
If antihypertensive users are no longer prescribed any antihypertensives, their follow-up will be 
censored following a seven-day wash-out period from the end of their prescription. That is, they will 
not move into the control group because they are likely to be systematically different to the existing 
control group since there will be a clear clinical reason for withdrawal of all antihypertensive 
medications (e.g. frailty). 
10. Covariates 
We aim to use a directed acyclic graph (DAG) to guide the development of covariates to be included 
in regression models. Examples of the covariates we will use are: ethnicity, socioeconomic status, 
chronic comorbidities, proteinuria, body mass index (BMI), smoking status, alcohol use, and non-
steroidal anti-inflammatory drugs (NSAIDs). We will include age and sex as forced variables. 
10.1 Age 
Age will be categorised into the following age bands: 18–44, 45–54, 55–59, 60–64, 65–69, 70–74, 75–
84, 85+. However, we will also examine the age distribution of the cohort to inform the final the age 
bands used in the analysis, should a high proportion (e.g. more than 40%) of the cohort fall into only 
one of the a priori defined age bands will we split this age band more finely (e.g. into five-year rather 
than 10-year intervals). For descriptive analyses age will be defined as age at cohort entry. For 
regression analyses age will be entered as a time-updating variable in the age bands defined above (or 
those informed by the age distribution of the cohort). 
10.2 Socioeconomic status 
Individual socioeconomic status will be measured using index of multiple deprivation (IMD). CPRD 
offers index of multiple deprivation as quintile, decile or twentile data for 2004, 2007 or 2010. Our 
study dates are from 1997 to 2012, since patients can enter and leave the study at any point during 
the study period, we will use the 2004 IMD data because it is as close to the midpoint of the study 
period as possible.  
10.3 Ethnicity 
Ethnicity will be classified according to both Read and ICD-10 coded data to improve data 
completeness (20). However, research suggests (20) that a large proportion of ethnicity data is 
missing. We will therefore only rely on ethnicity as a covariate in secondary analyses.  
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10.4 Chronic comorbidities 
The following chronic comorbidities will be considered as covariates: diabetes mellitus, hypertension, 
ischaemic heart disease, cardiac failure, rhythm disorders, and chronic kidney disease (CKD).  
10.4.1 Comorbidities recorded as present or absent 
With the exception of CKD, chronic comorbidities included as potential covariates (diabetes mellitus, 
hypertension, ischaemic heart disease, cardiac failure, and rhythm disorders) will be recorded as 
present or absent based on recorded Read or ICD-10 codes. For descriptive analyses chronic 
comorbidities (excluding CKD) will be defined as those recorded prior to cohort entry. For regression 
analyses chronic comorbidities (excluding CKD) will be entered as a time-updating variables, with 
disease status changing with the first recorded code for each specific condition. 
10.4.2 CKD 
CKD stage will be established using estimated glomerular filtration rate (eGFR) calculated using serum 
creatinine test results. We will not use Read codes or creatinine clearance test results to identify CKD 
stage (in the main analysis) as adding these measures may compromise the granularity of CKD stage 
classification (21). 
CKD will be categorised as stage two and below, and stages 3–5 based on eGFR levels (stage 2 and 
below: eGFR >=60; stage 3a: eGFR 45–59; stage 3b: eGFR 30–44; stage 4: eGFR 15–29; and 5: eGFR 
<15). Patients with no recorded serum creatinine results will be excluded from the main analysis. 
Estimated GFR will be calculated using the Chronic Kidney Disease Epidemiology Collaboration (CKD-
EPI) equation (22) with serum creatinine measures, age, gender and ethnicity. The CKD-EPI equation 
contains a variable for Afro-Caribbean ethnicity, however research suggests (20) that a large 
proportion of ethnicity data is missing. Since the proportion of people of Afro-Caribbean ethnicity in 
England and Wales is just over 3% (23) for the main analysis we will calculate eGFR without regard to 
ethnicity.  
Serum creatinine measurements were not standardised until 2013, we will therefore assume that all 
creatinine results are not standardised and multiple results with a correction factor of 0.95 (24) 
before using the CKD-EPI eGFR formula (unstandardized creatinine results will give a falsely low 
estimate for GFR). 
We will use both baseline and time-updated measures of CKD status: 
a. Baseline CKD status 
Baseline CKD status will be defined as: i) best of two: the highest eGFR from the most recent two 
serum creatinine results recorded in the 12 months prior to baseline and separated by a minimum of 
three months (three month timeframe chosen to correspond to the requirement for eGFR to remain 
at a consistent level of impairment for at least three months in order for a patient to be diagnosed at 
a specific CKD stage); or ii) if only one suitable creatinine result is available, the single most recent 
serum creatinine recorded prior to baseline (excluding patients without two serum creatinine results 
could systematically exclude healthier individuals, since healthy patients are less likely to serum 
creatinine levels monitored). 
b. Time-updated CKD status 
Time-updated CKD status will be defined using the ‘last-carried-forward’ method (25,26). Here CKD 
stage is defined based on the most recent creatinine result (allowing CKD stage to be updated over 
time). However, taking this approach may misclassify AKI episodes as worsening CKD. To avoid this, 
when establishing CKD status, we will ignore serum creatinine results within 28 days either side of an 
AKI episode identified by our AKI case definition (see Section 8.2). This approach however, will not 
remove the risk of misclassifying episodes AKI missed by our definition as declining CKD status. It is 
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hoped that increased monitoring of renal function in these cases (until serum creatinine stabilises) 
will minimise the amount of time patients are misclassified. 
For descriptive analyses we will define CKD status using the baseline measure described above. For 
regression analyses we will use time-updated CKD status.  
10.5 Proteinuria 
Presence of proteinuria will be established using specific morbidity codes (Read and ICD-10) and 
biochemical test results from primary care electronic health records. Since urinary tract infection can 
cause a transient proteinuria, proteinuria recorded on the same day as a morbidity code for UTI will 
be disregarded (i.e. a record of proteinuria on the same day as UTI will not change a patient’s 
proteinuria status to positive). The first valid record of proteinuria will change a patient’s status from 
negative to positive for the remainder of the study. 
10.6 Lifestyle 
BMI, smoking status and alcohol use will be defined as those recorded prior to cohort entry. BMI will 
be calculated directly from weight and height records. Smoking status and alcohol use will be 
categorised based on primary care Read-coded electronic medical records.  
10.7 Covariate morbidity code lists 
Final morbidity code lists for ethnicity, smoking status, alcohol intake, proteinuria and chronic 
comorbidities are yet to be developed. A number of existing code lists have already been tested and 
used (20,21,27–30), and the CALIBER data portal (31) also offers a source of case definition algorithms 
and code lists. Where code lists/case definition algorithms have already been developed for existing 
electronic health record studies or as part of the CALIBER project we will identify relevant lists and use 
them to inform the development of our own code lists. Where existing code lists are unavailable, 
morbidity codes will be identified by a series of consensus exercises. A list of search terms to identify 
each relevant covariate will be developed. These search terms will then be used to search a data file 
containing all the available Read codes. We (LT and KM) will classify the lists of codes returned by the 
search terms independently as either probably or possibly representing the relevant outcome. The 
code lists we generate will be compared with each other and any disagreements discussed in order to 
generate the lists of codes to be used in the project. 
We will document the decisions taken regarding code list eligibility, and where necessary we will 
conduct sensitivity analyses to compare codes that we feel definitely represent the relevant covariate 
to those that we feel only possibly represent it. 
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11. Sample size/power calculation 
A feasibility count using CPRD (January 2014 build) (see Table 1) shows that: i) for those with a 
minimum of six months registration prior to their first antihypertensive prescription, there were more 
than 1,400,000 people with a first prescription for one or more classes of antihypertensive (ACEI/ARB, 
BB, CCB or diuretic) during the study period (1st April 1997 to 31st March 2012); and ii) for those with 
a minimum of twelve months prior registration there were more than 1,300,000 with a first 
prescription for an antihypertensive during the study period. Of those identified in the CPRD database 
with a first antihypertensive prescription during the study period, 59% were eligible for HES linkage 
(HES version 9) (n=839,622 patients with a minimum of six months prior registration; and n=795,464 
with a minimum of 12 months prior registration). 
Our study design allows a patient to move between multiple exposures if their prescription changes 
over time. Consequently numbers in the different exposure groups will be dynamic. Therefore, we 
have based our calculation of the minimum effect size that our study can detect on the most 
conservative sample size, i.e. the smallest group who are prescribed only one class of 
antihypertensive drugs during the study period, this is the group of individuals prescribed CCBs as 
their only hypertensive in those with a minimum of 12 months prior registration (n=64,078). If we are 
cautious and allow for 20% of this sample to be ineligible for inclusion in the study, we are left with a 
sample size of 102,524 for calculation of the minimum effect size detectable (A previous study (32) 
within CPRD, where follow-up started after more than 12 months of exposure to an ACEI/ARB, 
identified 377,649 individuals with a mean duration of follow-up of 4.6 years).  
A previous study (8) has estimated the incidence of hospital admission for AKI the adult general 
population to be 0.7% during median follow-up of 35 months. This translates to a 1.2% probability of 
AKI assuming an average of 5 years follow-up. This is a conservative estimate of AKI incidence, as not 
all cases will lead to hospital admission. Based on a cautious estimate of a sample size (n= 102,524), 
we will have greater than 90% power (alpha 0.05) to detect a relative risk of 1.2 or more for incident 
AKI comparing each class of antihypertensive with a group of individuals not taking antihypertensives 
(Table 2). [Calculation done in G*Power version 3.1.9.2 (33), and cross-checked in both OpenEpi (34) 
using the ‘Sample size and power’ module for cohort studies, and Stata (35) using the stpower logrank 
command]. 
There is only a 5% drop in the number of patients identified using the more stringent requirement for 
12 months antihypertensive-free interval prior to study entry compared to only 6 months. Therefore, 
given that there is sufficient power to detect a relative risk of 1.2 or more, we will use the more 
robust 12-month (prior to ‘first’ antihypertensive) definition for cohort entry. 
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Table 1. Results of feasibility count: Number of patients aged 18 years and over identified with a first 
prescription for a class of antihypertensive between 1st April 1997 and 31st March 2012 in CPRD (January 
2014 build), and, of those identified in CPRD, the number eligible for HES linkage (HES version 9). 
  ACEI/ARB BB CCB Diuretic Total 
Minimum 6 
months 
registration 
prior to first 
prescription 
First prescription in study period 732,514 
(52%) 
576,740 
(41%) 
501,394 
(35%) 
600,759 
(42%) 
1,420,953 
First prescriptions in study period in 
those eligible for HES linkage 
438,344 
(52%) 
338,518 
(40%) 
302,806 
(36%) 
355,078 
(42%) 
839,622 
 
First class of antiHt drug prescribed in 
study period  
233,151 
(28%) 
238,785 
(28%) 
134,185 
(16%) 
233,501 
(28%) 
839,622 
 
Prescriptions for only one class of 
antiHt during the study period 
129,850 
 
147,492 
 
66,082 
 
109,046 
 
452,470 
 
Minimum 12 
months 
registration 
prior to first 
prescription 
First prescription in study period 700,839 
(52%) 
538,173 
(40%) 
477,549 
(35%) 
563,526 
(42%) 
1,348,019 
First prescriptions in study period in 
those eligible for HES linkage 
419,343 
(53%) 
315,587 
(40%) 
288,419 
(36%) 
332,724 
(42%) 
795,464 
 
First class of antiHt drug prescribed in 
study period  
225,555 
(28%) 
222,187 
(28%) 
129,030 
(16%) 
218,692 
(27%) 
795,464 
Prescriptions for only one class of 
antiHt during the study period 
126,827 136,495 64,078 101,976 429,376 
 
antiHt: antihypertensive 
ACEI: Angiotensin converting enzyme inhibitor 
ARB: Angiotensin receptor blocker 
BB: Beta-blocker 
CCB: Calcium channel blocker 
 
Table 2. Minimum effect sizes given α=0.05, sample size=102,524, power=0.80–0.95 
Power Minimum risk ratio detectable 
 Assuming mean  
5-yrs follow-up  
(base rate 1.2%) 
Assuming mean  
4-yrs follow-up  
(base rate 1.0%) 
Assuming mean  
3-yrs follow-up  
(base rate 0.7%) 
80% 1.17 1.19 1.22 
85% 1.18 1.20 1.23 
90% 1.19 1.22 1.25 
95% 1.22 1.24 1.28 
 
We plan to undertake our main analysis twice by defining exposure as either exposure to a single class 
of antihypertensive only or using multiple binary indicators for exposure to each class of 
antihypertensive (see Section 9.1). Defining exposure using multiple binary indicators will allow for 
individuals to be exposed to more than one class of antihypertensive at a time, maximising follow-up 
time for each exposure. Therefore, if using the single-agent exposure definition leads to the study 
being underpowered (due to insufficient follow-up time) we will define exposure using the multiple 
binary indicator approach only. 
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12. Analysis 
All analyses will be undertaken in Stata version 13 (35). Analysis of the data will include the following 
stages: 
1. Basic baseline descriptive statistics for the five exposure groups: 
i. ACEI/ARB 
ii. BB 
iii. CCB 
iv. Thiazide diuretic 
v. Age, sex and GP practice matched control group 
2. Main analysis: Incidence of drug associated AKI in the five exposure groups (crude and 
adjusted using Poisson regression).  
3. Incidence of AKI when other drugs are prescribed in combination with ACEI/ARBs. 
4. Comparison of AKI incidence in ACEI users versus that in ARB users. 
5. Incidence of AKI when recurrent AKI is taken into account. 
6. Outcomes following AKI in the five exposure groups including mortality and ESRD rates. 
7. The effect of changes over time. 
8. Sensitivity analyses. 
12.1 Descriptive statistics 
We will present basic descriptive statistics to describe the five exposure groups: i) ACEI/ARB; ii) BB; iii) 
CCB; iv) thiazide diuretics; and v) an age, sex and GP practice matched control group not prescribed 
any of the classes of exposure drug. Membership of each exposure group will be determined by any 
contribution of time at risk to that exposure (e.g. if a patient contributes time at risk to both the 
ACEI/ARB and BB exposures that patient will contribute to both the ACEI/ARB and BB exposure 
groups). 
For each exposure group we will present the number and percentage of the group: 1) who are 
female; 2) in each predefined age band (18–44, 45–54, 55–59, 60–64, 65–69, 70–74, 75–84, 85+) at 
cohort entry; 3) have CKD stage two and below, and stages three to five at cohort entry; 4) have 
diabetes mellitus, cardiac failure, ischaemic heart disease, arrhythmia, hypertension or proteinuria at 
cohort entry; 5) in each smoking status category (non-smoker/ex-smoker, current smoker, or 
missing); 6) in each alcohol use category (non-problem drinker or problem drinker); 7) in each BMI 
category (underweight, normal, overweight/obese, or missing); 8) in each ethnic group; and 9) in each 
quintile of index of multiple deprivation. 
We will use this information to populate the skeleton table included in Appendix 3 (Table A3.1). No 
statistical tests are planned at this stage of analysis we will present summary statistics alone. 
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12.2 Main analysis: Drug associated AKI incidence 
For the main analysis, exposure status will be defined in two different ways: i) time exposed to a 
single class of antihypertensive drug; and ii) exposure defined by multiple binary indicator variables 
for each class of antihypertensive or control status. 
12.2.1 Primary analysis: exposure defined as time exposed to a single class of 
antihypertensive  
Our primary analysis will compare the incidence of AKI in the five exposure groups. Patients will 
contribute time only when they are prescribed the drug of interest alone (no simultaneous 
prescriptions for other classes of antihypertensive) and patients will swap between drug exposure 
groups when a prescription is changed. We will calculate crude AKI incidence rates and adjusted 
incidence rate ratios for each exposure group. Robust standard errors will be used to account for 
clustering by practice. Poisson regression will be used to calculate adjusted incidence rate ratios, 
initially adjusted only for time-updated age (data is split into the following age bands: 18–44, 45–54, 
55–64, 65–74, 75–84, 85+) and sex, and then estimated using a fully adjusted model including 
covariates informed by a directed acyclic graph (DAG). Time-updated age and sex will be included as 
forced variables, examples of other possible covariates include: proteinuria, chronic comorbidities 
(CKD stage, diabetes mellitus, ischaemic heart disease, cardiac failure, hypertension and arrhythmia), 
and baseline smoking, alcohol intake, socioeconomic and BMI status. Rate ratios will be calculated 
using the control group as the reference category. Before fitting the fully adjusted model we will add 
each covariate independently to a Poisson regression model including the exposure, and age and sex.  
The results of this analysis will be used to populate skeleton Tables A3.2 and A3.3 included in 
Appendix 3. 
The exposure definition we have chosen for this analysis (where time at risk will be counted only 
when an individual is prescribed a single class of antihypertensive) allows for easier interpretation of a 
regression model because the coefficients returned by the model offer a direct comparison between 
the different types of exposure. However, it will reduce available follow-up time as we will not be able 
to include time when a patient is prescribed more than one class of antihypertensive agent. 
Therefore, we will repeat the main analysis using an alternative definition of exposure status. 
12.2.2 Secondary analysis: exposure status defined by binary indicators 
We will repeat the primary analysis defining exposure status using five time-updating, binary indicator 
variables to indicate exposure. The approach will maximize the available follow-up time for each 
exposure, control for exposure to other antihypertensives, allow drug combinations to be investigated 
through interaction terms in the model, and more closely model real life. 
We would expect results from the two analyses to be broadly similar. However, rate ratios for 
exposure in the single-drug class exposure model will compare rates for each class of drug to 
incidence in the control group, while rate ratios for exposure in the multiple binary indicators model 
will compare rates of AKI in each anti-hypertensive class to those not exposed to that class of drug 
controlled for other classes of antihypertensive. 
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12.3 Combination prescriptions  
There is evidence that combinations of ACEI/ARBs, diuretics and NSAIDs may impair renal function (9–
12). We will therefore investigate combination drug therapy in ACEI/ARB users using time-updating 
exposure status. Time at risk will be defined in the following categories: 
i. ACEI/ARB alone 
ii. ACEI/ARB + thiazide diuretic  
iii. ACEI/ARB + loop diuretic 
iv. ACEI/ARB + loop diuretic + thiazide diuretic 
v. ACEI/ARB + loop diuretic + potassium-sparing diuretic 
(spironolactone/eplerenone/amioloride/triamterene) 
vi. ACEI/ARB + loop diuretic + potassium-sparing diuretic + thiazide diuretic 
vii. ACEI/ARB + NSAID +/- any BB, CCB or diuretic. 
Combination drugs (e.g. valsartan/hydrochlorothiazide, a combination of an ARB and a thiazide 
diuretic) will be considered as dual exposure to the classes of drug included in the preparation. 
We will investigate how AKI incidence rate changes in ACEI/ARB users who are also prescribed 
additional medications by calculating crude and adjusted (for all covariates used in the main analysis) 
AKI incidence rate ratios comparing exposure to ACEI/ARBs alone (reference category) with exposure 
to ACEI/ARBs in addition to other drugs. 
These data will be used to populate a skeleton table included in Appendix 3 (Table A3.4). 
12.4 ACEI versus ARB 
We will investigate AKI incidence rate in ACEI users versus that in ARB users. We will repeat the main 
analysis this time defining exposure as time at risk to ACEIs alone compared to ARBs alone. We will 
use these data to populate the skeleton table presented in Appendix 3 (Table A3.5). 
12.5 Recurrent AKI 
Our main analysis uses first recorded episode of AKI as the outcome measure. Patients therefore stop 
contributing time at risk at their first episode of AKI. To investigate the effect of multiple episodes of 
AKI we will repeat the main analysis including recurrent episodes of AKI. We will account for clustering 
in the analysis using a random effects model.  
We will define recurrent AKI differently depending on whether AKI has been defined using morbidity 
coding or biochemistry results. Two or more successive AKI codes will be considered to represent 
recurrent episodes of AKI. However, if AKI is defined using biochemical data, to be classified as being a 
recurrent episode there would have to be a return to baseline creatinine before a second increase in 
serum creatinine.  
12.6 Outcomes following AKI 
We will investigate outcomes following AKI by investigating rates of mortality, ESRD and 
hyperkalaemia among those who develop AKI. We will compare rates of mortality, ESRD and 
hyperkalaemia in AKI patients from each of the five exposure groups in order to compare health 
outcomes following AKI in those on different antihypertensives compared to the control group. 
Exposure will be defined based on exposure status at time of an AKI event, for example, an individual 
will be classified as being exposed to a beta-blocker if they are prescribed a beta-blocker when they 
experience an episode of AKI. 
We will investigate mortality following AKI episodes by calculating crude mortality rates following AKI 
episodes. We will also calculate crude, age and sex adjusted, and fully adjusted mortality rate ratios 
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for overall mortality and mortality at 0–3 months following the AKI episode, 4–6 months and 7–12 
months. These data will be used to populate the skeleton table presented in Appendix 3 (Table A3.6). 
12.7 Changes over time 
There have been some important changes in diagnostic and administrative practices that may 
influence the number of cases our AKI definition identifies and the classification of CKD. These 
include: 
i. 2004: Publication of RIFLE (36) AKI definition 
ii. 2006: Introduction of standardised serum creatinine measurements. 
iii. 2007: Standardised lab reporting (Pathology Messaging Implementation Project (37)) and 
publication of AKIN (38) AKI definition. 
iv. 2012: Publication of KDIGO (19) AKI definition. 
We will therefore investigate changes in AKI incidence rates over time using the following epochs: i) 
before 2004; ii) 2004–2005; iii) 2006–2007; iv) 2007–2011; and, v) from 2012. We will repeat the 
main analysis including calendar period as a covariate (after splitting the data on the calendar periods 
defined above). 
12.8 Sensitivity analyses 
We will test the validity of some of the variable definitions used in the analysis by repeating the main 
analysis a number of times either in select patient populations or using alternative variable 
definitions. 
12.8.1 Person-time 
The analysis will be repeated using an alternative approach to calculating person-time. In the main 
analysis person-time will be calculated from cohort entry to cohort exit, without taking hospital 
admission time into account. Our AKI outcome definition uses hospital coding, therefore, for the 
duration of a hospital admission, we can only define the outcome once, effectively reducing available 
time at risk. To check whether this influences our findings we will repeat the main analysis calculating 
person-time from cohort entry to cohort exit with any hospital admission time excluded from person-
time.  
12.8.2 Exposure status 
The analysis will also be repeated defining exposure status on the basis of two or more consecutive 
prescriptions to investigate a subgroup with a more reliable exposure to the drugs interest. 
12.8.3 Ethnicity 
We will also repeat the main analysis in a group who are more likely to have complete ethnicity data. 
After 2006 recording of ethnicity was rewarded as part of the Quality and Outcomes Framework 
leading to improvements in the completeness of ethnicity recording in CPRD (20). We will therefore 
repeat the main analysis in new entrants to the cohort from 2006 onwards who have ethnicity data 
recorded in CPRD or HES. In this sensitivity analysis we will include ethnicity both as a covariate and in 
the equation used to calculate eGFR. 
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12.8.4 Renal function 
Our analyses rely on serum creatinine test results both to establish biochemically defined AKI and as a 
measure of CKD status. We plan a number of sensitivity analyses to test the validity of both variable 
definitions. 
a. Limited numbers of serum creatinine results 
i) Limited to patients with diabetes mellitus 
Patients with limited numbers of serum creatinine measures available may have their CKD status 
misclassified or be incorrectly identified as having biochemical AKI. Further, they are likely to be 
systematically different to those with multiple serum creatinine results (since regular renal function 
testing is more likely in those perceived to be at risk of kidney disease). Therefore, to test the validity 
of both our AKI and our CKD definitions we will repeat the main analysis only in those who are also 
recorded as having diabetes mellitus. Regular checking of renal function has been remunerated in 
diabetics through the Quality and Outcomes Framework. Using this group will therefore reduce 
information bias occurring as a result of kidney function being measured only in those perceived to be 
at risk of the outcome.  
ii) Two serum creatinine results before index-infection code in biochemically defined AKI 
We will further test the validity of our AKI definition by repeating the main analysis including only 
those biochemically defined AKI episodes where there is a minimum of two serum creatinine results 
(recorded at least three months apart) available prior to the recording of the index acute morbidity 
code that defines the AKI episode (UTI, gastroenteritis, URTI – see Section 8.2) in order to establish a 
more robust baseline serum creatinine. 
b. CKD status definition 
i) CKD status defined using morbidity coding and test results 
Our main analysis requires a minimum of one available serum creatinine result to establish CKD 
status. This will limit the number of patients eligible for inclusion and is also likely to result in an 
unusual control group since it is unlikely that routine serum creatinine measures will be available in 
healthy controls. We will therefore repeat the main analysis, without the requirement for a serum 
creatinine result, using an alternative CKD definition. CKD will be defined as present or absent on the 
basis of: i) eGFR calculated using serum creatinine results (see Section 10.4.2); ii) morbidity codes for 
CKD; and iii) intrinsic renal disease codes (e.g. glomerulonephritis). 
ii) Baseline CKD status rather than time-updated CKD status 
We will also repeat the main analysis using baseline CKD status rather than the time-updated variable 
(see Section 9.4.2) to investigate: i) the association between CKD stage at initial prescription of 
antihypertensive medication and subsequent risk of AKI; and ii) to ensure that rapidly worsening CKD 
status has not affected the results of the analysis – AKI episodes in patients with rapidly worsening 
CKD status may lead to a falsely high rates of AKI at more severe stages of CKD (patients with rapidly 
worsening renal function will contribute less person-time at more severe levels of CKD than patients 
who had maintained consistently levels of CKD, therefore, episodes of AKI occurring in patients with 
rapidly worsening renal function would lead to a falsely high rate of AKI at higher stage of CKD).  
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c. Transient serum creatinine increases not representing renal disease 
We may also misclassify CKD status or incorrectly identify biochemical AKI in two specific clinical 
scenarios that may result in a raised serum creatinine that does not represent renal disease 
(trimethoprim prescription or ACEI/ARB initiation). We will therefore repeat the main analysis in the 
following two sensitivity analyses: 
i. Excluding the first recorded serum creatinine result after starting an ACEI/ARB from the algorithm 
used to identify biochemical AKI – Since ACEI/ARB initiation results in an acute increase in serum 
creatinine (39).  
ii. Excluding any serum creatinine results in the two weeks following trimethoprim prescription from 
AKI/CKD definitions – Since trimethoprim also temporarily increases serum creatinine (40). 
13. Missing data 
Patients on antihypertensive drugs are likely to have other cardiovascular risk factors considered 
when their medications are prescribed; consequently, we anticipate the proportion of completeness 
to be high in this population. We will therefore undertake a complete case analysis unless missing 
data is greater than 30% when we will undertake further sensitivity analyses (in addition to those 
discussed in Section 12.8 above). For example, if necessary, we will repeat the main analysis 
restricting it to more recent calendar periods when BMI, alcohol and smoking data is more complete 
(41), in order to reduce any selection biases due to data being missing. 
14. Limitations of study design, data sources and 
analytic methods 
The main limitation in this project is one common to all studies using electronic medical records. It is 
the problem of accurately defining measures for outcomes, exposures and covariates. Coding may be 
a reflection of individual GPs’ diagnostic beliefs and the patterns and context of their coding 
behaviour (42,43). Variation in coding practices will impact on the reliability of the definitions we use 
to identify outcomes, exposures and covariates in our study. However, research (44) suggests that 
most diagnoses within GPRD (CPRD) are recorded accurately, and, further research suggests that 
there have been improvements in data quality in the domains assessed by the Quality and Outcomes 
Framework (QOF) (45,46). We hope that any misclassification due to variability in coding practices will 
be mitigated by careful development of code lists and, where possible, use of previously validated 
code lists. In relation to our primary outcome measure, previous research has (17) has shown a high 
agreement between ICD-10 coding for AKI and a clinical AKI diagnosis.   
The first guidelines for the diagnosis of AKI date from 2004, we might therefore expect changes in AKI 
recording as awareness of the diagnosis increases. Any observed increases in AKI incidence over time 
might therefore be attributed to changes in diagnostic awareness rather than real changes in AKI 
incidence. This must be acknowledged when interpreting our results. However, we will use 
biochemical data in addition to coding data where this temporal change should not contribute to an 
apparent increase in incidence. 
In order to establish a more robust measure for CKD status with the ability to classify CKD into stages 
we have chosen to limit the study population to only those with serum creatinine measures available. 
Further, in those with no serum creatinine result available in the 12 months prior to cohort entry, we 
will only include follow-up time after the first serum creatinine result available following cohort entry. 
This will limit the number of patients eligible for inclusion, reduce follow-up time, and also result in 
select group of controls (since it is unlikely that routine serum creatinine measures will be available in 
healthy controls). However, it is assumed that most patients will have their renal function tested prior 
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to initiation of antihypertensive therapy limiting the reduction of follow-up time for cases. In addition, 
we plan to repeat the main analysis, without the requirement for those included to have a serum 
creatinine result recorded, using an alternative CKD definition that uses both biochemical test results 
and morbidity coding (see Section 12.8.b.i). 
The ability of both our biochemical AKI definition and our CKD algorithm to reliably classify renal 
disease is likely to limited by the frequency of serum creatinine measures. However, we plan a 
number of sensitivity analyses (Section 12.8.4) to account for differences in the frequency and timing 
of serum creatinine measures between patients. In relation to the biochemical AKI definition 
specifically, since we do not have access to hospital test results, we have modified the ACB AKI e-alert 
algorithm (18) to account for differences in primary care biochemical data (compared to hospital lab 
data) and included AKI morbidity coding as part of the outcome definition. 
Missing ethnicity data may limit the findings of the study. Ethnicity has been shown to be related to 
CKD risk (47) and should therefore should be considered as a covariate. However, research has shown 
that a high proportion of ethnicity data in incomplete (20), therefore rather than reducing sample size 
by excluding those with incomplete ethnicity data from the main analysis we will only rely on ethnicity 
as a covariate in a sensitivity analysis to check the validity of our findings (see Section 12.8.3). In 
addition, calculation of eGFR requires a variable for Afro-Caribbean ethnicity. Since census data shows 
the proportion of people of Afro-Caribbean ethnicity in England and Wales to be just over 3% (23) we 
plan to calculate eGFR without regard to ethnicity for the main analysis and check the validity of our 
findings in the sensitivity analysis presented in Section 12.8.3. 
Undertaking the study in HES linked practices only will reduce the size of the study cohort. However, a 
feasibility count has shown that, while using linked practices reduces the number of patients in the 
cohort by 41%, there are still over 795,000 individuals with a new prescription for an antihypertensive 
during the study period. By using an analysis that limits follow-up time to time exposed to a single 
class of antihypertensive only may reduce follow-up time further and may limit the generalizability of 
the findings (individuals on single therapy are likely to have less morbidity than those on multiple 
antihypertensives). However, we hope to mitigate this by repeating the main analysis using an 
alternative definition for exposure that allows for multiple antihypertensive usage and maximises 
follow-up time (Section 12.2.2). 
We aim to reduce confounding by assessing and adjusting for a covariates informed by development 
of a DAG. We hope to reduce confounding by indication by using prescriptions for other classes of 
antihypertensive agents as control groups. However, slight differences in the indications for different 
classes of antihypertensives may result in some degree of confounding by indication. It is hoped that 
this will be limited by controlling for a number of chronic comorbidities that are indications for these 
drugs. 
There is some concern regarding the number of comparisons being made in some of our secondary 
analyses (particularly our analysis of combination prescriptions in ACEI/ARB users – Section 12.3). Our 
study will focus on the primary objective (to examine the association between ACEI/ARBs and AKI) 
and this will be given prominence in the write-up. We will interpret with caution the results of 
secondary analyses where high numbers of comparisons are made. 
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15. Dissemination 
15.1 Patient or user group involvement 
We plan to share our findings with patient/user groups via Kidney Research UK. We aim to develop 
some materials to communicate the balance of risks and benefits regarding the use of specific 
medications for patients with CKD. 
15.2 Disseminating and communicating study results 
The study findings will be submitted for publication in peer-reviewed scientific journals, and will be 
presented both at appropriate conferences and at other meetings; the latter will include scientific 
meetings externally, for example, The European Renal Association and European Dialysis and 
Transplant Association Congress, The American Society of Nephrology Kidney Week and internally 
within the London School of Hygiene and Tropical Medicine. 
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Glossary of acronyms 
ACEI Angiotensin converting enzyme inhibitor 
AKI Acute kidney injury 
AKIN Acute Kidney Injury Network: the group to produce the AKIN AKI criteria (38) 
ARB Angiotensin receptor blocker 
BB Beta-blocker 
BNF British national formulary 
CCB Calcium channel blocker 
CKD Chronic kidney disease 
CPRD  Clinical Practice Research Datalink 
DAG Directed acyclic graph 
DM Diabetes mellitus 
eGFR Estimated glomerular filtration rate 
ESRD End stage renal disease 
HES Hospital episode statistics 
IMD Index of multiple deprivation 
KDIGO Kidney disease improving global outcomes 
NSAID Non-steroidal anti-inflammatory drug 
RIFLE     The AKI criteria produced by Acute Dialysis Quality Initiative (36): Risk, Injury, 
Failure, Loss and End stage renal disease. 
SCr Serum creatinine 
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Appendix 1 – AKI definitions 
 
Table A1.1 The staging of acute kidney injury in adults1 – comparing RIFLE, AKIN and KDIGO (adapted from NICE 
2013 acute kidney injury clinical guidelines)(15). 
Stage RIFLE(36) 2 
serum creatinine criteria 
AKIN(38) 
serum creatinine criteria 
KDIGO(19) 
serum creatinine criteria 
Urine output 
RIFLE Risk or  
AKIN/KDIGO 1 
eGFR decrease by ≥ 25%  Rise of ≥26μmol/L 
within 48 hours 
Rise of ≥26μmol/L 
within 48 hours 
< 0.5 ml/kg/h for 
more than 6h 
 OR  
50–99% SCr rise from 
baseline* 
(1.50–1.99 x baseline) 
OR 
50–99% SCr rise from 
baseline* 
(1.50–1.99 x baseline) 
OR 
50–99% SCr rise from 
baseline* 
(1.50–1.99 x baseline) 
RIFLE Injury or  
AKIN/KDIGO 2 
eGFR decrease by ≥ 50%  
OR 
  < 0.5 ml/kg/h for 
more than 12h 
100–199% SCr rise from 
baseline* 
(2.00–2.99 x baseline) 
100–199% SCr rise from 
baseline* 
(2.00–2.99 x baseline) 
100–199% SCr rise from 
baseline* 
(2.00–2.99 x baseline) 
RIFLE Failure or 
AKIN/KDIGO 3 
eGFR decrease by ≥ 75% 
OR 
  < 0.3 ml/kg/h for 
24h or anuria for 
12h 
 ≥ 200% SCr rise from 
baseline* 
(≥ 3.00 x baseline) 
≥ 200% SCr rise from 
baseline* 
(≥ 3.00 x baseline) 
≥ 200% SCr rise from 
baseline* 
(≥ 3.00 x baseline) 
 OR 
SCr rise to ≥354μmol/L 
with acute rise of 44μmol/L 
OR 
SCr rise to ≥354μmol/L 
with acute rise of 44μmol/L 
OR 
SCr rise to ≥354μmol/L 
with acute rise of: 
≥ 26μmol/L within 48hrs or 
≥ 50% rise within 7 days 
  any requirement for renal 
replacement therapy 
any requirement for renal 
replacement therapy 
1. The initial diagnosis or detection of AKI is based on a patient meeting any of the criteria for stage 1. Staging is carried out retrospectively 
when the episode is complete. Patients are classified according to the highest possible stage where the criterion is met, either by 
creatinine rise or urine output. 
2. RIFLE: for simplicity the Loss and End stage categories of RIFLE are not included here (these can be regarded as clinical outcomes rather 
than AKI stages). 
SCr - Serum creatinine. 
*Increase from baseline serum creatinine is either known (based on a prior blood test) or presumed (based on the patient history) to have 
occurred within 7 days. 
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Appendix 2 – Code lists 
 
Table A2.1 Search terms to identify morbidity codes which may represent AKI. 
Condition Symptoms Tests Procedures 
*kidney* 
*renal* 
*tubular* 
*nep* to pick up nephritis +- 
nephropathy etc. 
*glomerulo* 
*uria* to pick up oliguria, 
anuria, etc. 
*urine* to pick up reduced 
urine output 
 
*creatinine* 
*hyperkalaemia* 
*electrolyte* 
 
*dialysis* 
*haemofiltration* 
 
* represents wildcard operator. 
Table A2.2 Search strings to identify codes from CPRD code browsers/code data files. 
Variable 
 
Search string to identify relevant medcode/prodcode 
AKI *kidney*;*renal*;*tubular*;*nep*;*glomerulo*;*uria*;*urine*;*creatinine*;*hyperkalaemia*; 
*electrolye*;*dialysis*;*haemofiltration* 
ACEI *captopril*;*cilazapril*;*enalapril*;*fosinopril*;*imidapril*;*lisinopril*; 
*moexipril*;*perindopril*;*quinapril*;*ramipril*;*trandolapril*; 
*capoten*;*noyada*;cozidocapt*;*capozide*;*vascace*;*innovace*;*innozide*;*tanatril*;*zestril*
;*carace*; 
*zestoretic*;*perdix*;*coversyl*;*accupro*;*accuretic*;*tritace*;*triapin* 
ARB *azilsartan*;*candesartan*;*eprosartan*;*irbesartan*;*losartan*;*olmesartan*;*telmisartan*;*val
sartan*; 
*edarbi*;*amias*;teveten*;*aprovel*;*coaprovel*;*cozaar*;*olmetec*; 
*sevikar*;*micardis*;*diovan*;*exforge* 
Beta-
blockers 
*propranolol*;*acebutolol*;*atenolol*;*bisoprolol*;*carvedilol*;*celiprolol*; 
*co-tenidone*;*esmolol*;*labetalol*;*metoprolol*;*nadolol*;*nebivolol*;*oxprenolol*; 
*pindolol*;*sotalol*;*timolol*; 
*bedranol*;*beta prograne*;*sectral*;*tenormin*;*cardicor*;*carvedilol*;*celectol*;*tenoret*; 
*tenoretic*;*brevibloc*;*trandate*;*betaloc*;*lopresor*;*corgard*;*nebilet*; 
*slow-trasicor*;*visken*;*beta-cardone*;*sotacor* 
 
with diuretic: *kalten*;*viskaldix*;*prestim* 
with CCB: *beta-adalat*;*tenif* 
Calcium 
channel 
blockers 
*amlodipine*;*diltiazem*;*felodipine*;*lacidipine*;*lercanidipine*;*nicardipine*;*nifedipine*; 
*nimodipine*;*verapamil*;*istin*;*exforge*;*diltiazem*;*tildiem*;*adizem*;*angitil*;*dilcardia*; 
*dilzem*;*slozem*;*viazem*;*zemtard*;*plendil*;*triapin*;*motens*;*zanidip*;*cardene*;*adala
t*; 
*adipine*;*coracten*;*fortipine*;*nifedipress*;*tensipine*;*valni*;*tenif*;*nimotop*;*cordilox*; 
*securon*;*univer*;*verapress*;*vertab* 
Thiazide 
diuretics 
*bendroflumethiazide*;*chlortalidone*;*cyclopenthiazide*;*indapamide*;*metolazone*; 
*xipamide*; 
*aprinox*;*neo-naclex*;*hygroton*;*navidrex*;*natrilix*;*ethibide*;*tensaid*;*diurexan* 
Loop 
diuretics 
*bumetanide*;*furosemide*;*torasemide*;*frusemide*; 
*lasix*;*torem* 
K+ sparing 
diuretics 
*amiloride*;*triamterene*;*eplerenone*;*spironolactone*; 
*inspra*;*aldactone* 
with other diuretics: *co-amilofruse*;*frumil*;*co-amilozide*;*moduret*;*moduretic*;*frusene* 
Other 
diuretics 
*acetazolamide*;*mannitol* 
NSAIDs *aceclofenac*;*acemetacin*;*celecoxib*;*dexibuprofen*;*dexketoprofen*;*diclofenac*; 
*etodolac*;*etoricoxib*;*fenoprofen*;*flurbiprofen*;*ibuprofen*;*indometacin*; 
*ketoprofen*;*mefenamic*;*meloxicam*;*nabumetone*;*naproxen*;*piroxicam*;*sulindac*; 
*tenoxicam*; *tiaprofenic*;*aspirin*; *phenylbutazone*;*ketorolac*;*parecoxib*;*tolfenamic* 
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Table A2.3 Read codes for AKI. 
Read code Read term Definite* 
K04..00 Acute renal failure 
K04..11 ARF - Acute renal failure 
K04..12 Acute kidney injury 
K040.00 Acute renal tubular necrosis 
K040.11 ATN - Acute tubular necrosis 
K04y.00 Other acute renal failure 
K04z.00 Acute renal failure NOS 
K0E..00 Acute-on-chronic renal failure 
Kyu2000 [X]Other acute renal failure 
1AC1.00 Oliguria x 
8H2M.00 Admit renal medicine emergency x 
K043.00 Acute drug-induced renal failure x 
K043000 Acute renal failure due to ACE inhibitor x 
K043400 Acute renal failure induced by non-steroid anti-inflamm drug x 
K044.00 Acute renal failure due to urinary obstruction x 
K045.00 Acute renal failure due to non-traumatic rhabdomyolysis x 
K04B.00 Acute renal failure due to traumatic rhabdomyolysis x 
K0C1.00 Nephropathy induced by other drugs meds and biologl substncs x 
K0C2.00 Nephropathy induced by unspec drug medicament or biol subs x 
R085000 [D]Oliguria x 
R085z00 [D]Oliguria and anuria NOS x 
SK08.00 Acute renal failure due to rhabdomyolysis x 
SP15400 Renal failure as a complication of care x 
SP15411 Kidney failure as a complication of care x 
SP15412 Post operative renal failure x 
*Codes that possibly represent AKI (i.e. not definite AKI codes) will be used in a sensitivity analysis to test the validity of the AKI definition – 
the main analysis will be repeated using both possible and definition AKI codes as an outcome definition. 
Table A2.4 ICD-10 codes for AKI 
ICD-10 code ICD-10 term Definite 
N17* Acute renal failure 
N17.0 Acute renal failure with tubular necrosis 
N17.8 Other acute renal failure 
N17.9 Acute renal failure, unspecified 
N14  Drug- and heavy-metal-induced tubulo-interstitial and tubular conditions   x 
N14.1  Nephropathy induced by other drugs, medicaments and biological substances   x 
N14.2  Nephropathy induced by unspecified drug, medicament or biological substance   x 
N17.1 Acute renal failure with acute cortical necrosis x 
N17.2 Acute renal failure with medullary necrosis x 
N19 Unspecified kidney failure x 
N99.0 Postprocedural renal failure x 
R34  Anuria and oliguria   x 
R94.4  Abnormal results of kidney function studies   x 
*Due to variability in coding practices between hospitals and trusts, it is difficult to place reliance on numbers after the decimal place in ICD-
10 codes: suggestion is that all N17 codes are included regardless of subcategories. 
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Appendix 3 – Skeleton tables 
 
Table A3.1 Characteristics of study population on ACEI/ARBs, BBs, CCBs, thiazide diuretics, and an age, sex and GP 
practiced matched control group of patients not prescribed any of these drugs. Data are number (%). 
 ACEI/ARB 
(n=x) 
Beta-blockers 
(n=u) 
Calcium channel 
blockers 
(n=y) 
Thiazides 
(n=z) 
Control 
(n=w) 
Female (%) n (%)     
Age (at baseline)      
18–44      
45–54      
55–59      
60–64      
65–69      
70–74      
75–84      
85+      
Comorbidity (at baseline)      
CKD stage      
   eGFR >=60 (stage 1/2)      
   eGFR 45–59 (stage 3a)      
   eGFR 30–44 (stage 3b)      
   eGFR 15–29 (stage 4)      
   eGFR <15 (stage 5)      
Diabetes mellitus      
Ischaemic heart disease      
Cardiac failure      
Hypertension      
Cardiac arrhythmia      
Proteinuria      
Index of multiple 
deprivation (quintiles) 
     
0–20      
21–40      
41–60      
61–80      
81–100      
Ethnicity      
White      
South Asian      
Black      
Other      
Missing      
BMI      
Underweight      
Normal      
Overweight/obese      
Missing      
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Table A3.1 continued. 
 ACEI/ARB 
(n=x) 
Beta–blockers 
(n=u) 
Calcium channel 
blockers 
(n=y) 
Thiazides 
(n=z) 
Control 
(n=w) 
Smoking      
Non-smoker/ex-smoker      
Current smoker      
Missing      
Alcohol use      
Non-problem drinker      
Problem drinker      
Missing      
 
 
Table A3.2 AKI incidence rates and rate ratios for HES linked CPRD population with a new prescription for 
ACEI/ARBs, BBs, CCBs, thiazide diuretics (between April 1997 and October 2011), and a age, sex and GP practice 
matched control group not prescribed any of these drugs. 
Exposure Person 
years 
AKI cases Crude AKI 
incidence rate 
(95% CI) 
Age and sex 
adjusted IRR 
(95% CI)* 
Fully adjusted IRR 
(95% CI)** 
Primary analysis – exposure to a single class of antihypertensive only 
ACEI/ARB      
BB      
CCB      
Thiazides      
Control    1 1 
Sensitivity analysis – binary indicators for exposure to each class of antihypertensive 
ACEI/ARB      
BB      
CCB      
Thiazides      
Control    1 1 
IRR: Incidence rate ratio. 
*Adjusted for: age and sex using Poisson regression. 
**Adjusted for: age, sex, and covariates informed by DAG.   
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Table A3.3 Poisson regression model comparing AKI incidence rate ratios (95% CIs) in each of the exposure groups 
prescribed ACEI/ARBs, BBS, CCBs or thiazide diuretics with the control group as the reference category – 
unadjusted and adjusted incidence rate ratios. 
 Incidence rate ratio (95% CI) 
 Crude Age & sex adjusted Fully adjusted* 
Exposure    
ACEI/ARB    
BB    
CCB    
Thiazides    
Control reference reference reference 
Sex    
Female    
Male reference reference reference 
Age    
18–44 reference reference reference 
45–54    
55–59    
60–64    
65–69    
70–74    
75–84    
85+    
Comorbidity    
CKD    
   eGFR >=60 (stage 1/2) reference reference reference 
   eGFR 45–59 (stage 3a)    
   eGFR 30–44 (stage 3b)    
   eGFR 15–29 (stage 4)    
   eGFR <15 (stage 5)    
Diabetes mellitus    
Ischaemic heart disease    
Cardiac failure    
Hypertension    
Arrhythmia    
Proteinuria    
*Adjusted for: age, sex, and covariates informed by DAG.   
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Table A3.4 Crude and adjusted AKI incidence rates (95% CIs) for subgroups of ACEI/ARB users taking additional 
medications compared to those on an ACEI/ARB alone. 
Exposure Person years AKI cases Crude AKI 
incidence rate 
(95% CI) 
Age and sex 
adjusted IRR 
(95% CI) 
Fully adjusted 
IRR 
(95% CI)* 
ACEI/ARB alone    reference reference 
ACEI/ARB + thiazide diuretic      
ACEI/ARB + loop diuretic      
ACEI/ARB + loop + thiazide      
ACEI/ARB + loop + potassium-sparing 
diuretic 
     
ACEI/ARB + loop diuretic + potassium-
sparing diuretic + thiazide 
     
ACEI/ARB + NSAID (+/- any BB, CCB or 
diuretic) 
     
IRR: Incidence rate ratio. 
*Adjusted for: age, sex and covariates informed by DAG. 
 
 
Table A3.5 AKI incidence rate for CPRD adult population on ACEI compared to ARBs. 
Exposure Person years AKI cases Crude AKI 
incidence rate 
(95% CI) 
Age and sex 
adjusted IRR 
(95% CI) 
Fully adjusted 
IRR 
(95% CI)* 
ACEI alone    reference reference 
ARB alone      
IRR: incidence rate ratio. 
*Adjusted for: age, sex and covariates informed by DAG. 
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Table 3.6 Mortality following AKI episodes. 
 Exposure 
 AKI on ACEI/ARB AKI on BB AKI on CCB AKI on thiazides AKI control 
Person years      
Deaths      
Crude mortality rate (95% CI)      
Any time following AKI      
0–3 months      
4–6 months      
7–12 months      
Mortality rate ratio (95% CI)      
Any time following AKI      
- crude     reference 
- age and sex adjusted     reference 
- fully adjusted*     reference 
0–3 months      
- crude     reference 
- age and sex adjusted     reference 
- fully adjusted*     reference 
4–6 months      
- crude     reference 
- age and sex adjusted     reference 
- fully adjusted*     reference 
7–12 months      
- crude     reference 
- age and sex adjusted     reference 
- fully adjusted*     reference 
*Adjusted for: age, sex and covariates informed by DAG. 
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Amendment 
A. Background 
A recent meta-analysis demonstrated an association between socioeconomic deprivation and 
risk of chronic kidney disease (CKD).1 The review estimated that the odds of low renal 
function was 1.41 times greater in those with low socioeconomic status (SES) compared to 
high SES. CKD is also a main risk factor for acute kidney injury (AKI). Therefore, in our original 
protocol we requested SES as a confounding variable for our main analyses (the association 
of ACEI/ARB use with AKI).  
As expected, a preliminary analysis for the study described in the main protocol revealed an 
association between SES and AKI. Risk of AKI increased with increasing level of deprivation. 
For example, after adjusting for age, sex, calendar period, antihypertensive drug exposure 
(ACEI/ARB, BB, CCB, thiazide diuretics), time-updated chronic comorbidities (DM, IHD, cardiac 
failure, arrhythmia, hypertension), baseline CKD stage, and lifestyle covariates (smoking, BMI, 
alcohol intake), those in the most deprived IMD quintile were 1.59 (95% CI 1.41, 1.66) times 
more likely to have AKI than those in the least deprived quintile; While those in the second 
quintile were 1.07 (95% CI 0.96, 1.19) times more likely to have AKI than those in the least 
deprived (first) quintile. 
Therefore, as a secondary analysis using the cohort identified in the main protocol, we aim to 
investigate the association between SES and AKI in a cohort of antihypertensive users. 
B. Objectives 
The overall aim is to investigate the association between SES and risk of acute kidney injury 
(AKI) in new antihypertensive users. Specifically we aim to: 
1. Describe rate of AKI by level of deprivation defined by quintiles of Index of Multiple 
Deprivation (IMD).  
2. Assess whether there is a dose-response relationship between level of deprivation and 
risk of AKI. 
3. Explore any variation in AKI rates in different levels of deprivation over time, and by age, 
sex, and geographical region (London versus the rest of England – postcode derived IMD 
may have a different meaning for people living in London compared to elsewhere). 
4. Investigate mediators of the association between socioeconomic status AKI, for their 
presence and magnitude, and whether they vary with ethnicity. 
C. Study type 
This study will test the null hypothesis that, among patients taking antihypertensives, there is 
no association between SES and rate of AKI. 
D. Study design and study population 
This will be a population-based cohort study. We will use the same cohort as that described 
in the main protocol; that is, new users of antihypertensive medications aged 18 and over. 
However, to avoid selection bias, we will include those without serum creatinine results 
recorded in the 12 months prior to cohort entry. Those with baseline serum creatinine test 
results may represent a select group of patients (renal function is more likely to be tested in 
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those who are acutely unwell, or routinely monitored as part of incentivised programs; 
diabetics for example). 
E. Sample size – power calculation 
In the study documented in the main protocol, we identified a cohort of 570,445 eligible new 
users of antihypertensive drugs (including those without baseline serum creatinine results). 
During follow-up, 14,907 people developed AKI. Twenty-four percent of the cohort 
(n=135,536) were in the lowest quintile of Index of Multiple Deprivation (IMD). Taking those 
in the lowest quintile of IMD as the exposed group, we have a power of 80% to detect an 
effect size of 1.02 or more (Calculated using G*Power, version 3.1.9.2).  
F. Selection of comparison group(s) or controls 
Comparison groups will be defined within the cohort according to exposure status (see 
Section G below). 
G. Exposures, outcomes and covariates 
G1. Exposures 
Our primary exposure will be socioeconomic status level defined using quintiles of IMD 
scores for 2004. We will use the 2004 IMD data because it is as close to the midpoint of the 
study period as possible. 
G2. Outcomes 
The outcome will be AKI as defined in the main protocol. 
G3. Covariates 
Based on a priori knowledge, we will consider the following pre-specified variables as 
potential confounders: age, sex, calendar period, region (London versus rest of England – 
postcode derived IMD may have a different meaning for people living in London compared to 
elsewhere), and ethnicity. We will include calendar period (1997–2000, 2001–2004, 2005–
2008, 2009–2011, and 2012–2014) as a covariate to adjust for the many changes in clinical, 
diagnostic and administrative practices over the study period that may influence the 
measurement of baseline renal function and registration of outcomes. Research suggests2 
that a large proportion of ethnicity data is missing. We will therefore only rely on ethnicity as 
a covariate in secondary analyses. Ethnicity will be classified according to both Read and ICD-
10 coded data to improve data completeness.2 
We believe that the following variables are on the causal pathway between SES and AKI and 
we will therefore not adjust for them the main analysis: lifestyle factors (smoking, alcohol 
intake, and body mass index), chronic comorbidities (diabetes mellitus, hypertension, cardiac 
failure, ischaemic heart disease, and arrhythmia), and antihypertensive medications. 
However, we will consider the magnitude of their contribution in mediation analyses. 
F. Analysis 
We will present descriptive characteristics for individuals in the cohort by level of deprivation 
(quintile of IMD). We will calculate absolute rates of AKI for each level of deprivation; initially 
overall and then stratified by age, sex, calendar period, and region (London versus rest of 
England). We will calculate incidence rate ratios comparing AKI rates for each level of 
deprivation with the least deprived quintile using Poisson regression, adjusting for potential 
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confounders and using robust standard errors to account for clustering by general practice. 
We will initially adjust for age and sex only, and then fit an adjusted model informed by a 
priori knowledge including the following covariates: age, sex, calendar period, and region. 
Finally, we will fit a model additionally adjusting for ethnicity.  
Subsequently, using a conceptual framework, we will attempt to indirectly assess the 
contribution of each health-related behaviour (lifestyle covariates) and time-updated 
comorbidity to the association between SES and AKI using a multiple regression model and 
investigate whether they vary by ethnicity. 
As sensitivity analyses we will stratify by region (London versus rest of England – postcode 
derived IMD may have a different meaning for people living in London compared to 
elsewhere), and restrict to post 2006 data (in order to: i) limit differential misclassification of 
the outcome over time; ii) improve the reliability of baseline CKD stage – since 2006 GPs 
were reimbursed for providing a register of CKD patients); and iii) improve the reliability of 
ethnicity data – after 2006 recording of ethnicity was rewarded as part of the Quality and 
Outcomes Framework leading to improvements in the completeness of ethnicity recording in 
CPRD). 
All data management and analyses will be performed using Stata version 14 (StataCorp, 
Texas). 
References 
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Amendment II 
A. Background 
The original ISAC protocol proposed to “undertake a complete case analysis unless missing 
data is greater than 30% when we will undertake further sensitivity analyses”. In the data 
described, there are two key confounders each with missing data greater than 50%: baseline 
chronic kidney disease stage (a measure of kidney function) and ethnicity.  
The published analysis took a complete case approach to missing data in variables other than 
kidney function and ethnicity (due to the large amount of missing data in these two 
confounders, sensitivity analyses were undertaken). The absence of a kidney function 
measurement was treated as a separate “unmeasured” group rather than as missing values. 
So with respect to this major confounder, the missing data was handled using a missing 
indicator approach. With respect to missing ethnicity values, a sensitivity analysis was 
undertaken restricting the main analysis to a subset of patients with recorded ethnicity. 
We have undertaken mathematical work (not involving any data) investigating the 
circumstances under which the missing indicator approach and the missingness pattern 
approach are valid. The missing indicator approach involves creating a “missing” variable for 
each confounder with some missing data, indicating whether that variable was missing or not 
for each patient, and incorporating that indicator into the analysis model. The missingness 
pattern approach adds interactions between the missingness indicator variable(s) and the 
other confounders in the analysis model. These approaches are simple, transparent, and less 
computationally intensive than other popular approaches. Our theoretical work suggests that 
the missingness pattern approach may be a reasonable analysis option in many settings using 
data taken from electronic health records, and that the even simpler missingness indicator 
approach is likely to be approximately unbiased in many of these scenarios.  
In order to demonstrate the usefulness of our proposed approach in practice, we would now 
like to: (i) apply these methods (missingness indicator and missingness pattern approach) to a 
CPRD dataset which has been used to address a substantive clinical question, (ii) compare 
them to other popular approaches (complete case and multiple imputation) which require 
very different underlying assumptions, and (iii) use our theoretical framework to explain 
differences between the resulting estimated treatment effects.   
Our theoretical framework supports the use of the simple missingness indicator and 
missingness pattern approaches in a wide range of studies using data from electronic health 
records. By demonstrating the results of applying this theoretical framework to the clinical 
setting described above, we hope to illustrate the value of our methodological work for 
researchers using CPRD data. 
B. Objectives 
The overall aim is to compare the results of the original analysis and sensitivity analyses 
(conventional approaches to handle missing data), with the results obtained using our new 
approach to missing data. This will illustrate the value of our methodological work in the 
context of CPRD data. Specifically, we aim to determine: 
1. The estimated effect of prescription of renin-angiotensin system blockers on the risk of 
acute kidney injury using a missing indicator approach (as published analysis).  
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2. The estimated effect using the missingness pattern approach (our variant of the 
missingness indicator approach).  
3. The estimated effect obtained using multiple imputation.  
4. The estimated effect obtained using full complete case analysis (i.e. additionally excluding 
people with unmeasured kidney function; which results in a much smaller sample than 
the original analysis).  
C. Study type 
As per original protocol. 
D. Study design 
As per original protocol. 
E. Study population 
As per original protocol.  
F. Exposure, outcome and covariates 
F1. Exposure 
Binary baseline ACEI/ARB exposure status derived using time-updating exposure status as 
described in original protocol. 
F2. Outcome 
We will use a dichotomised version of the AKI outcome as defined in the original protocol (eg. 
within 5 years from cohort entry or not). 
F3. Covariates 
We will use covariates deemed of importance in the published analysis, as per original 
protocol. 
G. Analysis 
All analyses will be undertaken in STATA version 14 (StataCorp, Texas). 
We will undertake propensity score analysis to estimate the effect of ACEI/ARB prescription 
on the risk of AKI in new users of antihypertensive drugs using different missing data 
methods:  
1. Missing indicator approach 
2. Missingness pattern approach 
3. Multiple imputation 
4. Complete case analysis 
References 
1 Mansfield KE, Nitsch D, Smeeth L, et al. Prescription of renin–angiotensin system blockers and risk of 
acute kidney injury: a population-based cohort study. BMJ Open 2016; 6: e012690.     
doi: 10.1136/bmjopen-2016-012690 
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Appendix B
Resources for the planned systematic
review
B.1 Protocol of the systematic review
Sources: Searches will be performed in Embase, Medline, PubMed and Scopus to
select papers published between 1 January 1983 (following the publication of the
first paper proposing propensity scores to account for confounding) and 13 May
2016.
Search algorithm: To restrict our review to studies using propensity scores in
which missing data was a particular concern, the search strategy will be constructed
for all four databases in order to search for articles referring to propensity score and
missing data in either the title or the abstract. Eligible papers will have `propensity
score' as a phrase in the title, abstract or keyword fields. Variations of this phrase
will be also considered in the search strategy, for example phrases with the words
`propensity' and `match' in close proximity. In addition to mentioning propensity
scores, the search strategies will require some variations of the phrase `missing data',
such as `incomplete data' or phrases using Rubin's taxonomy of missing data. The
search strategies for each database will be constructed with the aim of being as
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similar as possible, with some variation resulting from differing syntax used in some
databases. For example, the search strategy for Pubmed will be:
(("propensity-score"[MeSH Terms]) OR propensity analys*[Title/
Abstract] OR propensity match*[Title/Abstract] OR propensity adjust*
[Title/Abstract] OR propensity stratif*[Title/Abstract] OR propensity
covariate*[Title/Abstract] OR propensity weight*[Title/Abstract]) AND
(missing data[Title/Abstract] OR incomplete data[Title/Abstract] OR
missing value*[Title/Abstract] OR mcar data[Title/Abstract] OR mar
data[Title/Abstract] OR mnar data[Title/Abstract] OR missing
random[Title/Abstract])
Screening: After search results are obtained, references will be reviewed to
identify and exclude duplicates, first using the "Find Duplicates" function in End-
note X7 to identify a preliminary list of duplicate records, then conducting a manual
review to identify remaining duplicates. The criteria for deciding which record to
keep and which to discard as a confounder, will be decided on the basis of the
amount of information available in each record, favouring records with more infor-
mation. I will review the resulting references by considering the title, abstract and
keywords of the articles, retrieving the full text when further information is required.
Exclusion criteria: I will exclude articles if: they are unrelated to propensity
score analysis of observational data; missing data methods focused on methods for
handling missing data in the treatment or outcome, rather than missing confounder
data; they are conference abstracts, commentary, editorials or letters; if they have
no data example, real or simulated; or if they are published in languages other than
English. Articles with a methodological focus will not included in the general re-
view, but will be considered separately.
Data extraction: For each article included in the literature review, I will extract
information on:
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• propensity score method (matching, stratification, adjustment, weighting, or
not reported)
• the number of confounders with missing data (number, or not reported)
• the overall proportion of missing data (percentage, or not reported)
• the missing data method(s) used (complete records analysis, multiple imputa-
tion, MPA, MIA, other, or not reported)
• whether the justification for the choice of missing data method(s) was discussed
• whether the plausibility of missingness assumptions were discussed
• whether further details were given regarding implementation of the missing
data method (s)
B.1.1 Literature review: results of the screening for
eligibility
From 13th May 2016: Searching the four databases listed above yielded 559 records
(see Table B.1). Using Endnotes's Find duplicates function identified 192 dupli-
cate records to be excluded. Manual review of the author field identified 40 more
duplicate records, and manual review by title identified 4 further duplicates. After
excluding these duplicate records, 323 records remained.
Table B.1: A table showing the number of records retrieved from each database searched
on 13th May 2016.
Database Number
of
records
retreived
Duplicate
records
excluded
Number
of undu-
plicated
records
Embase 178 107 71
Medline 83 79 4
PubMed 47 41 6
Scopus 251 9 242
TOTAL 559 236 323
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